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ABSTRACT 
 
Stem cells hold great promise for regenerative medicine as they have the potential to repair 
almost any tissue. The use of induced pluripotent stem cells (iPSC) offers several advantages 
over human embryonic stem cells (hESC). Nevertheless, an issue that has slowed the use of 
iPSC (as well as hESC) in the clinic is safety. The pluripotent capacity that gives these cells 
their regenerative potential also gives them tumorigenic abilities. Moreover, the 
reprogramming procedure of iPSC can also affect the quality and safety of the final 
population. In the search for safer iPSC, we optimized an integration free method of 
reprogramming that is GMP compliant, which represents a step closer to their clinical use.  
 
Hepatocyte-like cells derived from iPSC have proven useful in research, as in disease 
modelling and toxicity screening, and in the context of cellular therapy could represent a 
breakthrough for the treatment of liver disorders. We worked on an optimized method that 
allows quick and efficient hepatocyte differentiation from iPSC. We used this as a model to 
tap into embryonic development in the context of coagulation, and into the regulators of 
coagulation, with the goal to better understand coagulation. Similar studies can then be used 
to study other pathways besides coagulation and help increase the knowledge on the liver and 
its many functions.  
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Chapter 1 Literature review 
 
1.1 Stem cells 
 
Stem cells are cells that have the ability to self-renew and to differentiate into multiple 
lineages. This concept was first described in the 1960s, when James Till and Ernest 
McCulloch showed that the injection of bone marrow cells into irradiated mice led to 
multiple lineage hematopoietic colonies in the spleen. While not known at the time, the first 
transplant of hematopoietic cells was performed. 
Humans and mammals in general, begin their lives with the fertilization of an egg by a sperm 
cell. The fertilization process results in a cell – the zygote - that has the potential of growing 
into a whole organism composed of very different cell types. The process by which cells go 
from an undifferentiated state to a specialized state is called differentiation. Waddington’s 
model (Figure 1) helps explain the process by which a zygote differentiates into the multitude 
of cells that compose an adult organism, and has become key in the field of developmental 
biology. 
 
Figure 1 – Waddington’s model on epigenetic landscape 
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The model shows a ball on top of a hill. As it rolls down, the ball can take several possible 
routes. This metaphor fits well with the specialization process cells undergo during 
development, as once a cell goes down a specific route it is hard for it to “go up the hill” or 
“across to another trough”. Limited options are possible after a route has been taken until the 
ball reaches the end of the hill, which depicts the different levels of differentiation ability 
cells have. And so, stem cells can be divided into 3 categories according to their 
differentiation potential: totipotent, pluripotent and multipotent. Upon fertilization and within 
the first cell divisions, cells are totipotent with the ability to form the developing organism as 
well as extra embryonic structures such as the placenta. Four-to-five days after fertilization, 
the zygote reaches the blastocyst stage where pluripotent cells located in the inner cell mass 
are encountered. These cells have the ability to differentiate into any of the 3 germ layers: 
endoderm, mesoderm and ectoderm, and therefore form every cell of an organism. 
Multipotent cells come into a more specialized area as they can only give rise to cells of a 
specific lineage/tissue type.   
Due to their inherent characteristics, stem cells are considered to have invaluable potential as 
cellular resources for the treatment of several disorders. There is much interest surrounding 
pluripotent stem cells for these cells can be differentiated into any cell of the human body and 
we currently have the knowledge to develop such cell lines. Different pluripotent stem cells 
have been derived, among which embryonic stem cells (ESCs) and induced pluripotent stem 
cells (iPSCs) are included.  
 
1.1.1 Embryonic Stem Cells 
ESCs are the in vitro derivatives of the inner cell mass of the blastocyst. These cells preserve 
the pluripotency and self-renewal characteristics of the cells in vivo and allow the study of an 
organism’s early development. By harnessing the differentiating potential of pluripotent cells 
in vitro, the field of regenerative medicine observed the beginning of a new era. 
In 1981, the first mouse ESC lines were established, and almost 2 decades later James 
Thomson was able to generated the first human ESC line
1
.   These cells have the ability to 
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differentiate into cells of the 3 germ layers and since their discovery, many protocols have 
been established to differentiate ESCs to specific cell types of all germ layers.  
Despite all the potential these cells present for regenerative medicine, there are challenges 
that need to be overcome, primarily the ethical issue of destroying human embryos in order to 
retrieve ESCs from the inner cell mass. Furthermore, there is the challenge of obtaining 
suitable donor cells that are safe and effective. Additionally, tissue or cells to be used in 
patients need to overcome the problem of immune rejection. 
 
1.1.2 History of reprogramming 
Even before the concept of stem cell existed, reprogramming experiments by somatic cell 
nuclear transfer (SCNT) were being performed. In 1952, cells of late blastula were injected 
into an enucleated frog egg that resulted in the formation of a complete blastulae and, 
occasionally, more developed embryos
2
. Even though none of the blastulae came to term, this 
was the first in a series of experiments where reprogramming by SCNT was successful
3, 4
. 
Decades later, a breakthrough came when the first successful reprogramming of mammalian 
cells was achieved with the generation of Dolly the sheep
5
. This was done by electrofusion of 
an adult sheep mammary epithelial cell with enucleated ewe egg followed by transplantation 
into a recipient animal. A great furor surrounded this scientific achievement as it was the first 
instance of mammalian cloning. Since then, other successful cloning of mammalian species 
have been achieved, including mice, rabbit, pigs and many others
6-9
. 
Even though the process is incredibly inefficient, the SCNT experiments demonstrated that 
oocytes contain the factors necessary to reprogram differentiated cells. Considering 
Waddington’s model, these experiments showed it was possible to revert cells “up the hill” 
back to a pluripotent state (Figure 2). 
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Figure 2 – Modification of Waddington’s epigenetic landscape showing reprogramming possibilities of differentiated 
cells. Model showing cell populations at different developmental stages according to Waddington’s model. Development 
potentials shown on the left with examples of cells at each stage. Figure from Hochedlinger and Plath10.      
 
In 1976, Miller and Ruddle showed the first reprogramming by cell fusion in which fusion of 
diploid murine embryonal carcinoma cells (ECCs) and diploid thymocytes resulted in a 
hybrid cell where the phenotype of pluripotent stem cells (PSCs) dominated
11
. The cancerous 
phenotype of ECCs led to the replacement of these cells by ESCs, which showed similar 
abilities in reprogramming by cell fusion
12
. Even though the hybrid cells possess 
characteristics of PSCs, such as teratoma formation, they are tetraploid or near-tetraploid 
containing DNA from both cell types, which greatly impedes their use. Cell fusion 
experiments with ESCs showed that ESCs possess reprogramming capabilities similar to that 
of oocytes.  
SCNT and fusion studies suggest that both oocytes and ESC possess factors that allow the 
reprogramming of somatic cells. This led to the hypothesis that cellular extracts from these 
cells can induce reprogramming of somatic cells. 
In 2005, reprogramming with cellular extract was achieved, by which HEK 293T and 
NIH3T3 cells were permeabilized, incubated with ESC extract and resealed
13
. The cells 
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changed and were reprogrammed to a pluripotent state by which they present similar 
morphology to ESC, the pluripotency gene OCT4 was found upregulated and showed ability 
to differentiate into other lineages in presence of retinoic acid (RA)
13
. 
The evolution of reprogramming allowed us to understand that there are factors present in 
PSC that allow the reprogramming of somatic cells to a pluripotent state. This knowledge 
was the basis for the development of iPSCs. 
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1.2 iPSC reprogramming 
 
In 2006, the first iPSC were derived. These were obtained by the over-expression of four 
transcription factors: Oct4, Sox2, Klf4 and c-Myc (known as Yamanaka factors or OSKM) 
by retrovirus-mediated transduction of mouse fibroblasts
14
 (Figure 3). This was a 
revolutionizing study by which somatic cells were induced into a pluripotent state by the 
introduction of exogenous factors. Since then, the interest in this technology has boomed 
greatly due to its potential in regenerative medicine and disease modelling. The increased 
interest was accompanied by expansion on the reprogramming methods.    
 
Figure 3- Reprogramming process. Simplified schematic of the reprogramming of somatic cell into iPSC state by 
introduction of the OSKM factors.  
 
These cells have potential in several fields of research and despite the multitude of methods 
available we should be aware how different factors can influence the reprogramming process 
and the quality of the final population. The donor cell type, the reprogramming cocktail, the 
culture condition and the delivery systems are the main ways by which the reprogramming 
process can be affected. 
 
1.2.1 Donor cell type  
The donor cell type greatly influences the efficiency and kinetics of the reprogramming 
process. The most common cell type used are fibroblasts, but when we compare efficiency of 
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mouse embryonic fibroblast (MEFs) to human foreskin fibroblast (HFF) we observe an 
almost 2 fold increase in the time required for reprogramming. This difference in the kinetics 
of reprogramming might result from species differences in cells but most likely due to the 
different developmental stage of the cells: embryonic vs adult.  
The effect of the differentiation status of cells on the reprogramming process is also shown 
by Eminli et al. where haemotopoietic stem cells (HSCs) generate 300x more iPSC colonies 
than terminally differentiated B and T cells
15
. The differentiation status of cells relies on their 
epigenetic state. Epigenetic modifications allow differential expression in otherwise 
genetically identical cells in the human body, and thus provide a unique signature of a cell 
differentiation status. The more differentiated cells are, the more repressive marks they have, 
locking them into a specific status. The pluripotent state requires an open epigenetic state, 
and so during the reprogramming process the repressive marks need to be removed so that the 
iPSC state can be reached. This refers back to Waddington’s model (Figure 1 and Figure 2) 
by which the amount of epigenetic markers in the cells correlates to their differentiated state 
and so, as cells “go down the hill”, they acquire marks locking them into specific lineages. 
This explains why less differentiated cells have faster kinetics of reprogramming.  
The donor cell type can also affect the composition of the reprogramming cocktail as certain 
donor populations are known to endogenously express certain reprogramming factors which 
obviates their expression in trans. This is exemplified in melanocytes: as these express high 
levels of endogenous SOX2, reprogramming can be done with only 3 factors
16
. Another 
example that shows the extent of how the cell type can affect the reprogramming cocktail was 
reported by Scholer et al. when it was demonstrated that the sole introduction of OCT4 in 
fetal neural stem cells  was enough to achieve reprogramming
17
. 
As shown, several cell types besides fibroblasts have been used for the reprogramming 
process, including blood cells. Reprogramming from blood cells is highly appealing as cells 
can be collected in a non-invasive procedure for patients, already routinely used in the clinic, 
which is advantageous when compared to skin biopsies required to obtain fibroblasts. 
Unfortunately, the efficiency observed in differentiated T and B cells is reduced when 
compared to HSCs. Availability of cell type also affects their use for reprogramming, as in 
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the case with HSCs, and so, until higher efficiencies can be obtained from differentiated 
blood cells, fibroblasts might remain the preferred cell type for reprogramming. 
Different features affect the suitability of each cell type for the reprogramming process, with 
each having its own advantages and limitations. It can thus be suggested that the ideal cell 
type for reprogramming should be (1) easily accessible, (2) with minimal risk in obtaining the 
cells from patients, (3) available in large quantities with relative high efficiency and (4) speed 
of reprogramming should be taken into consideration. 
 
1.2.2 The reprogramming cocktail 
The initial cocktail for reprogramming comprised the OSKM factors but other combinations 
have been used, often using factors expressed early during development and involved in the 
maintenance of pluripotency. Such factors include Nanog, UTF1 or SALL4 that, when added 
to the core reprogramming factors, increase efficiency and reduce the reprogramming time
18
. 
Other factors such as MYC and KLF, have shown to affect cell proliferation, both directly or 
indirectly. Increased cell proliferation expedites the appearance of colonies, increasing the 
kinetics of the process. Telomerase reverse transcriptase (TERT) and the SV40 large T 
antigen (SV40LT) are proteins with known effects on proliferation, and indeed their positive 
effect on the reprogramming process has been shown
19
. Chemical compounds can also be 
used to aid in cell proliferation, and consequently in the reprogramming process. The use of 
chemical compounds extends beyond their effect on cell proliferation. Different compounds 
can affect a range of different cellular mechanisms, with modifications at the epigenetic level 
showing great improvements in the reprogramming process in various cell types. The 
epigenetic state of the donor cells is a known limitation, mainly due to the chromatin 
remodeling step
20
. Chromatin remodeling can be facilitated by altering DNA methylation 
status or by modifying chromatin, which can be achieved by using histone deacetylase 
(HDAC) inhibitors (such as hydroxamic acid and valproic acid)
20
. Some compounds can even 
have additive effects on the reprogramming, such as the case with Vitamin C that has shown 
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to improve the process both by inducing DNA demethylation
21
 and by alleviating cell 
senescence
22
.  
The reprogramming cocktail can be affected by the donor cells used as each might have 
different requirements for reprogramming, as it has been described that some cell types can 
endogenously express some of the factors which limits their requirements in the 
reprogramming cocktail.  
MicroRNAs (miRNAs) have been shown to support iPSC induction, both in combination 
with other factors and by themselves
23
. These miRNAs have been identified by being 
preferentially expressed in ESCs and are thought to help maintain the pluripotent state
24, 25
. 
This avenue is highly appealing as it allows to regulate gene expression without the need of 
protein elements, reducing the processing time and effort of cells. 
 
1.2.3 Culture conditions 
The environment cells are cultured also affects the reprogramming process. Generally, iPSC 
are kept in identical conditions to ESC, which are permissive to the pluripotent state.  
One of the most influential variants in terms of culture condition is the use of a supportive 
cell layer. These cells are known to secrete factors required for PSCs survival, proliferation 
and pluripotency maintenance and often MEFs and neonatal human dermal fibroblasts are 
used.  The risk of contamination from the feeder layer led to development of supportive 
systems without the use of these cells. A range of feeder-free systems have been developed, 
be it protein extracts, recombinant proteins or even synthetic matrices
26-32
. These have 
varying degrees of efficiency in maintaining stem cell culture and supporting the 
reprogramming process. Some only work in combination with specific media, which shows 
the importance of the combined effects of culture conditions for proper iPSC regulation.  
Medium composition can also affect the reprogramming and while in early times it relied 
mostly on the factors secreted by the feeder layer, it has come a long way since then. Better 
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understanding of the signals required to maintain pluripotency allowed to develop more 
defined media that contain all the necessary elements to maintain the correct phenotype of 
cells. 
Changing the conditions so that these resemble the natural niche of cells has been suggested 
as a way to improve the culture conditions. Indeed, when cells were cultured in hypoxic 
conditions, reprogramming efficiencies of both mouse and human iPSC showed an 
increase
33
. This was based on the knowledge that stem cell niches often possess lower O2 % 
than the atmospheric 21% O2.  
Others have suggested the effect of stress conditions in the reprogramming of somatic cells. 
This process has been observed in plants, by which the exposure to drastic environmental 
changes can convert cells from a mature state to an immature state
34
.  Although a paper came 
out showing how low-pH conditions were amenable to acquisition of pluripotency
35
, it was 
later retracted
36
 and so no evidence exists that environmental effects can solely reprogram 
cells into a pluripotent state. Even so, it has been shown that environmental conditions aid the 
reprogramming process, as in the case of hypoxic conditions. It is known that environment 
conditions can regulate gene expression and so it is possible that other environmental cues 
can help improve the reprogramming process.  
 
1.2.4 Delivery systems 
No other field observed such variety as the delivery systems. A method to introduce the 
reprogramming cocktail in the cells is needed, and while the initial study relied on retrovirus 
many other ways have been used to do so. We can subdivide the wide range of methods 
available into two important categories: integrative and integration-free. 
Retrovirus and lentivirus are two common viral vectors used to generate iPSC and both are 
integrative systems. As the name suggests, the transgenes are incorporated in the genome of 
the host cell, and in general have higher reprogramming efficiencies as the integration in the 
genome allows consistent expression of the reprogramming factors. This expression, even if 
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advantageous for the reprogramming process, creates a problem for the resulting iPSC in 
terms of safety. Genomic integration of exogenous DNA can affect the stability of the 
genome and depending on the site of integration it can affect tumour suppressor genes or 
oncogenes – issues already seen in a gene therapy study using retrovirus37. Furthermore, 
constitutively expression of the reprogramming factors after the reprogramming process also 
poses risks as some of the factors are potent oncogenes (such as c-Myc).  
While in the case of retrovirus the transgenes are generally silenced
38
, the risk of re-activation 
is still present. In the case of lentivirus, silencing of transgenes is less effective
39
 which led to 
adaptation of drug-inducible systems to allow controlled expression of the factors
40, 41
. This 
type of system improves the silencing efficiency but again the risk of re-activation is still 
present. The advantage of lentivirus compared to retrovirus is the fact that it allows 
transducing non-diving cells and dividing cells with similar efficiencies
39
. 
To avoid the use of viral vectors, DNA transfections were used and showed a significant 
decrease of efficiency as lower numbers of cells underwent complete reprogramming. The 
design of polycistronic vectors allowed a slight increase in reprogramming efficiency
42
.  The 
lower efficiency coupled with a still integrative method does not bring much advantages 
compared to viral methods. In an attempt to remove the integrated DNA from the host 
genome, vectors with loxP sites flanking the reprogramming cassette were used and shown to 
indeed induce pluripotency of transfected cells. Upon transient expression of Cre 
recombinase in these cells, the loxP flanked sites are deleted from the genome, which allows 
to remove the transgenes thus improving the cells overall safety by reducing oncogenic 
potential. 
Even if the removal of transgenes can be achieved, the use of the loxP method still leaves 
genomic scars behind that could still disrupt expression of tumour suppression genes or 
oncogenes. The only integrative method shown to be able to remove the inserted DNA with 
no scars behind are vectors based on the PiggyBac (PB) transposon
43
. While it allows 
complete removal of transgenes, DNA alterations have been reported and therefore sequence 
verification is needed
19
. 
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The development of integration-free reprogramming methods removed these issues and made 
the final iPSC population safer overall. Several methods exist and their general disadvantage 
compared to integrative methods is lower reprogramming efficiencies (Figure 4). 
 
Figure 4 – Graph showing the relation between efficiency and safety of different reprogramming methods. Adapted 
from González et al.44 
 
One of the first attempts at integration-free methods, and with some of the lowest 
efficiencies, was using integration defective viral delivery by using replication-defective 
adenoviral vectors
45
. Despite the ability to create iPSCs, it was only successful when 
hepatocytes were the donor cell type, requiring integrative expression of factors for other 
donor cells
45
. This shows us once more how the donor cell type can influence the 
reprogramming process, not only by itself but in combination with all other factors that affect 
the reprogramming process. 
Another viral vector used in integration-free manner is the Sendai virus. These viruses belong 
to the RNA virus family that replicate in the cells’ cytoplasm, which means no genomic 
integration occurs
46
. Using F-deficient sendai virus reprogramming of human fibroblasts and 
T cells has been successfully achieved
47, 48
. Despite the safety measures to prevent viral 
replication, it was difficult to eliminate viral vectors from the host cells and, even at higher 
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passages, clones with transgene expression are detected
47
. And so, even if sendai virus are 
integration-free, the late detection of transgene expression creates a hurdle to their use. 
To avoid the use of viral particles, researchers turned their focus to other integration-free 
options such as episomal plasmids. These allow the transient expression of transgenes in the 
host cells. Expression allows reprogramming to occur and is subsequently lost, allowing the 
removal of any exogenous material in the cells. While non-replicating episomal plasmids 
showed success in reprogramming MEFs, they proved unable at reprogramming human 
cells
49
. The inefficiency at reprogramming human lines is probably due to the short window 
the transgenes are expressed, which coupled with low transfection efficiencies and dilution of 
factors as cells proliferate makes it even harder for cells to undergo changes that lead to 
pluripotency. Even when successful, non-replicating plasmids showed cases where 
integration into the genome occurs
49, 50
. 
To try and circumvent this issue, Yu et al. used oriP/Epsein-Bar nuclear antigen-1 based 
episomal vectors (oriP/EBNA1)
51
. These vectors can be kept under selection conditions and, 
in the absence of drug selection, are lost at a 5% rate per cell division. The longer periods 
allows for the reprogramming process to occur. The low efficiencies led Okita et al. to 
optimize the process by introducing elements that increase reprogramming efficiency: p53 
small hairpin and L-Myc instead of c-Myc
52
. 
To try and improve the low transfection efficiencies that are observed with episomal vectors, 
minicircle vectors were developed. These are super-coiled DNA molecules that lack a 
bacterial origin of replication, which in turn gives them longer transgene expression times as 
it helps evade exogenous DNA-silencing mechanisms
53, 54
. The higher transfection 
efficiencies allows the mini circles to compensate for serial dilution and for reprogramming 
to occur
55
. 
Replacing genetic-based techniques by other methods represents an important step in the 
search for safer methods. The use of RNA or proteins are viable alternatives as, not only they 
remove the risk of genomic integration, but allow to reduce the cellular processes for 
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transgene expression (transcription and translation), reducing the time necessary for 
transgene action.   
Warren et al.  were able to achieve high efficiencies of reprogramming with faster kinetics 
when using synthetic mRNAs
56
. Their success depended on two important features: (1) 
modifications of the mRNAs in order for these to avoid the cells defense mechanisms against 
RNA virus and (2) daily transfections required to allow sustained expression of the factors as 
mRNA molecules have a fast turn over time.  
The use of proteins is more challenging than RNA as the mechanisms for their delivery are 
not as easy, relying on peptides fused to the reprogramming factors that mediate their 
transfections
57, 58
. The low efficiency and kinetics coupled with the difficulty in protein 
purification and high amounts required make it highly unlikely for routine use, but as proof of 
concept, it has been shown to work.  
 
Overall, the rapid progress of the iPSC field was accompanied with improvements in iPSC 
derivation methodologies, and currently a wide range of options is available. Different factors 
can affect the reprogramming process and even though we presented them as separate fields, 
the reality is that these are not independent and should be taken together when determining 
the best method of reprogramming. The ideal reprogramming method should comply with 
safety and efficiency requirements, but ultimately the best reprogramming method may vary 
depending on the specific application of the iPSCs  
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1.3 Applications of iPSC 
 
One of the main interests surrounding iPSC is the advantages it can bring to the field of cell 
transplantation. Various cell types can be obtained from PSCs and their unlimited 
proliferation ability allows to obtain any number of cells required to repair tissues damaged 
by disease or injury. The autologous nature of iPSC removes the risks of rejection and 
infection making them ideal for cellular therapies. Furthermore, it allows to overcome the 
ethical issues associated with the destruction of embryos for the acquisition of ESCs. 
The therapeutic effects of ESC have been extensively described in animal models of several 
disorders, including spinal cord injury
59
, retinal disease
60
 and Parkinson’s disease61. A proof-
of-concept study with a humanized sickle cell anemia mouse model showed that iPSC could 
be used to treat single gene defects
62
. In this study, Hanna et al. corrected the sickle 
haemoglobin allele in iPSC by homologous recombination and upon differentiation into 
haematopoietic progenitors and transplantation into mice showed successful rescue of the 
disease phenotype
62
. Other studies have shown the feasibility of iPSC to treat disease or 
injured phenotypes
63-67
, and even though their clinical use is still at its infancy, two 
encouraging clinical trials using ESC-derived cells have been approved by the FDA 
(www.clinicaltrials.gov) and are paving the way for PSCs clinical use. The first one was for 
the treatment of spinal cord injury using ESC-derived cells while the second was focused on 
macular degeneration of the eye using retinal pigment epithelial (RPE) cells from ESCs. 
These studies are important milestones in the transition of PSCs therapies to the clinic, 
especially in safety matter as in the case of macular degeneration where no hyper 
proliferation, abnormal growth or immune rejection was observed in the patients
68
.  
Even if cellular therapies using iPSC are still in a preliminary phase, iPSC have shown useful 
in other areas. The ability to retain the genomic information from a specific patient allows the 
opportunity to study “disease in a dish”.  
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Figure 5 – Applications of iPSC. Possible applications of iPSC technology. Figure from Robinton and Daley69. 
 
Disease modelling gives the opportunity to study the development and functional 
implications of human diseases (Figure 5). The first model to study human pathogenesis was 
for the study of spinal muscular atrophy, where the patient derived iPSC showed the same 
phenotypical hallmarks of the disease when differentiated into motor neurons
70
. The study of 
human neurological disorders benefited greatly with the development of iPSC technology as 
the complexity of the neuronal system and the difficulty in culturing neurons in vitro made it 
hard to study the development and function of human neurons
71
. iPSC have allowed not only 
to replicate the disease phenotype in vitro 
70
 but even aided in elucidating the molecular 
mechanisms underlying disease
72-74
. Neurological disorders are not the only ones that have 
been modelled using iPSC. To date, a variety of disorders affecting other tissues or organs 
have also been used, including immunological disorders and cancer
75-77
.  
The in vivo niche where cells exist are very complex and determinant for their phenotype. In 
vitro culture systems have greatly improved in their ability to replicate the in vivo situation 
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but they are still short of a perfect system. For disease modelling, stress factors might be 
necessary to mimic the pressures cells are under in the disease state. Furthermore, 
improvements on the quality of cell differentiation are needed as seldom these give rise to 
homogeneous population of cells, with the most common issue being the correct 
synchronization of the developmental stage of cells in culture
78
. Despite the possibility for 
improvements the usefulness of iPSC in disease modelling cannot be challenged.  
By helping elucidate disease mechanisms, iPSC also open the door for toxicology screens. By 
comparing normal development with diseased state, the possibility of identifying new targets 
creates opportunities for new therapeutical agents
74
. Parallel to toxicology screens, drug 
metabolism studies represent an important feature of iPSC. These take advantage of the 
ability to use specific genetic backgrounds as a starting point for hepatic or cardiac 
differentiation.  
The majority of drugs fail to reach the market due to cardiotoxicity or hepatotoxicity. The 
current systems are limited in their ability to predict unforeseen effects (such as absorption, 
distribution, metabolism and even toxicity) which incurs high cost in the drug-screening 
process and consequently in the pharmaceutical industry.   iPSC technology has proved 
innovating in modelling human physiology in vitro as it allows to use a large genetic pool and 
use both healthy and disease phenotypes as models for drug screening. In the liver context, 
individuals with different cytochrome p450 enzymes can show different metabolic profiles of 
drugs, which makes the use of different genetic backgrounds extremely valuable when 
assessing the effect and safety of drugs. The same concept can be used in the context of the 
heart, as certain drugs can affect the cardiac action potential and cause long QT syndrome 
(LQTS) which can result in lethal arrhythmias. The ability to differentiate iPSC into beating 
cardiomyocytes allows to test, in an in vitro setting, the sensitivity to drugs and their effect in 
the action potential of cells. 
The use of human cellular products for drug testing is not new but the unlimited source of 
cells from iPSC allows overcoming the limiting problems of cellular supply.  
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This technology greatly surpasses the use of animal models as it reproduces human 
physiology in a way animals (even genetically modified) cannot. An example is shown in the 
case of different pathophysiological features seen in the hearts of transgenic mice versus 
human heart where variations in ion channel types and distribution results in faster heart rates 
and shorter action potential duration in the mouse
79
.  Despite the limitations, animal models 
continue to be important for understanding disease mechanisms and drug screening. In the 
future, better iPSC-derived models should be chosen over its animal counterpart, as often 
these do not truly mimic what happens in humans. 
In addition, iPSCs are also emerging as helpful tools in the field of developmental biology. 
The differentiation of iPSC into somatic cells allows to replicate in vitro the natural 
processes. Even if the differentiation protocols are limited comparing to in vivo development, 
they allow us to tap into periods of development that otherwise cannot be studied. 
Overall, iPSC technology has proven itself useful for research purposes with optimistic data 
regarding their use in cellular therapies. Despite the promises of this technology, there are 
challenges that still need to be addresses and considerations to be taken into account if this 
technology is to be used therapeutically.  
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1.4 Questions and challenges of the iPSC field 
 
Since the first iPSCs were derived in 2006, the field has observed a progress at a breathtaking 
pace. With the development of the field the unanswered questions and challenges associated 
with the cells also increased. Some of the main issues that surround the iPSC field are 
presented here. 
 
1.4.1 ESCs Vs iPSC 
The iPSC field piggybacked on the ESC field, but the question on how equivalent these cells 
truly are still remains. Indeed, the development of the iPSC field relied on factors shown to 
maintain pluripotency in ESCs. It is then expected that iPSC and ESC should be equivalent. 
As anticipated, many if not all of the features of ESC are observed in iPSC. These are 
morphological identical and show the same developmental potential as ESCs
80
 with the 
ability to generate cells from the three different germ layers.  
Other molecular assays, which compare gene expression and epigenetic characteristics allow 
a more quantitative comparison between the two. While initial reports showed that profile of 
global expression, histone modifications, X-chromosome inactivation and DNA methylation 
profiles of iPSC were similar, if not indistinguishable from ESC 
81
, later studies contradicted 
these findings. These showed iPSC as having its own gene expression signature, different 
from ESC
82-84
. Differences in DNA methylation between the two type of cells were also 
identified
85, 86
, with epigenetic memory of donor cell also reported
87-89
. 
However, the analysis of a large collection of gene expression and histone modification data 
shows that the differences seen in the previous studies might represent “experimental noise”, 
by which there is an overlap in the variations between ESC and iPSC clones, thus clustering 
iPSC and ESC together
90, 91
 (Figure 6). 
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Figure 6 - Overlapping quality between iPSC and ESC. Variations observed between iPSC and ESC regarding a range of 
properties (including gene expression, DNA methylation and differentiation propensity). While most lines are grouped 
together there are some iPSC that differ from ESC. Figure from Yamanaka92. 
 
While these studies cluster iPSC and ESC together there are questions regarding epigenetic 
memory in iPSC, especially observed in early passage lines
93
. Soldner et al. proposed that the 
changes in gene expression might just result from residual transgene induction that are 
specific to cell of origin
94
. This shows that there are factors external to iPSC but relevant for 
its induction that can affect how much they resemble ESC. Some of the parameters that 
complicate the comparison include presence of incomplete silencing of transgenes, different 
reprogramming cocktails, genetic background of cells, natural heterogeneity among ESC 
lines, and incomplete reprogramming to pluripotent state
95
. 
How important are the differences between iPSC and ESC for the differentiation of 
functional cells is not clear as tolerance towards some epigenetic and gene expression 
aberrations has been shown. The level that is tolerated is another question that might depend 
on how closely related the lineages of the target and donor cell type are. 
The use of ESC as the standard control for iPSC quality makes sense as iPSC were developed 
from knowledge obtained in ESC. Nevertheless ESCs are seen as in vitro cells of the inner 
cell mass (ICM), while they - similarly to iPSCs - are a man-made cell type. Changes 
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between ESC and cells of the ICM have also been reported, both at the methylation level
96
, 
gene expression level
97
 and even regarding the length of telomeres
98
. And so, both the 
differences and similarities of iPSC with ESC can have implications in their quality that 
escape our knowledge. 
 
1.4.2 Safety concerns with iPSC 
Concerns regarding the quality and safety of these cells remain the main focus in the iPSC 
field.  
As discussed previously, much has been done to improve the safety of iPSC when it comes to 
the reprogramming method. Besides the safety of the method one must consider efficiency 
and consistency of manufacture in order to ensure reproducibility of the process. This is an 
important factor in the manufacturing process as regulatory concerns can hold the clinic use 
of these cells. 
In addition to the aforementioned, there are other features of iPSC that need to be considered 
in terms of their safety. We previously saw that iPSC and ESC show differences at the 
genetic and epigenetic level, with implications still unclear. Even if the differences between 
these two cell types are not significant, the implications regarding their forward 
differentiation is crucial information for their use. 
Genetic stability is an important feature to any cell, as instability is one of the hallmarks of 
cancer 
99
. While genetic instability of human ESC and iPSC in culture has been shown
100, 101
, 
evidence is starting to emerge suggesting it results from in vitro culture rather than the 
pluripotent state, as instability was also detected in adult stem cells in culture
102, 103
. 
Karyotype profiling might not be sufficient, and more precise genetic analysis should be done 
104
. As the risk of genetic instability increases with time in culture
105, 106
, low number of 
passages might be required to decrease the risk of genetic alterations, however low passage 
numbers might implicate presence of transgene in the clones. As a minimum time in culture 
is required for the pluripotent state to be reached, optimization of the time in culture is 
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required. Other genetic differences among iPSC have been shown including somatic 
mutations
107
, copy number variations (CNVs)
108
 and immunogenicity
109
. Nevertheless, some 
studies have shown these variations were there prior to the reprogramming process
110, 111
. An 
acceptable threshold of genetic changes should be determined as some of these can be natural 
occurring differences that do not affect quality of cells (such as CNVs).  
 
It is also crucial to assess the heterogeneity of a culture as there is tumorogenic or 
immunogenic risks associated with the engraftment of undifferentiated or incorrectly 
differentiated cells. Tumours following stem cell use have been reported
112
 demonstrating the 
tumorigenic risk associated with PSCs. It is not easy to quantify the tumorigenic risk of a cell 
population and while the pluripotency inherent to PSCs is a risk, it is its cellular derivatives 
that have interest for therapeutic use. The tumorigenic risk is still present either from 
instability correlated with time in culture or from quality of differentiation protocols. This 
risk can be decreased with increased purity of population (either with improved protocols or 
by purification of the final population) as well as by monitoring for contamination. The study 
of biodistribution of iPSCs and its derivatives must take into consideration a range of factors 
such as the route of administration, methods for cellular detection and their sensitivity, 
number of cells, as well as the species used as models. Different methods for in vivo tracking 
are available but “sensitivity vs specificity” has made it hard to conclusively determine the 
biodistribution of cells in vivo. Animal studies for assessment of human PSC derivatives 
generally rely on use of immuno-suppressed or immuno-compromised animals, but masking 
the effect of the immune system could also play a role in the biodistribution of cells, further 
complicating the significance of any findings. 
Although the use of iPSC technology should remove the risk of immunogenicity, an initial 
study by Zhao et al. showed a T-cell dependent immune response when mouse iPSC were 
used in syngeneic recipients
109
. Cellular therapy will rely on PSC derivatives rather than on 
PSC in their native state and so, even if the study by Zhao et al. begs caution in terms of an 
immune response, similar studies with the use of differentiated cells were needed. Such 
studies have shown contradicting data, some showing similar results to Zhao where iPSC 
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derivatives produced an immune response
109
 while others claimed “negligible” or “lack of” 
immunogeneicity
113
. These studies suggest that not all tissues derived from iPSC elicit an 
immune response, and that these might be dependent on the quality of the starting iPSC 
population and/or final population. In general, iPSC still present a better alternative to ESC 
when considering immunological issues as shown by a study where differences in the 
immunogenicity of endoderm cells derived from iPSC and ESC were observed
114
. Quality of 
the iPSC population and maturation status of the cells are not the only factor that can affect 
immunogeneicity, with other factors such as site of administration, number of doses, the 
immunological basis of the disease and even the age of the recipient being able to affect the 
immune response to treatment
115
. 
 
1.4.3 Quality of differentiation protocol  
Quality and maturation state of the iPSC derivatives are important in terms of safety 
(tumorigenic risk) but go beyond the use of iPSC for the clinic. The iPSC field has 
applications in disease modelling, drug toxicity and even developmental biology. For any of 
these, the results obtained are as good as the quality of the differentiation protocol and the 
final population of cells. 
In vitro differentiation protocols aim to mimic the developmental stages for each specific 
lineage, but fall short of perfect systems. Most protocols result in a heterogeneous population 
of cells that present a foetal phenotype.  A great deal of research has been done to improve 
those, either by use of small molecules
116
 or better culture systems (such as in the 
cytoarchitecture of cells) during the differentiation protocol.  
Small molecules have the added advantage of being cheaper and easier to produce than 
recombinant protein factors and show higher ease of scalability
117
. Another feature specific to 
small molecules is the ability to inhibit rather than activate signalling pathways. This has 
been shown in neural specification
118
, with highly synchronized and efficient induction. 
Similar approaches were seen for other lineages
119
.   
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Three-dimensional (3D) structures allow cells a more physiological cytoarchitecture, a 
crucial feature for several cell types. During development, cells interact not only with each 
other but with extracellular matrix (ECM), interactions important for multiple functions such 
as cell growth, differentiation, cell maintenance and even tissue morphogenesis
120
. This lead 
to increase interest in developing systems that mimic the natural niche of cells during 
embryogenesis
121-123
, as these can help modulate the behavior of cells. A great deal of work 
has been done to improve the cytoarchitecture of cells but limitations still exist and need to be 
considered. Collaboration between the fields of developmental biology, stem cell and 
biomaterials will be key for development of better and more suitable culture systems.  
Another consideration to take into account is the choice of cell source. We have seen that 
epigenetic memory can exist in iPSC, and while this represents a downside in the search for a 
pluripotent cell, it might be beneficial when considering differentiation of cells into a specific 
lineage. The donor cell type can influence the differentiation potential of iPSC and so one 
might consider using iPSC from related lineages when differentiating them. This is a 
controversial idea as truly pluripotent cells should not have differentiation bias toward any 
lineage, and thus can put into question the quality of the iPSC population.  
 
The knowledge on iPSC is continuously increasing and becoming ever more complex. The 
more is understood, the more questions arise that need to be answered. Despite this, the 
interest in this technology has not faded, with growing hopes for its prospective clinical use. 
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Chapter 2 Materials and methods 
 
2.1 Cell culture 
Tissue culture was performed in level 2 safety hoods under sterile conditions. All media were 
sterile filtered and supplemented with 1mg/ml Penicillin/Streptomycin (P/S, Sigma). 
Solutions were pre-warmed at room temperature prior to use.  
Table 1 - List of fibroblast cell lines used for reprogramming 
Cell line Description 
RDP1 Skin fibroblast cell line  from a 49 year old patient with rapid onset 
Parkinsonism dystonia (RPD) 
RDP2 Skin fibroblast cell line  from a 31 year old patient with rapid onset 
Parkinsonism dystonia (RPD) 
IMR90 Fibroblasts cell line derived from the lungs of a 16-week female foetus 
BJ Fibroblasts cell line derived from neonatal foreskin  
 
RDP1 and RPD2 cell lines were obtained from skin fibroblast from a 49 and 31 year old 
patients, respectively, with rapid onset Parkinsonism dystonia (RPD). We used these cells for 
the induction of iPS cells with a maximum of thirteen passages in culture. IMR90 fibroblasts 
from the lungs of a 16-week female foetus and BJ fibroblasts from neonatal foreskin were 
also used for the induction of iPS cells. These human fibroblast lines and Platinum A 
amphotrophic packaging (PLAT A) cells were maintained in MEF medium: Dulbecco’s 
modified eagle medium with L-glutamine (DMEM, Gibco Life Technologies) containing 
10% heat-inactivated  foetal bovine serum (HI-FBS, Gibco Life Technologies) and 1mM Non 
Essential Amino acids (NEA, Life Technologies) in a 5% CO2 humidified atmosphere at 
37°C . Human HEK 293 cells, HUH7 and HepG2 cells were cultured in D10 medium: 
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DMEM supplemented with 10% HI-FBS, in a 5% CO2 humidified atmosphere at 37°C .For 
passaging, medium was discarded and cells washed twice with phosphate buffered saline 
without calcium and magnesium (PBS, Life Technologies). TryPLE (Life Technologies) was 
added and cells were incubated at 37°C for approximately 5 min. Cells were resuspended 
with medium and centrifuged for 5min at 400x g. The supernatant was discarded and cells 
transferred into a new flask with fresh medium. Cells were passaged every 2-3 days using a 
split ratio of 1:3. 
iPSCs were generated and maintained in irradiated newborn human foreskin foetal fibroblasts 
feeders with mTeSR1 (STEMCELL technologies) or human ES medium: KO-DMEM (Life 
Technologies) containing 20% Knouckout serum replacement (KSR, GIBCO), 1mM 
GlutaMax (Life Technologies),  1mM NEA and 0.1mM β-mercaptoethanol (Invitrogen). hES 
medium was supplemented on the day of use with 4 ng/ml recombinant human basic 
fibroblast growth factor (bFGF, Life Technologies). Medium was refreshed every day. For 
passaging, human iPS cells were washed once with PBS and then incubated with 1mg/ml 
Dispase (STEMCELL technologies) at 37˚C for ~7min. When edge of colonies started to 
curl, dispase was removed and cells washed with PBS. Appropriate volume of mTeSR1 or 
hES was added and cells were scraped off the plate using a 5ml short glass pipette and 
transferred to a new dish with Nuff feeder cells. The split ratio was routinely 1:3.  
For feeder-free culture and induction of iPS cells, cells were maintained in one of the 
following combinations: matrigel (Corning)/geltrex (Life technologies) and mTeSR1 or 
recombinant vitronectin (Life Technologies/STEMCELL technologies) and essential 8 (E8) 
medium (STEMCELL technologies). Plates were coated with matrigel/geltrex and kept at 
4˚C overnight. Before use, plates were warmed to room temperature. For dispase passaging, 
cells were washed once with PBS and then incubated with 1mg/ml dispase. When the edges 
of the colonies began to curl, dispase was aspirated and cells washed with PBS. Fresh 
medium was added and cells scraped off the plate using a 5ml short glass pipette (Corning). 
Disaggregated colonies were transferred immediately to matrigel/geltrex coated plates. The 
medium was changed daily. For EDTA passaging, cells were washed once with PBS and then 
incubated with gentle dissociation reagent (STEMCELL technologies). After 3-5 mins, 
EDTA was aspirated and fresh medium added. Using a 1000µl pipette tip, cells were washed 
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off the plate and gentle pipetting was performed to break up the colonies. Disaggregated 
colonies were transferred immediately to matrigel/geltrex coated plates. Medium was 
changed daily. The split ratio was routinely 1:6 (range between 1:3 and 1:10) for dispase 
method and 1:10 (range between 1:6 and 1:20) for gentle dissociation method. Similar 
process for E8 + vitronectin conditions. 
 
2.1.1 Cryopreservation of hPSCs 
For long-term storage cells were cryopreserved in liquid nitrogen using bambanker freezing 
medium (Anachem). Cells were collected in small clumps as described above and spin down 
for 5 minutes at 200x g. The cell pellet was resuspended in 500µl of bambanker freezing 
medium and transferred into cryovials (Greiner Bio-One). Cells were immediately transferred 
to -80°C in a Mr. Frosty (Sigma Aldrich) to achieve a rate of cooling of -1°C/minute. After 
24h in a Mr. Frosty vials were transferred into liquid nitrogen where they were stored until 
use. 
 
2.1.2 Thawing hpSC 
Cryopreserved stem cells were thawed in a 37°C water bath until a small fraction was still 
frozen. 6ml of prewarmed mTESR1 medium was added drop-by-drop and cells were spin 
down for 5 mins at 200x g. Medium was aspirated, cells resuspended in fresh mTESR1 and 
transferred to matrigel/geltrex coated wells. 
 
2.2 Cloning  
miR302 cluster flanked with SgrAI cut sites was amplified from mouse genomic DNA by 
PCR and cloned into TOPO (life technologies K4500-02). miR302 fragment was cut out of 
TOPO-miR302 using SgrAI (NEB) and introduced into the SgrAI site of the rAAV vector.  
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miR302 cluster flanked with BamHI cut sites was amplified by PCR and cloned into TOPO 
(life technologies K4500-02). Shp53 fragment was removed from pCXLE shp53 hOCT4 
plasmid by restriction enzyme digest using BamHI (NEB) resulting in pCXLE hOCT4. 
miR302 fragment was cut out of TOPO-miR302 using BamHI (NEB) and was introduced 
into the BamHI site of pCXLE hOCT4 vector.  
All cloned plasmids were checked by restriction enzyme digestion and sequencing. All 
restriction enzyme digests were done according to manufacturers’ instructions.  
 
2.3 Reprogramming 
 
2.3.1 Using retrovirus 
PLAT A were plated at 2x10
6
 cells per 100 mm dish and incubated overnight. Next day, the 
cells were transfected with pMXs vectors with Fugene 6 transfection reagent (promega 
E2311). Twenty four hours after transfection, the medium was collected as the first virus-
containing supernatant and replaced with a new medium, which was collected after twenty-
four hours as the second virus-containing supernatant. Human fibroblasts were seeded 10
5
 
cells per well of a 6 well plate in MEF medium 1 day before transduction. The virus-
containing supernatants were filtered through a 0.45 mm pore-size filter (Merck Millipore). 
Equal amounts of supernatants containing each of the four retroviruses were transferred to the 
fibroblast dish, and incubated overnight. Twenty-four hours after transduction, the virus-
containing medium was replaced with the second virus-containing supernatant. 48h after last 
transduction fibroblasts were harvested by trypsinization and replated in a 100mm dish 
seeded with 10
6
 Nuff feeders. Next day medium was replaced with hES medium 
supplemented with 4ng/ml bFGF. The medium was changed every day for 30 days. After 10 
days hES replaced by conditioned hES medium.  
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2.3.2 Using rAAV 
rAAV vector particles were made by  transient transfection of 293T using PEI, an adenoviral 
helper plasmid (HGT1), AAV pseudotyped vectors (2, 5 and 8) and transgene plasmids 
(expressing reprogramming factors and miRNA) as described in Davidoff et al.
124
. Virus 
vectors were purified by the previously described ion exchange chromatography method
124
.   
Human fibroblasts were plated at 5-10x10
4
 cells per well from 6 well plate and incubated 
overnight. For 4 days, cells were transduced sequentially with OCT4, SOX2, Nanog and 
Lin28 AAV at MOI of 2x10
6
. 48h after the last transduction, medium was changed to hES 
medium supplemented with 4ng/ml bFGF. The next day fibroblasts were harvested by 
trypsinization and replated in a 100mm dish on a Nuff feeder layer. The medium was 
changed every day for 30 days. After 10 days hES medium was replaced by conditioned hES 
medium. Similar protocol for AAV expressing miRNA 302   
 
2.3.3 Using episomal plasmids 
Proliferating human fibroblasts ready for transfection were harvested by trypsinization and 
10
6
 cells ressuspended in 100µl nucleofector solution (Amaxa Nucleofector kit R - Lonza) 
that had been equilibrated to room temperature. Appropriate amounts of episomal plasmids 
added directly to ressuspended cells: Yamanaka’s plasmids (1µg of each of pCXLE hSK, 
pCXLE hUL and pCXLE shp53 hOCT4), Thomson’s plasmids (7.3µg EBNA EN2L and 
3.2µg EBNA ET2K) and miR302 plasmid (1µg). The cell suspension was gently mixed and 
transferred to a cuvette. Cell suspensions were transfected using program U-023 of Amaxa 
Nucleofector 2b machine. Immediately following transfection, cells were re-suspended in 
10ml of pre warmed MEF medium and transferred to 0.1% gelatinised 100mm dish.  Daily 
medium changes with MEF medium supplemented with 0.5mM sodium butyrate was started 
the next day. On day 7 post transfection, cells were harvested by trypsinization and 10
5
 plated 
into 100mm dish with Nuff feeder cells in MEF medium. The next day, medium was replaced 
with hES medium with 10ng/ml of bFGF and 0.5mM sodium butyrate. By day 12 post 
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transfection, sodium butyrate treatment was stopped and conditioned hES medium 
supplemented with 10ng/ml of bFGF was used instead until day 30 post transfection. 
 
2.3.4 Using episomal plasmids in feeder free conditions 
10
6 
fibroblasts were transfected with episomal plasmids as described above. However, at day 
7 post transfection 2x10
5
 viable cells were seeded into one well of a 6 well plate coated with 
matrigel/geltrex, recombinant vitronectin, laminin-521 or Synthemax-R in mTeSR1 or E8 
medium supplemented with 0.5mM sodium butyrate. At day 12 post transfection, sodium 
butyrate treatment was stopped and cells continued to be cultured in mTeSR1 or E8 only until 
day 30 post transfection. 
 
2.4 Pluripotency 
 
2.4.1 Embryoid body formation 
To demonstrate spontaneous in vitro differentiation, iPS cells were grown to confluency and 
harvested. Cells were re-suspended in hES medium without β-Fgf and transferred to non-
tissue culture treated 6 well plates (Grenier Bio One). Medium was changed every 3-4 days. 
Day 12 embryoid bodies (EBs) were transferred to a 12 well plate coated with 0.1% gelatine 
and cultured for a further 12 days in fibroblast medium. Differentiated cells were harvested 
for RNA isolation. 
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2.4.2 Teratomas 
For in vivo pluripotency, iPS cells were grown to confluency and harvested. Cell pellets were 
re-suspended in 30% matrigel and 70% medium (mTESR1 or E8).Total of one confluent 6 
well plate were used per animal. 6-8 week old NOD-SCID mice were anaesthetised by 
isoflurane inhalation and 50μl of the iPSC suspension was injected into each testis capsule. 
Analgesia (Carprofen, 5mg/kg) was administered intraperitonally following surgery to 
minimise pain. After 10-12 weeks, animals were sacrificed by carbon dioxide asphyxiation 
and teratomas excised and fixed in HistoChoice® Tissue Fixative (SIAL). Histological 
processing and H&E staining were performed by either, The Research Department of 
Pathology, Faculty of Medical Sciences, University College London or The Research 
Department of Oncology, UCL Cancer Institute. 
 
2.4.3 Scorecard 
Pluripotency and trilineage differentiation potential was also assessed using the TaqMan® 
hPSC ScorecardTM kit 384w following manufacturer’s instructions and run on a ViiA 7 
system. Data analysis was performed using the cloud based TaqMan® hPSC ScorecardTM 
analysis software. 
 
2.5 RNA isolation, RT-PCR and qPCR 
MicroRNAs were isolated using mirPremier microRNA isolation kit from Sigma. Reverse 
Transcriptase PCR of microRNA was performed using MultiScrib Reverse Transcriptase 
from Invitrogen. Finally expression was analysed using miR302 TaqMan MicroRNA Assay. 
All procedures were done according to manufacturers’ instructions. 
RNA extraction was performed using RNeasy kit (Qiagen) or using Trizol method 
(Invitrogen).  1-3µg of RNA was used for subsequent reverse transcriptase reactions with 
      
48 
 
Superscript III first strand synthesis system (Life Technologies) as per manufacturer’s 
instructions.  
1µl of cDNA was used per PCR reaction with GoTaq green mastermix (Promega). All -
procedures were done according to manufacturers’ instructions. 
cDNA samples dilutes in appropriate volume in H2O and 5 µl of cDNA was used per qPCR 
reaction with SYBR Green (Quiagen). All procedures were done according to manufacturers’ 
instructions.QPCR data analyzed using the standard curve method for gene expression. 
GAPDH used as endogenous control.  
List of primers used in Table 2 and Table 3 
 
2.6 Phenotype analysis by flow cytometry  
Cells were prepared as a single cell suspension in PBS/0,1% FBS and were labelled with the 
following fluorochrome-conjugated monoclonal antibodies (mABs): APC mouse anti-human 
CD184 (BD pharmingen) and ROR1 (Biolegend). Tra-1-60 (Santa Cruz), Tra-1-81 (Santa 
Cruz), SSEA5 (eBioscience) are non-conjugated mouse monoclonal IgM antibodies used in 
combination with an AlexaFluor®488 goat anti-mouse IgG, IgM (Life Technologies).   
Control staining with appropriate isotype controls was performed using APC mouse IgG1 
(BD Bioscience and Biolegend) and AlexaFluor®488 goat anti-mouse secondary alone. For 
viability cells were stained with propidium iodide (PI, BD Bioscience) and analysed using 
FACS.  
Samples were analysed by using either BD FACSVerse
TM
 flow cytometer with BD 
FACSuite
TM
 software or BD Accuri flow cytometer with BD Accuri C6 software.  
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2.7 Immunostaining 
Cells were washed once with PBS and then fixed with 4% paraformaldehyde (PFA, Santa 
Cruz) for 20 minutes. Cells were washed 3 times with PBS and then stored at 4°C in PBS. 
Prior to immunostaining, cells were blocked for 30 minutes with 5% goat serum (Life 
technologies), 0.1% bovine serum albumin (Sigma) in PBS. If performing nuclear staining, 
cells were permeabilised with ice-cold 100% methanol for 5 minutes prior to blocking. 
Primary antibodies SSEA5, SOX17 (Sigma), HNF4a (Santa Cruz) and AFP (Santa Cruz) 
were used at a 1:100 dilution and used to stain cells at room temperature for one hour. 
Primary antibodies were washed off 3 times with PBS and then goat anti-mouse IgG/IgM 
Alexa 488 diluted 1:400 added. Secondary antibody was incubated at room temperature for 
30 mins. Cells were washed 3 times with PBS and then DAPI (Cell Signalling Technology) 
added for 5-10 mins. Cells were washed 3 times with PBS and immediately visualised. For 
alkaline phosphatase staining, cells were stained with the alkaline phosphatase staining kit as 
per manufacturer’s instructions (Stemgent or Millipore). 
 
2.8 Hepatic differentiation 
The in vitro differentiation protocol was similar to Chen et al. In brief, human iPS cells were 
used either as 70% confluent colonies or as single cells in mTeSR1. For single cell 
differentiation, cells were collected using accutase (Sigma) and plated at 2.6x10
5
 cells/cm
2
 in 
mTeSR1 medium supplemented with Y27632 ROCK inhibitor (CALBIOCHEM).For 
endodermal differentiation mTeSR1 medium was replaced with Roswell Park Memorial 
Institute (RPMI-1640, Sigma-Aldrich) with B27 (Invitrogen), 100 ng/mL activin A 
(Preprotech), 50 ng/mL Wnt3a (R&D Systems), and 10 ng/mL HGF (Life technologies) for 3 
days, medium changed daily. During the next step, the culture medium was replaced with 
hepatic commitment medium: knockout/DMEM containing 20% knockout serum 
replacement, 1 mM L-glutamine, 1% NEA, 0.1 mM 2-mercaptoethanol, and 1% dimethyl 
sulfoxide. By the end of the hepatic commitment stage, cells were collected using accutase 
and plated at 2.1x10
5
 cells/cm
2, cultured in Iscove’s modified Dulbecco’s medium (IMDM, 
Life Technologies) supplemented with 20 ng/mL oncostatin M (R&D systems), 0.5 µM 
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dexamethasone (Sigma), and 50 mg/mL Insulin-Transferrin-Selenium premix (ITS, Life 
Technologies). 
All medium prepared under sterile conditions and filtered through a 0.22 mm pore-size filter 
(Merck Millipore).   
 
2.9 Periodic Acid-Schiff (PAS) Stain for Glycogen  
Cells were fixed in 4% PFA, and then permeabilized with ice cold methanol for 10 min. 
Samples were then oxidized in periodic acid solution (Merck Millipore) for 5 min, rinsed for 
3 minutes in deionized water (dH2O), treated with Schiff’s reagent (Merck Millipore) for 15 
min, and rinsed in dH2O for 3minutes. Samples were counterstained with hematoxylin 
solution (Merck Millipore) for 2 minutes and then rinsed in dH2O for 3 minutes. Cells were 
incubated sequentially in ethanol 70%, 96% and 100% for 2min each. Lastly cells were 
incubated with Xylene (Merck Millipore) for 5 minutes and finally samples were observed 
under the light microscope.  
 
2.10 ELISA Analysis 
 For the determination of Albumin production by Hepatocyte-like cells, cells and blood 
samples were collected and used in human serum albumin kit (Aviscera Bioscience). 
 
2.11 Liver failure model 
Male BALB/c nude mice, 8 weeks old and weighing 15–20 g, were used for our experiments. 
Fulminant hepatic failure was induced by Intra Peritoneal (IP) injection of CCl4 (Sigma) 2.5 
mL/kg body weight; 1:10 v/v in mineral oil. Solution kept on ice until IP injection in nude 
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mice using insulin syringes (TERUMO). Hepatic damaged assessed by measurement of 
survival and histological analysis of organs.  
For liver rescue, 24 hours after CCl4 administration, mice were injected with Hepatocyte-like 
cells day 8 or Hepatocyte-like cells day 13.  1x10
6
 cells/mouse diluted in PBS were 
administered via tail vein injection in a total volume of 100µl. In order to observe rescue of 
hepatic damage, measurement of survival and collection of organs for histological analysis 
was performed.  
 
2.12 Isolation of mouse embryos 
CD1 mice were mated, and conception was assessed by the presence of a coital plug with 
morning of the plug being scored as 0.5 days post coitum  (E0.5). Pregnant females were 
sacrificed at various developmental time points and embryos were carefully removed by 
dissection. 
Dissection of embryos was done under microscope with separation of the liver bud from the 
rest of the embryo when possible (termed “liver” and “embryos” respectively). Samples of all 
embryos from same plug were pulled together (except for E11.5 where individual embryos 
were enough for RNA extraction). Samples were placed in liquid nitrogen and stored at -80C 
until RNA isolation.  
 
2.13 GEO datasets 
Query GEO to obtain list of datasets fitting our settings (foetal mouse liver samples and 
human iPSC hepatic differentiation). Gene expression data was obtained and analysed using 
Affymetix consoles: Expression Console (EC) and Transcriptome Analysis Console (TAC). 
Figures obtained from TAC both on hierarchical clustering and gene expression data. 
Affymetrix programmes downloaded from Affymetrix site. 
      
52 
 
2.14 Bioinformatics 
Bioinformatics analysis of our RNA-seq data starts with aligning the reads to the reference 
sequence, the human genome (EnsEMBL build 70, accessed October 2014) using STAR, a 
splice-aware aligner. The advantage of aligning to the reference genome is the identiﬁcation 
of novel features, if any. We have not found any such feature, which in respect to what we 
are looking for, is good since our genes of interest are already very well annotated in the 
human genome. Post-alignment analysis includes the quantiﬁcation of gene or transcript 
isoform expression. The RNA-seq data are “analogous” and the quantiﬁcation of expression 
is based on the one-to-one relationship between RNA fragments and reads (Figure 7). The 
quantiﬁcation process requires a normalisation step that takes into consideration the length of 
the gene or transcript and the total number of reads mapped. Expression is reported in 
Fragments Per Kilobase of transcript per Million mapped reads (FPKMs). Downstream 
analysis includes guided assembly of the transcriptome, where the assembly uses any existing 
transcript annotation as a guide
125
 and differential expression analysis for the identiﬁcation of 
statistically signiﬁcant differences in expression levels between different conditions126-128.  
 
2.14.1 RNA-sequencing Analysis 
RNA samples were obtained as previously described (section2.5). RNA sample preparation 
kit and paired-end sequenced to a length of 125 bp from 3 biological replicates for each of the 
four time points of day 0 (d0), day 4 (d4), day 8 (d8) and day13 (d13) during hepatocyte 
differentiation of iPS cells (Figure 8). The RNA-seq reads were mapped to the transcript and 
cDNA sets of the Ensemble human genome (version 70) using STAR and Bowtie 1.0.1 
allowing for multiple mapping between reads and transcripts.  The resulting BAM files were 
merged using SAMTOOLS and made ready for further quantification analysis. 
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Figure 7 – One-to-one relationship between RNA fragments and reads. Adapted and edited from Garber et al. 129 
 
 
 
Figure 8 - Time-series RNA collection for analysis 
2.14.2 Quantifying RNA-seq data 
The resulting transcriptome alignments were used in MMSEQ gene expression algorithm to 
further quantitatively estimate transcript and gene expression levels. The MMSEQ gene 
expression analysis tool was used to estimate transcript expression levels (read counts). To 
perform a sample by sample comparison and estimate the expression from the RNA 
concentration in each microarray sample, the MMSEQ marginal posteriors for the set of 
Ensembl 70 transcripts mapped to by each Illumina BeadChip probe were collapsed. 
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Similarly, MMSEQ collapses marginal posteriors for the set of transcripts belonging each 
gene, thus providing gene-level expression estimates. Note that the expression estimates are 
roughly proportional to the RNA concentrations in each sample. The marginal posterior mean 
(log_mu) and the posterior standard deviation (ds) of the mean corresponding to each 
transcript or set of transcripts (i.e., gene or probe) from the MMSEQ analysis was then used 
as the outcome in a Bayesian model selection algorithm implemented in the MMDIFF 
method and count data in the DNASeq2 software.  
 
2.14.3 Rna-seq Analysis 
DNASeq2 performs differential gene expression analysis based on the counts data from the 
MMSEQ results. The count data was normalized and quantified for the statistical inference of 
systematic changes between time point conditions (d0, d4, d8, d13). DNASeq2 was used to 
check if the results from MMDIFF
130
 could be reproduced. Similarly, the log_mu and sd from 
MMSEQ were quantified for the statistical inference of differential expression and fold 
change between two conditions in the regression based MMDIFF model which allows for 
comparison of complex experimental designs (Figure 9).  
 
 
Figure 9 - Background of transcript quantification using MMSEQ and MMDIFF. Figure adapted from Turro et al130. 
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The hypothesis of this study (based on what was observed in QPCR) was that few of the 
coagulation genes are expressed between d4 and d8 during hepatocyte differentiation and 
therefore the transcription factors required for the expression of these coagulation genes must 
be activated prior or along with these genes. Therefore, clustering and modeling the genes 
differentially expressed should result in identification of clusters within coagulation cascade 
based on their point of expression and expanding the same onto the entire data set would help 
identify the master regulators of the coagulation cascade. For differential analysis, the 
following design matrices were compared to quantify the differences in fold levels between 
d0 and d4, d4 and d8, d8and d13 and d0d4 vs d8d13 (difference of difference of fold-change 
between two groups of two time points): 
 
𝑀(0) = (1 1 1   1 1 1   1 1 1   1 1 1 )𝑇 
 
𝑀(1) = (
1 1 1
0.5 0.5 0.5
   1 1 1
   0.5 0.5 0.5
    1 1 1
   −0.5 −0.5 −0.5
   1 1 1
  −0.5 −0.5 −0.5
)
𝑇
 
 
In another model, in order to quantitatively asses, if the log-fold change in expression 
between d0, d4, d8 and d13 differed with time, models were compared using the following 
matrix: 
 
𝑀(𝑑0,𝑑4,𝑑8,𝑑13) = (
1 1 1
0 0 0
   0 0 0
   1 1 1
    0 0 0
    0 0 0
   0 0 0
   0 0 0
0 0 0
0 0 0
   0 0 0
   0 0 0
    1 1 1
    0 0 0
   0 0 0
   1 1 1
)
𝑇
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In both models, the rows correspond to d0, d4, d8 and d13 in consecutive set of three 
replicates and the prior distribution for the global intercept was fixed to alpha=0. To identify 
differentially expressed genes between d0d4 and d8d13, the simple model assumed that the 
log-fold change between d0 and d4 was the same between d8 and d13, while the more 
complex model allowed the log-fold changes to differ. The prior probability of the more 
complex model being true was set to 10% (p=0.1). The posterior probability of the more 
complex model (Bayes Empirical factor) was used as the basis for preferring the more 
complex model (differential expression or difference of difference, respectively) to the 
simpler model in order to check if a set of genes were expressed between different time 
points.  Only genes that were differentially expressed with a posterior probability< 0.5 were 
considered (note that posterior probability is different from p value). 
 
2.14.4 Promoter Sequence Analysis for potential TFBS 
The 5’UTR sequences of the 14 coagulation genes were obtained from Ensembl Genome 
Browser using in-house Perl scripts via Ensembl Perl API.  These sequences containing 
transcription factor binding sites (TFBS) were aligned using pro-coffee which uses a 
substitution matrix estimated on TRANSFAC multiple sequence alignments of TFBS.  The 
alignment was manually curated and studied for potential TFBS that are shared between the 
coagulation genes keeping in mind their evolution. 
 
2.14.5 Statistics 
All the statics were performed in R, unless otherwise stated. Where p-values have been 
compared between different groups, Q-values from False Discovery Rate analysis have been 
calculated.  
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2.14.6 DATA 
In addition to the sequence and TF data mentioned above, we also built local databases of 
human genes with meta data that allows extracting, genes expressed in the liver. All the gene 
names and IDs (ENTREZ, ENSEMBL, HGNC) were obtained from Ensembl BioMart and 
stored in our local database for easy access.  
 
2.14.7 Graphs  
All the graphs have been generated in R and networks drawn using Cytoscape 3.0. Inkscape 
was used to edit and generate publication quality high-resolution graphics. 
 
2.15 siRNA 
HNF4a siRNA (HNF4a ON-TARGET plus SMART pool) and negative control siRNA (ON-
TARGET plus non-targeting pool) were purchased from Dharmacon.  
HUH7 and HepG2 cells were plated at suggested densities in D10 medium: DMEM 
supplemented with 10 % HF FBS and incubated overnight. On day 1, cells were transfected 
with 25nM of siRNA using Dharmafect reagent according to manufacturer’s instructions 
Cells were incubated for 36 hours and used for further experiments: viability (PI staining), 
gene expression and western blot.  
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2.16 Western Blotting 
Whole cellular protein extracts were obtained by incubating cell pellets with RIPA buffer 
(Sigma) supplemented with protease inhibitor (Roche) for 5 minutes, spinning down at 8500g 
for 10 min and collecting supernatant.  Use protein or store at -80C until use.  
Protein extracts were run in a NuPAGE 10% Bis-Tris gel (novex) 125V, 35mA for 2h. 
Protein was transferred to a nitrocellulose membrane (Bio-Rad) for 1:30 hours at 25V, 
125mA. 
Membrane was blocked by incubation with 5% non-fat milk in TBST (10 mM Tris, pH 8.0, 
150 mM NaCl, 0.5% Tween 20) for 60 min. After incubation the membrane was washed once 
with TBST and incubated with antibodies against HNF4a (Santa Cruz) at 1:1000 and 
GAPDH (Cell Signalling) at 1:2000 at 4 °C overnight. Membranes were washed three times 
for 10 min and incubated with a 1:3000 dilution of horseradish peroxidase-conjugated anti-
mouse (Dako) or anti-rabbit (Dako) antibodies for 2 h. Blots were washed with TBST three 
times and developed with the ECL Western Blotting substrate (thermos scientific) according 
to the manufacturer’s protocols 
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2.17 Primers 
Table 2 – List of human Primers 
Name Sequence 
GAPDH Fwd GGCAACAATATCCACTTTACC 
GAPDH Rv GGAGTCAACGGATTTGGTCGT 
OCT4 Fwd GACAGGGGGAGGGGAGGAGC 
OCT4 Rv CTT CCC TCC AAC CAG TTG CCCCAA AC 
SOX2 Fwd GGG AAA TGG GAG GGG TGC AAA AGA GG 
SOX2 Rv TTG CGT GAG TGT GGA TGG GAT TGG TG 
Nanog Fwd CAGCCCCGATTCTTTCCACCAG 
Nanog Rv CGGAAGATTCCCAGTCGGGTT 
REX1 Fwd CAGATCCTAAACAGCTCGCAG 
REX1 Rv GCGTACGCAAATTAAAGTCCA 
SOX17 Fwd CAG TGA CGA CCA GAG CCA GAC C 
SOX17 Rv CCA CGA CTT GCC CAG CAT CTT 
CXCR4 Fwd CCGCATCTGGAGAACCAGC  
CXCR4 Rv GGTGCAGCCTGTACTTGTCCG 
Nestin Fwd AGCGTTGGAACAGAGGTTGG 
Nestin Rv CCTCTGGGGTCCTAGGGAAT 
Brachyury Fwd ATGATGGAGGAACCCGGAGA 
Brachyury Rv ACTGCATCTTTCGGGACCTG 
FoxA2 Fwd CTACGCCAACATGAACTCCA 
FoxA2 Rv CGGTAGAAGGGGAAGAGGTC 
HNF4a Fwd CCA  AGT ACA TCC CAG CTT TC 
HNF4a Rv TTG GCA TCT GGG TCA AAG 
AFP Fwd CCAAACAAAGGCAGCAACAG 
AFP Rv CAGACAATCCAGCACATCTCC 
Albumin Fwd AACCTCTTGTGGAAGAGCCT 
Albumin Rv GACCACGGATAGATAGTCTTCTG 
TTR Fwd CATGCAGAGGTGGTATTCACAG 
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TTR Rv TTGGTTACATGAAATCCCATCCC 
Fibrinogen A Fwd AACCGTGATAATACCTACAACCGA 
Fibrinogen A Rv AATATCAATGTCCACCTCCAGTC 
Fibrinogen B Fwd AATATCCCAACTAACCTTCGTG 
Fibrinogen B Rv TTTCCTCACATTCTTTGCCA 
Fibrinogen G Fwd TGTGTTTCAGAAGAGACTTGATGG 
Fibrinogen G Rv ATATGTTAGGCGGTACTTGTCAG 
Prothrombin Fwd ACATAAGCCTGAAATCAACTCC 
Prothrombin Rv CGCTACAGTGACTTGATCCT 
FV Fwd CCATTTCAGGACTTCTTGGG 
FV Rv TCCATTCATAGGTGTATTCTCGG 
FVII Fwd CACACCCACAGTTGAATATCC 
FVII Rv GCTCCATTCACCAACAACAG 
FVIII Fwd CGCAAGATTTCCTCCTAGAGTG 
FVIII Rv GACCTAGCAGACCCATCCAG 
FIX Fwd TCGGCCAAAGAGGTATAATTCAG 
FIX Rv GATCTCCATCAACATACTGCTTCC 
FX Fwd GGAAAGTCTGTTCATCCGCA 
FX Rv GCCTTCGAATCCTTCTAAACAG 
FXI Fwd TTACACAGATTCTCAACGACCC 
FXI Rv CCTACCAGATGCCAGACCTC 
FXII Fwd AGTCAACACTTTCGATTCCACC 
FXII Rv GGTCTTTCACTTTCTTGGGCT 
FXIIIa Fwd CGAAACCCAGAAACAGACAC 
FXIIIa Rv ATGCCATCTTCAAACTGACCA 
FXIIIb Fwd AACTCTATGCAGAAGAGAAACCC 
FXIIIb Rv GTTTGCTCTTCTTGTCTTCCA 
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Table 3 - List of mouse Primers 
Name Sequence 
GAPDH Fwd TGG AGA GCC CGC TCA GAC CC 
GAPDH Rv GGA TTG GGT GTC CCT GCG CC 
Fibrinogen B Fwd TCTGGGAAAGAGTGTGAGGA 
Fibrinogen B Rv GCCAAGCCAATATTCACCTG 
Fibrinogen G Fwd GTAGTTTCTGCCCAACCACC 
Fibrinogen G Rv TCCTGTAAATACCGAATGCTTGTC 
Prothrombin Fwd ACAAGCCTGAAATCAACTCC 
Prothrombin Rv TGTTGTCACAGCCAAATTCC 
FV Fwd CAAACGCCATTTCTCATCATAGAC 
FV Rv CTCCCAATAAGTCAGATATTCCGA 
FVII Fwd ATGAGGACTACACGCTACAG 
FVII Rv GAAGTCATGTTCACCCATCAC 
FVIII Fwd GGCACTCAGAAACAAACGAC 
FVIII Rv CATCCAATCAGACCTGGAAGAG 
FIX Fwd GCTCTCATCACCATCTTCCT 
FIX Rv ACACTGATCTCCATCAACATACTG 
FX Fwd CTGCTCAACCTCAACGAGAC 
FX Rv GTGTTCCGATCACCTACCCT 
FXI Fwd AGTGTCCCAGTATTCTGCCA 
FXI Rv GAGTATCCAGAGATGCCTCCC 
FXII Fwd TTTCCCTTTCAGTACCACCGT 
FXII Rv GGCTCAAAGCATTTCTCTTTCTG 
FXIIIa Fwd AGGAAGTACCCAGAGGCACA 
FXIIIa Rv CCCTCTGCGGACAATCAACT 
FXIIIb Fwd CCAAGGTGCTACAAGAAATGTC 
FXIIIb Rv GCATGTGTAAGCCACTATGTC 
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Chapter 3 Integration free reprogramming method 
 
3.1 Introduction  
 
Pluripotent stem cells have unlimited self-renewal and the capacity to differentiate into all 
cell types of the three germ layers: endoderm, mesoderm and ectoderm. Therefore, they have 
enormous potential for regenerative medicine as they can serve as an endless source of cells 
for the repair, replacement or regeneration of damaged or diseased tissues.  Furthermore they 
can serve as an important tool for the study of disease mechanisms as well as drug testing. 
ESCs are such cells and great promise surrounded them after their discovery. 
In 1998, James Thomson derived the first human ESCs from the ICM of the blastocyst
131
. 
Since then, many protocols have been developed showing that ESCs can be differentiated 
into cells of various lineages including neurons, cardiomyocytes, blood progenitors, 
hepatocytes and retinal precursors 
132
. However, the use of human ESCs has been hindered by 
the ethical concerns over the destruction of embryos. Another drawback is the difficulty in 
generating patient- or disease-specific ESCs due to the logistical difficulties in obtaining 
embryos. 
In 2006 a breakthrough was achieved by Kazutoshi Takahashi and Shinya Yamanaka when 
the first iPSCs were created from murine fibroblasts
14
. These iPSCs were obtained by the 
over-expression of four transcription factors: Oct4, Sox2, Klf4 and c-Myc by retrovirus-
mediated transduction of fibroblasts
14
. These 4 factors were chosen from a list of 24 genes 
that had been shown to be crucial for maintenance of pluripotent stem cell identity and 
proved to be sufficient for iPSC formation
14
. A year later, the same group generated human 
iPSCs using the same 4 transcription factors
133
. The mechanisms by which the 
reprogramming occurs are poorly understood but it was clear that the expression of the 
exogenous genes was only transiently required as upon reprogramming of pluripotent state, 
the endogenous genes Oct4, Sox2 and Nanog are reactivated, while the transgenes are 
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silenced. The generated iPSCs are similar to ESC in morphology, growth properties and the 
expression of phenotypic markers. Teratoma formation was used to assess the pluripotency of 
the iPSCs and confirmed the ability of these cells to differentiate into all three germ layers in 
vivo.  Despite the similarity between ESCs and iPSCs, these are not identical with small 
differences in gene expression and DNA methylation patterns
82, 85
. Interestingly, the same has 
been observed between different ESC lines
134
 and some studies show that is difficult to 
distinguish between iPSCs and ESCs
90, 91
, thus the implications of these minor differences 
remain unclear.  
Soon after Yamanaka’s discovery, Thomson revealed a different combination of 
reprogramming factors, Oct4, Sox2, Nanog and Lin-28 (OSLN) which were also capable of 
generating iPSCs
135
. This combination lacked the known oncogene, c-Myc and was therefore 
deemed to be safer. Since then, many other combinations of reprogramming factors have 
been described. Some of these combinations include the use of chemicals and/or small 
molecules such as valproic acid and RepSox which can replace some of the transcription 
factors
20
 
136
. It has also been extensively demonstrated that the somatic cell type can greatly 
influence the efficiency of iPSC derivation, for instance, CD34+ cord blood stem cells have 
been found to be one of most easily reprogrammed
15
. The multitude of factors and molecules 
found to influence in the reprogramming process shows the complexity and highly 
interconnected pathways necessary for the establishment of the pluripotent state (Figure 10).  
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Figure 10 - iPSC generation methods. Factors affecting iPSC reprogramming can be categorized into four groups (1) the 
origin of the cells (2) the induction method (3) the combination of reprogramming factors and (4) the culture conditions 
 
With the realization that pluripotency could be achieved using a wide range of methods, 
people started focusing their efforts on creating ‘safer’ iPSCs in anticipation of their use for 
cellular therapies. This was done by decreasing their tumorigenic potential, mainly working 
on two requirements: avoiding the use of genome-integrating methods and removal of 
oncogenes in the reprogramming factor cocktail. By using integrative methods we risk the 
activation of oncogenes and/or disruption of tumour suppressing genes which would thwart 
their use in a clinical setting. By using reprogramming factors that include oncogenes, such as 
c-Myc, there is always the risk of their re-activation.  
Many methods for generating iPSCs without the use of integrating vectors or oncogenes have 
since been developed. However, some of these methods such as the Cre-deletable viral 
vectors and PB transposons are not strictly integration free as they can leave genomic scars 
behind
137
. While other methods, such as protein delivery, avoid the introduction of exogenous 
genetic material, they are weighed down by low efficiency and slow kinetics of 
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reprogramming
138
. The advantages and disadvantages of some of the methods are outlined in 
Table 4.  
Despite the work done on developing the different methodologies, not much work has been 
invested on comparing them side by side – the only way to truly access which one is the best 
in terms of efficiency. With the wide range of methods available it is impossible to perform a 
systematic comparison between them all. With the goal of clinical translation, we decided to 
choose the methods that showed the greatest potential amongst the integration-free methods: 
viral delivery, episomal plasmid delivery and RNA delivery and compared this with the 
original retrovirus standard. 
Table 4 – Summary of advantages and disadvantages of different reprogramming method 
Reprogramming method Advantages disadvantages 
Retrovirus Efficient and stable Genome integration; transgenes 
present in the genome which may 
not be properly silenced 
Lentivirus Efficient and stable Genome integration; residual 
expression of the transgenes 
Adenovirus Rare genomic integration and 
vector lost by dilution 
Slow and inefficient 
Episomal non-replicative 
vectors 
Rare genomic integration Multiple transfections required; 
Slow and inefficient;  
oriP/EBNA episomal 
vectors 
Rare genomic integration Slow and low efficiency 
Mini circle Rare genomic integration Slow and low efficiency; labour-
intensive 
RNA No genomic integration; higher 
efficiency than retrovirus; No need 
to screen numerous colonies 
Multiple transfections required; 
Expensive; labour-intensive 
Proteins No genomic integration; No need to 
screen numerous colonies 
Slow and inefficient; Expensive 
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3.2 Viral delivery systems for reprogramming  
 
Two different viral approaches have been shown to produce integration free iPSC: adenovirus 
and Sendai virus
45
 
47
. The efficiency of the adenovirus approach was found to be 3 orders of 
magnitude lower than the retroviral approach (0.0001%-0.0018%) and hepatocytes were the 
only cell type that could be successfully reprogrammed without the help of a complementary 
vector
45
. On the other hand, F-deficient Sendai virus could reprogram both fibroblasts and T-
cells to a pluripotent state while viral RNA was not detected in the resulting iPSCs. Despite 
the use of Sendai viral vectors with a single gene defect, safety and regulatory concerns 
remain since F-deficiency only decreases the likelihood of viral self-replication but does not 
eliminate it. A further hindrance for the use of sendai virus in a clinical setting, is their high 
cost relative to other methods, which could eventually limit the availability of this technology 
to patients
47
.  
 
3.2.1 AAV reprogramming  
A recombinant adeno-associated virus (rAAV) vector mediated reprogramming of human 
somatic cells, could represent a new integration free viral method of reprogramming since 
AAV genomes normally don’t integrate into the host’s genome. rAAV offers a “hit and run” 
strategy for reprogramming somatic cells as they are kept episomally and are lost over time 
with cellular division. Furthermore, AAV vectors are attractive for generating clinical grade 
iPSCs as they have a great safety record in humans 
139
 
140
.  
The efficiency of rAAV transduction to fibroblasts was first optimised to ensure that the 
reprogramming factors could be delivered into the cells. As certain AAV serotypes are 
known to have tropism for different cell types, we first sought to determine which serotype 
would be best for transducing human fibroblasts. We generated rAAV containing the green 
fluorescence protein (GFP) transgene with 3 different serotypes: AAV2, AAV5 and AAV8. 
AAV8 showed the lowest transduction efficiency (24%) as expected, due to its tropism for 
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liver cells while AAV2 and AAV5 showed similar GFP expression (74±8% and 72.5±4% 
respectively) (see Figure 11). Due to the low yields of AAV2 during virus production, AAV5 
was chosen for generating rAAV containing the reprogramming factors. As we aimed to use 
an integration-free reprogramming method and avoid the use of oncogenes, we decided to go 
with Thomson’s set of transcription factors135 (OSLN) as these are deemed to be safer than 
Yamanaka’s original set (OSKM). 
 
Figure 11 –Transduction efficiency of IMR90 fibroblasts using different AAV serotypes. Transduction of IMR90 
fibroblasts with AAV serotypes 2, 5 and 8 expressing GFP under CMV promoter. AAV virus were added to 
IMR90 cells and incubated for 48h before accessing transduction efficiency. Transduction efficiency as percentage 
of GFP positive cells as detected by flow cytometry.. 
 
A limitation of rAAV is the packaging capacity (approximately 4.7kb). Due to the size of the 
transcription factors (approximately 1000 base pairs or more), it was necessary to generate 4 
different rAAV particles for each of the 4 transcription factors (OSLN). rAAV expressing 
GFP was also generated to allow the transduction efficiency to be measured. As a control, we 
first demonstrated that both the BJ cell line (derived from foreskin of newborn human) and a 
primary patient cell line (RPD1) could be readily transduced with GFP retrovirus (BJ: 
97.8±0.318%; RDP1: 98.8±0.084%). The same cell lines could also be transduced with 
rAAV GFP (BJ: 85.5±0.707%; RDP1: 79.5±0.707%) at similar efficiencies, as shown in 
Figure 12.   
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Figure 12 - Comparison of GFP transduction efficiency of fibroblasts using retrovirus and rAAV. Transduction of BJ 
and RDP1 cell lines using retrovirus and rAAV expressing GFP under CMV. AAV virus were added to IMR90 cells and 
incubated for 48h before accessing transduction efficiency. Transduction efficiency as percentage of GFP positive cells as 
detected by flow cytometry. 
 
The lack of knowledge regarding the process of reprogramming with AAV led us to decide to 
add the virus to the cells under two different conditions: all factors together and sequential 
addition of each factor. Addition of all the factors mirrors the original retroviral 
reprogramming protocol while the sequential introduction of factors would work as an 
attempt to increase the levels of expression of the individual factors, as later corroborated by 
Liu et al.
141
.  
While 4 factor transduction of BJ and RDP1 cells with retroviruses resulted in 112 and 49 
TRA-1-81 positive iPS cell colonies, respectively,  no successful reprogramming was 
achieved using rAAV in both conditions (n=2). A possible reason for this may be the 
competitive nature of rAAV particles. This competitive nature results from the fact that 
single-stranded rAAV with sense (plus) and anti-sense (minus) orientation are packaged 
equally well and upon transduction these form transcriptionally active dimers by the 
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annealing of single-stranded (ss) molecules with opposing polarities. This is an inefficient 
process under normal conditions and the presence of four different ssAAV cassettes in the 
same cell raises the possibility of reducing the efficiency by which double stranded AAV 
expression cassettes are formed. Serial transduction of each factor potentially offers a level of 
protection from this mechanism but it may not be enough. Alternatively, it is possible that the 
4 factors were not expressed in the target cells at the right time and levels required to promote 
reprogramming. Therefore, it may be advantageous to reprogram using only a single rAAV 
cassette that dispenses the need for 4 different rAAV vectors. Due to the limiting packaging 
capacity of rAAV, it isn’t possible to construct a polycistronic vector containing all 4 factors. 
Under this premise we thought of using a single cassette expressing microRNA (miR) 302 
cluster for AAV reprogramming.  
In 2011, microRNAs were also shown to be capable of inducing pluripotency
23
. MicroRNAs 
are small single stranded RNA molecules of about 22 base pairs that bind to complementary 
sequences in mRNA and regulate expression by gene silencing. These regulators are present 
in the human genome and are thought to target around 60% of the genome
142
. Due to the 
redundancy of each molecule, a single miRNA can have up to hundreds of targets. 
MicroRNAs are known to regulate development and differentiation throughout different 
tissues
143
 
144
. In ESCs, the expression of specific miRNAs is critical in the control of 
pluripotency-related genes
145
 
146
. Of these pluripotency associated miRNAs, the miRNA 302 
cluster (miR302) showed concomitant expression with OCT4 through development and in the 
same tissues, as well as being a direct target of both OCT4 and SOX2 – two of the critical 
factors required for iPSC reprogramming
147
. This cluster consists of 5 different miRNAs 
which are transcribed together, four of which belong to the miR302 family and are highly 
homologous:  mir-302b, mir302c, mir302a, mir302d and mir367 
148
. Reprogramming into an 
iPSC state was achieved directly using this miR302 cluster alone at a higher efficiency than 
with the standard OSKM retroviral method
23
. The use of molecules which lacks any further 
processing (protein translation) might be one of the underlying reasons of the higher 
efficiency observed. The multitude of miRNA targets may also allow for faster and more 
coordinated reprogramming.  However, in this report, the miR302 cluster was expressed in 
lentiviral vectors which are not the ideal methodology as these vectors integrate within the 
host’s genome23.  
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We exploited this finding by attempting to reprogram our cells using a single rAAV particle 
expressing the miR302 cluster alone. However, no iPSC colonies could be generated using 
this method. Expression of the mir302 cluster could be detected in transient transfections of 
293T cells with the miR302 vector plasmid but when the same 293T cells were transduced 
with the rAAV-miR302, the micro RNA could not be detected. The reasons for this are not 
clear but it is possible that interaction of the miR302 with the secondary structures of the 
inverted terminal repeats (ITR) within the genome of the single stranded proviral DNA could 
have interfered with its expression.  
During this period, Weltner and colleagues reported that rAAV of the 4 factors could be used 
to induce pluripotency in MEFs but not in human fibroblasts
149
. In this study, high viral titers 
were used to ensure adequate transduction which may be the reason behind the increased 
incidence of rAAV vector integration into the host genome. Furthermore, the authors found 
that the integrated rAAV transgenes were not silenced over time. Regardless of the 
underlying reason, this finding excludes rAAV as an integration-free approach. The low 
reprogramming efficiencies of MEFs (0.001-0.09%) coupled with the high rates of rAAV 
vector genome integration made the rAAV method unsuitable for generating clinical grade 
iPS cells and so the rAAV approach was abandoned. 
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3.3 Episomal reprograming 
 
Episomal plasmid vectors carrying the OSKM factors were first used to successfully induce 
pluripotency in MEFs but were unable to produce any iPSCs from human cells
150
 
49
 
50
. 
Possible reasons behind this failure are the low transfection efficiency of large plasmids, 
dilution of vectors in actively proliferating cells, or even the silencing of prokaryotic 
sequences contained in these vectors, which leads to a down regulation of the transcription 
factors. The timing of this down regulation is critical as human cells require a longer 
expression of OSKM than MEFs to reach pluripotency.   
Thomson was able to circumvent the problem of episomal dilution by using the oriP/EBNA1 
episomal vector
51
. These plasmids can be transfected without the need for viral packaging, 
are maintained episomally throughout cell division and without selection are lost at ~5% per 
cell generation, thereby allowing removal of the vectors but still giving it enough time for the 
reprogramming process. In this way, Thomson was able to generate iPSC from human 
fibroblasts by introducing a combination of 7 transcription factors: OCT4, SOX2, NANOG, 
LIN28, c-MYC, SV40 T large antigen and KLF4
51
. Although representing the first successful 
case of episomal derived human iPSC, the efficiency of the process was extremely low (3 to 
6 x10
-6
 %).  
To try and improve the efficiency of episomal reprogramming, Yamanaka combined 
Thomson’s findings with two of his own: p53 suppression greatly enhances iPSC formation 
and L-Myc is more potent and specific than c-Myc during human iPSC generation
52
.  In this 
way Yamanaka created his own set of oriP/EBNA1 vectors with 6 transcription factors 
(OCT4, SOX2, NANOG, LIN28, L-MYC and KLF4) and a small hairpin (sh) for p53. By 
introducing these 2 changes Yamanaka reported a higher efficiency than Thomson, producing 
integration free iPSCs at an efficiency suitable for stem cell therapy
52
. Even though 
Yamanaka showed a higher reprogramming efficiency, the differences between labs (from 
the technician, media and methods utilised) can affect the efficacy of the process, and so a 
side by side comparison in the same lab will be able to eliminate these from the equation. For 
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this reason we decided to first compare the Thomson episomal plasmids (encoding Oct4, 
Sox2, Klf4, c-Myc, Nanog, Lin28 and SV40 large T antigen) with the Yamanaka episomal 
plasmids (encoding Oct4, Sox2, Lin28, L-Myc and p53 shRNA) in order to confirm  what 
was shown in the literature. 
 The method for generating integration free iPSCs using episomal plasmids is simple, 
involving only a single transfection and thus has great potential for clinical translation. 
However, the protocol requires further optimization as the reported reprogramming 
efficiencies are relatively low compared with the retrovirus standard
51, 52
. For episomal 
reprogramming, the same stock and passage of the BJ fibroblast cell line used in the previous 
rAAV experiments were used here. The transfection efficiency of BJ fibroblasts using 
plasmids as measured by the pCXLE GFP construct was approximately 36±8.1% 
(mean±SEM, n=4) at 24 hours after electroporation (see Figure 13). 
 
Figure 13 - Transfection efficiency of human fibroblasts. GFP plasmid transfection of BJ fibroblasts analysed by 
immunofluorescence and FACs. Episomal plasmid (1µ) added directly to cells ressuspended in 100µl nucleofector solution 
(Amaca Nuclofector Kit R).Transfection efficiency as percentage of GFP positive cells as detected by flow cytometry. Scale 
bar is 200µm. 
 
Morphology changes in fibroblasts were observed in induced cells with the Thomson 
plasmids as early as 7 days post transfection (see Figure 15A), while for the Yamanaka 
plasmids, changes were first observed at days 10-12. However, by days 25-30 more iPS-like 
colonies emerged from Yamanaka plasmids, with better morphological features than with the 
Thomson plasmids (Figure 15B and Figure 15C). Bona fide iPSC colonies were identified by 
TRA-1-81 live staining and 43±29 colonies were observed for Yamanaka plasmids compared 
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with only 10.5±2.5 positive colonies for Thomson plasmids (n=2). After taking into 
consideration the transfection efficiency, the computed reprogramming efficiency of the 
Yamanaka plasmid combination was found to be over 10 fold greater (0.012±0.008% 
Yamanaka vs 0.003±0.001% Thomson) at generating iPS cells and was therefore used in all 
subsequent experiments. Reprogramming using patient fibroblast lines showed similar 
efficiencies to the BJ line (Supplementary figure 1).  
 
 
Figure 14 - Schematic of the cloning of the miR302 cluster into the pCXLE hOct4-shp53 plasmid  
 
As with the rAAV strategy we decided the implement the miR302 cluster in the episomal 
plasmid approach to see if we could improve the efficiency observed with the Yamanaka 
plasmids. Therefore, the miR302 cluster was cloned into one of the episomal plasmids, 
pCXLE-hOct4-shp53, specifically the miR302 sequence replaced the shp53 sequences in this 
plasmid (see Figure 14) due to the similar pathways between miRNAs and sh RNAs.  
      
74 
 
 
Figure 15 - Reprogramming with Yamanaka’s, Thomson’s and miR302 vectors. Phase contrast pictures of BJ 
fibroblasts reprogrammed using episomal plasmids A. BJ fibroblasts transfected with Thomson’s vectors at day 7. B.  BJ 
fibroblasts transfected with Thomson’s vectors at day 30. C. BJ fibroblasts transfected with Yamanaka’s vectors at day 30. 
D. BJ fibroblasts transfected with miR302 vector at day 30. 
 
Transfections of BJ fibroblasts were performed with Yamanaka’s episomal plasmids and the 
new miR302 plasmids to allow a side-by-side comparison. Some conformational changes 
could be observed in fibroblasts transfected with miR302 plasmid although no fully 
reprogrammed cells were present (see Figure 15D). To determine the reason behind this 
observation, BJ fibroblasts were transfected with the new pCXLE-hOct4-miR302 plasmid 
and its miR-302 expression level was compared with the H1 hESC line and un-transfected BJ 
fibroblasts. miR302 expression could be detected in transfected cells but levels were 3 orders 
lower than in hESCs (see Figure 16). The low expression levels reported for miR302 are the 
most likely reason for the absence of colonies as it has been shown that for efficient 
reprogramming of hair follicles, expression of miR302 needs to be at least 1.3 fold higher 
than in hESCs
151
. Even though miR302 can indeed achieve reprogramming, its use is 
dependent on the expression levels achieved. The delivery system can also impact on the 
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efficiency, as observed when the use of synthetic mature miRNAs 
152
 for reprogramming did 
not match the levels observed with lentivirus. 
 
Figure 16 - Comparison of miR302 expression levels. miR302 expression levels in H1 ES cell line, BJ fibroblasts and BJ 
fibroblast transfected with pCXLE hOCT4 miR302 detected by qPCR. Expression levels normalized to RNU48 endogenous 
control.  
 
The use of episomal plasmids to drive expression of the miR302 cluster is probably 
insufficient to reach the levels required to have a positive effect on the reprogramming 
process.  While shp53 cannot by itself reprogram somatic cells back to a pluripotent state, its 
presence in the episomal plasmids improves the reprogramming efficiency more effectively 
than when the miR302 cluster was added. Based on this, the original Yamanaka episomal 
plasmids were adopted for all future experiments. 
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3.4 RNA reprogramming 
 
The direct delivery of synthetic mRNAs into the cells completely avoids the use of DNA or 
viral vectors and is therefore ideal for clinical applications. This method requires serial daily 
transfections due to the short half-life of the mRNA molecules but was able to achieve the 
fastest and most efficient reprogramming reported so far
56
.   
For Warren et al. to be able to reprogram somatic cells using mRNA without causing cellular 
toxicity, they had to engineer the mRNA molecules in order for these to avoid the host cell’s 
innate immune defense mechanisms, defenses that are in place for protection against RNA 
viruses
56
.  This was done by generating synthetic mRNA molecules with a phophatase cap 
and modified ribonucleotides. These modifications coupled with supplementation of the 
interferon inhibitor, B18R in the medium attenuated the innate antiviral response and allowed 
high cell viability. Despite the high cost in  production of the synthetic mRNAs and the 
technically demanding work required, the use of mature mRNA is highly appealing as it 
allows the step of mRNA transcription to be skipped , making this the possible reason behind 
the faster reprogramming time observed. 
As observed by others, when reprogramming the BJ cell line using the mRNA methodology 
we observed the highest efficiency of reprogramming. The high transfection efficiency, 
approaching 100% (Figure 17B), greatly impacts the efficiency as the internalization of the 
mRNA cocktail in all the cells enhances the chances that all reprogramming factors will be 
present inside the cells. Morphological changes could be seen in the culture as soon as 4 days 
into the reprogramming, and colonies began to emerge after the 12 days of transfection, 
significantly earlier than observed by other methods (Figure 17A).   
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Figure 17 – mRNA reprogramming of BJ fibroblast line A. Phase contrast pictures of BJ fibroblasts transfected with 
reprogramming mRNAs at days 1, 4, 11 and 14 B. Immunofluorescence pictures of BJ fibroblasts transfected with GFP 
mRNAs at days 1, 4, 11 and 14.  
 
From analysis of the culture at day 18, TRA-1-81 staining revealed a reprogramming 
efficiency of 1.89% - the highest observed between all the different methods used, including 
the original retroviral approach. Despite the promising results obtained from BJ cell line, 
when using primary patient fibroblast lines, no successful reprogramming was observed 
(Figure 18).  This observation is not unique to our case as others have reported problems 
when using mRNA to reprogram patient fibroblast samples
153
. Furthermore, no successful 
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reprograming has been reported when using blood cells. The BJ line, derived from newborn 
foreskin, might be more susceptible to reprogramming, as it has been shown that the age of 
the patient can influence the efficiency or reprogramming
154
.   
 
Figure 18 - Comparison of mRNA reprogramming of patient Vs BJ fibroblasts line. Inefficacy of mRNA to reprogram 
patient lines. Phase contrast pictures of mRNA reprogramming of patient line and BJ line at days 1, 5, 10 and 14. 
 
As our choice of reprogramming methodology is linked to a practical application, the 
ineffectiveness of mRNAs with patient lines renders this technology obsolete. If this 
technology is to be used in regenerative medicine, we need a method capable of 
reprogramming cells from patients. Consequently we chose the episomal method of 
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reprogramming as, from all the integration-free methods, it was the only that was able to 
meet the required criteria: integration-free, efficient and able to effectively reprogram patient 
lines.   
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3.5 Characterization of the different lines 
 
Several methods are available for reprogramming cells into a pluripotent state, and we 
conducted a side by side comparison of some that could be considered safe as they carry no 
or little risk of integration into the genome of the host cell. In order to identify the emergence 
of iPSC colonies among the fibroblast population, morphological changes are used as a crude 
evaluation of efficiency, while TRA-1-81 staining allowed for a more precise 
characterization. Based on this, several colonies were picked and expanded for further 
characterization. 
Nevertheless, the premises on which the lines were established do not guarantee a true 
pluripotent state. During the reprogramming process cells undergo a series of changes, as a 
result of the introduction of exogenous factors. The process is still not completely understood 
and for that reason variability exists among different clones.  Multiple lines can be 
established from one round of reprogramming but not all lines will present equal genetic, 
epigenetic or phenotypic characteristics. It is important to pick more than one clone and 
evaluate them to ensure their pluripotency, avoiding any potential issues with data 
misinterpretation at later stages.  
The usual tests performed to characterize iPSC line include morphological analysis, in vitro 
differentiation by embryoid body (EB) formation, teratoma formation by injection of iPSC 
into immunodeficient animals, karyotypic analysis, expression of pluripotency markers such 
as OCT4, Sox2, Nanog, SSEA4, Tra-1-60, Tra-1-81 and integration status of reprogramming 
factors.  
In frame with what is routinely done, we performed a series of tests for quality controls of the 
different lines established using the different reprogramming methods. Comparing iPSC 
established using different reprogramming methods can also allow to see if there is any 
underlying abnormality that is method specific.  
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All iPSC lines derived from BJ fibroblasts using retrovirus, episomal and mRNA showed the 
typical hES-like morphology with large nucleus to cytoplasm ratio, highly visible nucleoli 
and growth as compact colonies (Figure 19A)
155
. Looking at pluripotent markers, both at the 
gene and protein level, we could observe the presence at similar levels to the control line H1 
(hESC line) (Figure 19B and C). We also showed that the parental BJ fibroblasts were 
negative for pluripotent markers such as Nanog, Rex1 and Sox2 (Figure 19C).   
 
Figure 19 – Characterization of established iPSC lines derived from BJ fibroblasts using retrovirus, plasmids and 
RNA. A. Representative phase images of established iPCS and H1 cell lines. B. Flow cytometry analysis with pluripotency 
markers SSEA-4 and TRA-1-81. SSEA-1 is a negative marker of human pluripotent stem cells. Green line denotes H1, red 
line denotes BJ-RV-iPS, blue line denotes BJ-Pla-iPS and black line denotes BJ-mRNA-iPS. C. RT-PCR analysis for 
expression of key pluripotency genes in the different lines and control BJ fibroblasts and H1 ESC line. 
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Presence of pluripotent markers still cannot assure these cells are able to differentiate into all 
three germ layers – the distinctive characteristic of pluripotent cells. In order to evaluate this 
ability, two different tests are routinely used –EBs formation and teratoma formation. They 
rely on similar foundations but while the former is performed in vitro, the latter is in vivo by 
injection of the iPSCs in mice. Spontaneous differentiation of the cells is induced, and due to 
their pluripotency, cells from all germ layers arise.  
EBs were generated from all iPSC lines, and from analysis of the differentiated culture we 
could observe down regulation of pluripotent genes and upregulation of different lineage 
specific genes. Complementary to the in vitro data, teratomas from the different lines arose in 
the mice and consisted of tissue derivatives of the three germ layers (Figure 20A). Here we 
confirmed both the in vitro and in vivo pluripotency of the iPSC lines derived.  
A recent substitute for these tests has recently been developed by Meissner’s group156 
consisting of a scorecard that is able to predict the pluripotency and germ layer bias of cell 
lines. We decided to perform this third test and evaluate the pluripotency of our different 
lines. In agreement with what we saw using the traditional pluripotency tests, all lines scored 
as pluripotent with differentiation score averages within the ranges considered as true tri-
lineage potential (Figure 21).  
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Figure 20 - Characterization of pluripotency potential of different lines Ability to differentiate towards the 3 lineages 
assessed by teratoma formation assay in iPSC lines from different reprogramming methods. Genomic stability assessed by 
karyotyping A. H&E stained slides of teratomas formed from injections of iPSCs into the testis capsule of NOD-SCID mice. 
Tissue derivatives indicative of the three germ lineages were observed. B. Representative image of karyotype 46, XY. BJ-
pla-iPSCs at passage 15 is shown. 
 
 
Further tests confirmed the normal karyotype of the different lines, as seen by the example of 
BJ-pla-iPSC (Figure 20B). From the analysis of the iPSC lines we can conclude that all 
methods are able to reprogram to a pluripotent state where the differentiation potential is kept 
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with a seemingly conserved genetic integrity. Regarding any method specific abnormality, in 
our sample population, there is no difference detected with the characterization done. Further 
genetic tests, such as SNP or CNV analysis, might uncover aberrations that karyotyping 
cannot detect. Also, a bigger cohort of samples would be necessary if method specific 
aberrations were found. 
 
 
Figure 21 - Human pluripotent stem cell scorecard assay results. New assay that allows to look at pluripotent potential of 
iPSC and ESC lines based on a qPCR assay. Results comparing BJ-pa-iPS and BJ-mRNA-iPS lines. 
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3.6 Discussion 
 
From the 3 reprogramming methodologies we chose to perform a comparative study, mRNA 
is the best in terms of efficiency. Nevertheless, the inefficiency at reprogramming patient 
lines (as observed by others
157, 158
) renders the previous finding innocuous, since iPSC 
technology’s greatest innovation was the ability to generate pluripotent cells from patients 
own cells. Another disadvantage of this method is the high cost and demanding process, 
requiring daily transfections for 12 days, thus making it more difficult to develop a good 
manufacturing practise (GMP) compliant process.  
Episomal plasmids overcome the issues that mRNA presented, as it is able to reprogram 
patient lines. Efficiencies although not as high, are sufficient to use this method routinely to 
derive patient lines. Also the low cost, ease of the process and the facility to obtain GMP 
grade plasmids make it highly desirable. 
But efficiency is not the only factor that needs to be taken into account when the ultimate 
goal is clinical translation. All 3 methods we compared were chosen under the premise of 
their safety – the most important factor – but another aspect that needs to be taken into 
account is the contamination from animal products. iPSCs must be derived and cultured 
under fully defined xeno-free reagents to comply with GMP requirements. In the next chapter 
we will depict the work done in deriving a method that is fully xeno-free and integration-free 
that can be then used for derivation of the first GMP grade iPSC line. 
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Chapter 4   GMP compliant reprogramming method 
 
4.1 Introduction 
 
Integration-fee iPSC lines are an important step towards their clinical use but there are other 
issues that need to be addressed for generating clinical-grade stem cells such as complying 
with current GMPs. Two different methods can be accepted for this purpose: 1) derivation of 
cells under GMP requirements and 2) conversion of cells derived under research-grade 
condition to GMP quality standards. The first methodology grants higher safety to the cells 
and less work as no tests are required to determine any contamination from adventitious 
products – the use of GMP grade products assumes no contamination. GMP are the practices 
that guarantee the minimum requirements that a product (pharmaceutical or not) must meet to 
assure high quality and minimal risk to the consumer. It covers both manufacturing and 
testing of the final product.   
The development of the ESC field and later the iPSC field relied greatly on the use of animal 
products
1, 14, 133
. These facilitated the derivation and culture of the cells, but as the promise of 
using these cells as medical products came to light, the need for safer and GMP compliant 
methods became evident.  Besides contamination with adventitious agents, the use of animal 
products containing undefined components presents two main problems: 1) unknown factors 
that can affect reprogramming, growth and differentiation of the stem cells, and 2) variability 
among cultures (not only among labs but inside the same lab).  
With increased knowledge of stem cells, their properties and their general requirements, the 
field of stem cells has observed great advances in the products used for their derivation and 
maintenance. A race for the derivation of the first GMP grade iPSC is underway, with several 
findings in the past that allowed for a fully defined, xeno-free and GMP compliant method to 
have been derived
155
. 
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4.1.1 Culture conditions 
Culture conditions serve to provide the desired signals to the cells, be it for their 
maintenance, differentiation or even reprogramming. In vivo, cell fate is regulated by a 
combination of intrinsic and extrinsic mechanisms. Intrinsic mechanisms include specific 
transcription factors expressed by the cells while extrinsic mechanisms are normally related 
to the signals the niche provides to the cells, including contact with other cells, the ECM and 
growth factors. It is the extrinsic mechanism that we try to replicate in vitro through the 
culture conditions. 
A great deal of work has been done on culture conditions for stem cells, with most of 
conditions for derivation and propagation of iPSC being based on work done for ESCs. While 
iPSC have only been around since 2006, the field of ESC is around since the 1980s
159
 and has 
seen several advances in culture conditions. Even though no GMP grade iPSC has been 
derived, much of the technology for such has already been developed.  
 
Culture media 
Culture media play a crucial role in achieving a defined culture system for human pluripotent 
stem cells. These should contain soluble factors that act on PSCs to control their fate, both in 
terms of self-renewal and differentiation. 
The media initially used to maintain ESC in culture contained FBS
131, 160
, which introduces 
the risk of transmission of disease (e.g. prion) as well as activation of host immune system by 
biomolecules, such as non-human sialic acid (Neu5Gc)
161, 162
. Xenogeneic products are also a 
common source of mycoplasma contamination, which are known to compromise several 
aspects of cell physiology and consequently affect experimental results
163
.  For increased 
safety of the resulting cells, human products were employed instead
164, 165
. These provided an 
extra level of safety, as they avoid contamination by inter-species products (molecules, 
prions, virus, etc.) and potential immune rejection of xeno-proteins
161
. Even though they 
represent a step closer towards safer conditions, they still carry problems such as batch-to-
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batch variability and its composition, as it is a complex mixture containing unknown 
compounds. Batch to batch variability is particularly problematic when it comes to albumin 
(one of the main components of serum), both because of the high concentration used in the 
culture medium compared to other proteins and its ability to bind lipids and other 
impurities
166
.  
The next step in improving the culture conditions of pluripotent cells was the complete 
removal of serum from culture. Using knockOut serum replacement (Ko-SR), several groups 
were able to show sustained culture of pluripotent cells
26, 167, 168
.  Serum replacement is a 
defined serum-free formulation optimized to grow and maintain undifferentiated pluripotent 
stem cells. Even though serum-free, it is known that the active ingredient in Ko-SR is lipid-
rich albumin
169
. Batch to batch variability is still a concern when using Ko-SR, and even 
though it allowed more standardized and better defined conditions, it still contains animal 
products.   
Media optimization can be a daunting process but it was possible to develop a defined 
medium – mTeSR1 – where 18 components are added to a DMEM/F12 basal medium that 
was able to support pluripotent cells. This medium was first developed for feeder free ESC 
culture but is has since been used for iPSC
170
. Even though the composition of the medium is 
known and there are no animal products, its components include human serum albumin and 
human sourced matrix proteins, which, as said previously, have a great batch to batch 
variability in their capacity to support pluripotency
171
. Despite this, mTeSr1 has been widely 
adopted for the culture of stem cells, being the most common one used in present days. 
Further work on media optimization led Thomson’s group to the development of Essential 8 
(E8) medium
171
. A first attempt showed that while removal of some of the 18 factors from 
mTeSR (TGFβ, LiCl and GABA) didn’t really affect short term survival and proliferation of 
ESCs, removal of Albumin and other factors led to a diminished maintenance of these 
cells
171
. The initial study did not take into consideration the complex interactions between the 
different factors in the medium, as shown by the fact that Albumin is required to counter act 
the toxic effect of β-mercaptoethanol171. Re-examination of all the components and their 
interactions allowed the removal of some factors, while reinforcing the importance of others 
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(such as insulin and FGF2)
171
. The understanding of the different interaction allowed the 
development of E8 medium which contains 8 essential ingredients added to DMEM/F12 and 
is therefore completely defined. This medium supports undifferentiated proliferation of both 
ESC and iPSC to a comparable level to TeSR medium
171
. The development of a highly 
defined medium that supports stem cell culture and reprogramming facilitates the transfer 
from basic research of hPSCs to the clinic, with cGMP E8 medium already available 
commercially.  
 
Support systems 
The natural environment of stem cells niches is hard to replicate and several factors affect the 
success in supporting the cells in an in vitro environment. These include 1) presence of 
soluble factors, such as cytokines and growth factors, 2) cell-to cell interactions, 3) 
interaction between cells and the niche and even 4) physical properties of the niche, such as 
rigidity.  
The initial culture of ESC relied on a layer of cells (feeders) to sustain stem cells. The use of 
animal feeder cells such as MEFs was crucial for the support and self-renewal of hPSCs by 
secretion of essential growth factors, cytokines and ECMs. However, the use of animal 
feeders carries similar problems to the use of animal sera: batch to batch variability, 
mycoplasma contamination, risk of transmission of disease and contamination with animal 
products that could lead to immunity problems if cells are used clinically. Soon after, several 
human cell types were tested as possible feeders and showed the ability to support stem cell 
growth and derivation
164, 172-174
. Even hESC-derived fibroblasts feeders have been used, 
which avoids the use of other cellular sources
175
, though not always have they proven suitable 
for stem cell maintenance
176
. Despite the evolution on the feeders used for stem cell culture, 
the possibility of contamination from the feeder layer restricts the clinical use of ESC and 
iPSCs. Variability among labs and batches can also affect characteristics and differentiation 
ability of these cells. Furthermore, the process of using feeder layers is elaborate and costly, 
limiting large scale use of the cells 
177
. 
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And so, as an alternative to feeder cells, several ECMs or cell adhesion molecules have been 
assessed.  Feeder-free culture initially involved the use of a complex mixture of matrix 
proteins derived from Engelbreth-Holm-Swarm mouse tumours – Matrigel26. Matrigel 
provided the required support for ESC and iPSC culture
26
. In an initial stage, Matrigel was 
able to support pluripotency only in conjugation with MEF conditioned medium (CM)
26
. 
MEF-CM has components that were produced by the MEFS, such as growth factors, ECM 
and cell binding molecules that help maintain stem cells in the absence of feeders. Successful 
maintenance of pluripotent stem cells without the use of CM has been shown with the 
addition of high concentrations of FGF-2, transforming growth factor β (TGF-β1) and 
Leukemia Inhibitory Factor (LIF) to the culture medium
178-180
. Later on, with a better 
understanding of stem cell culture, improved media were developed, such as mTeSR1 and 
E8, that if used in conjunction with Matrigel are able to maintain the pluripotent state in 
culture.   
Even though Matrigel removes the need for a feeder cell layer and can be used with 
completely defined media (E8), it is still not xeno-free as it is derived from mouse tumours. 
Several of the components that make up Matrigel –collagen IV, laminin and fibronectin181 - 
have been evaluated in their ability to individually support pluripotency.  While collagen IV 
and fibronectin failed to maintain pluripotency and self-renewing capability of ESC over long 
periods of time, laminin was successful in doing so
26
. Laminins are proteins of the 
extracellular matrix, expressed early during development and are a major component of the 
basal lamina
182, 183
. Several isoforms have been identified, each with its specific receptors, 
and that play different roles as cell adhesion proteins
183-186
. With regards to pluripotency 
maintenance, few isoforms have been identified with the ability to do so: laminin -111, -332 
and -511/521
27
.  
The knowledge that most cell-ECM interactions rely on integrins was extrapolated to hPSCs 
and led to the finding that vitronectin has the ability to support hESCS self-renewal via 
integrin ɑVβ528. Additionally, when using the fully defined mTeSR1 medium, only matrigel 
and vitronectin were able to support ESC growth
28
. Most of the matrix proteins capable of 
supporting pluripotency are expensive for large scale use, but vitronectin has the added 
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advantage of relative easy production and purification, making it highly appealing as a GMP 
compliant support system for iPSC
28
.   
The use of synthetic platforms for hPSC culture comes as an alternative to the use of 
biological ones, and several have been developed
29-32, 187
. These must allow cell adhesion, 
spreading, self-renewal and subsequent colony formation of undifferentiated hPSCs
188
. The 
combination of both strategies in a hybrid approach has also proven popular with a base 
polymer with biomolecules at the surface
187
. Despite the interest surrounding these 
approaches there are still issues to overcome, with only a few surfaces showing the ability to 
sustain hPSCs for longer periods 
32, 187, 189-191
. It is important that whatever system is 
employed, the sterility of the system is kept. This becomes problematic when only few of 
these platforms show compatibility with the sterilization process, as biological motifs can be 
degraded or denatured by it
187, 190, 191
.   
 
The use of defined conditions decreases variability and so translates onto a more reproducible 
and reliable culture system. Several defined media and matrixes have been shown to be able 
to support pluripotency but the question still remains to see if they are able to support the 
reprogramming process.  
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4.1.2 Beyond GMP practises   
The generation of stem cells for the use in patients is not simply a matter of getting an 
integration-free GMP compliant line. There are other issues that require attention if there are 
to be downstream applications of these cells.  
These issues are varied and range from quality controls of the cells themselves to ethical and 
legal issues. The ethical and legal part are beyond the scope of this thesis thus will not be 
developed into specific details; however some of the issues surrounding  the field include 
regulation on sourcing the donor tissue, ethical guidelines, intellectual property law and data 
sharing. To further complicate matters, regulations differ between national and/or regional 
authorities. Efforts are currently being made to form an international autonomous body with 
the aim of standardizing the existing regulations and proposing new regulations to accelerate 
the translation of PSC-based therapies to patients
192
. 
It is also important to monitor genetic abnormalities both in iPSC and its derivatives. A lot of 
work has been done in addressing the genetic and epigenetic stability of these cells, with 
several groups showing marked genetic aberrations, while others disputing these findings
44
. 
Initially a lot of focus was given on comparison of iPSCs with ESCs on a genetic basis. 
While the world was amazed at how similar iPSC were to ESC when they were first 
developed, from 2009 reports started recording differences between the two
82, 84
, including at 
the methylation level
85
. However, others studies show the difficulties to distinguish the 
differences between them
90, 91, 156
. 
When analysing the contradicting results, there is a tendency where the cohorts that analysed 
smaller sample sizes are the ones that show differences between iPSC and ESC, giving 
strength to the idea that the changes observed are not specific to ESC and/or iPSC but rather 
sample or laboratory specific. Furthermore, comparison between the original cell source and 
the derived iPSC have shown that most mutations are often carryover aberrations from the 
original cell source, mutations acquired during the reprogramming, insertional mutagenesis 
when using integrative methods or from the passaging process in cell culture
193
. Minimizing 
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aberrations is important, but understating them and controlling their effects might be more 
important as even imperfect cells can be used
69
.  
When considering clinical application, immunological problems beyond the ones caused by 
xeno-components should be addressed, such as immune rejection. Even though iPSC 
technology can be applied on a personalized level, the reality of such is not easily achieved. 
The long and expensive process of developing a line and testing it creates obstacles on 
routinely using it in a patient-specific manner. Derivation of GMP-compliant iPSC lines from 
healthy donors that included a variety of human leukocyte antigen (HLA) variants could 
represent a feasible alternative, as matching of the three major types of HLA loci between 
recipient and donor is expected to results in less immune rejection after transplantation
78
.  
Much still needs to be done before stem cells are routinely used in the clinic, with only a few 
trials existing so far
68
. The extensive work on quality controls and joined efforts for 
international regularization and cooperation in the field will hopefully bring is closer to clinic 
use of these cells.  
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4.2 GMP compliant method 
 
In the previous chapter, we compared several integration-free methods of reprogramming and 
concluded that the episomal plasmid method was the most efficient and robust when 
reprogramming primary patient fibroblasts. To develop a safe, GMP-compliant 
reprogramming protocol, it is necessary to develop a protocol free of feeder cells and animal 
products that is compatible with the episomal method.  
In the process of developing a GMP compliant method, we first needed to remove the use of 
a feeder layer and so we developed an approach where the plasmid transfected fibroblasts 
were transferred directly to a matrigel coated plate, in mTESR1 medium containing 0.5mM 
sodium butyrate 
194
. Sodium butyrate is a molecule that has been shown to increase efficiency 
of reprogramming. The mechanisms, by which butyrate helps increase the efficiency, 
promote epigenetic changes and expression of pluripotency-associated genes (methylation 
and demethylation)
195
. 
The above conditions gave rise to 76.33±5.6 TRA-1-81 positive colonies, which could be 
immediately transferred and sub-cultured in matrigel/mTESR1.  Under these modified 
conditions, the Yamanaka plasmids were even more efficient than under the feeder dependent 
protocol (Figure 22).  
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Figure 22 – Efficiency of reprogramming using episomal method in feeder Vs feeder-free conditions. Reprogramming 
of different human fibroblast lines under feeder (Nuff) and feeder-free (matrigel) conditions. Efficiency assessed as the 
number of iPSC colonies per number of transduced fibroblasts. n=3 
 
At this stage we were able to show a method free of feeders that supports the reprogramming 
of human fibroblasts with our chosen integration-free method – plasmids – at efficiencies 
higher than when using feeders. It seems possible that the combination of Matrigel/mTeSR1 
better reproduces the in vivo conditions of pluripotent stem cells, which translates in the 
higher efficiency observed.  
While using Matrigel allows the removal of feeders from the protocol, it is still an undefined 
mixture of proteins derived from mouse tumours and thus is not xeno-free. Several ECMs 
including laminin and vitronectin are known to support long term pluripotent stem cell 
growth
166
 
28
 
196
, however it is not known whether these ECMs can also support plasmid based 
reprogramming. Upon comparison of different ECMs we observed that laminin-521 was 
unable to support the generation of any iPSC colony. However, both vitronectin and 
Synthemax allowed robust generation of patient specific iPS colonies at efficiencies 
comparable to Matrigel (see Figure 23). Synthemax is a synthetic vitronectin-based peptide 
substract for culture of hPSCs among the few compatible with the sterilization process crucial 
for stem cell culture
191
. 
      
96 
 
 
Figure 23 - Assessment of the best xeno-free matrix and medium for iPSC reprogramming.  Comparison of different 
culture conditions in their ability to sustain iPSC reprogramming from human fibroblast. Reprogramming assessed as the 
number of iPSC colonies that stained positive for TRA-1-81 (crude evaluation). 
 
Once a xeno-free support system for the derivation of iPSC was established, it was necessary 
to replace mTeSR1 medium for a completely defined xeno-free medium. The development of 
E8 medium by the Thomson group
171
 was crucial as it was the first medium to satisfy all the 
criteria.    Again, several patient iPS lines could be derived under E8+vitronectin or 
E8+synthemax that could be picked and continually expanded using the EDTA method of 
passaging. So, replacement of mTeSR1 medium with E8 did not affect efficiency of 
reprogramming (see Figure 23). 
Morphological analysis showed that colonies derived in E8 + vitronectin were different than 
those maintained in matrigel+mTeSR1, with a more flattened appearance and less defined 
boarders (see Figure 24A). Interestingly, colonies derived in E8+synthemax showed no 
apparent differences (see Figure 24A). This discrepancy in morphology between iPSC 
derived in vitronectin and synthemax is surprising as both are vitronectin based. Others have 
also shown the ability to reprogram using vitronectin + E8, with colonies showing similar 
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morphological features
166
. Nevertheless, it is possible that the use of a synthetic platform 
where vitronectin in anchored might provide better configuration for cell-ECM interactions.  
As morphology is not a stringent test for pluripotency, we compared other aspects of colonies 
derived in mTeSR1+matrigel and E8+vitronectin. Flow cytometry analysis showed similar 
percentage of TRA-1-60 and TRA-1-81 surface antigens expression (see Figure 24B) while 
quantitative PCR showed similar expression levels of Oct4 and Nanog (see Figure 24C). For 
proper analysis of the pluripotent potential of the cells, teratoma and EBs formation are the 
most common methods used. And so, when we compared cells under the different conditions, 
we observed that all were truly pluripotent in their differentiation ability with cells from all 3 
germ layers present. Similarly, Chen et al. also observe that iPSC derived with vitronectin + 
E8 present true pluripotency despite the colonies showing small morphological differences
166
.  
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Figure 24 – Comparison of episomal reprogramming under different culture conditions A. Morphology and TRA-1-81 
staining of iPSC colonies reprogrammed in the different culture conditions B. Flow cytometry analysis of TRA-1-60 and 
TRA-1-81 surface antigens expression of fibroblasts (negative control) and iPSC reprogrammed in matrigel+mTeSR1 and 
vitronectin+E8 medium. C. Quantitative PCR of OCT4 and Nanog expression levels of iPSC reprogrammed in 
matrigel+mTeSR1 and vitronectin+E8 medium. 
  
Therefore, it seems that no obvious differences in pluripotency exist between the two 
conditions, making E8 + vitronectin/synthemax a desirable combination for the 
reprogramming process. Currently, Synthemax is the only synthetic platform commercially 
available and its elevated prices can hinder their use, mainly in scale up situations, since 
efficacy and safety are not the only considerations as costs can also affect technology 
adoption. 
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The success in reprograming skin fibroblasts does not mean this method is compatible with 
other cell types (eg blood cells) since different cells can rely on different signals and/or 
adhesion molecules for correct reprogramming to occur. Hence, if this process is to be used 
with a different starting population of cells, further optimization might be required. 
Variability in the reprogramming process is expected when changes are introduced since 
different signals can be provided in a range of ways (as soluble factors, secreted by feeders, 
provided by the ECM, etc). This can be observed by the success of Nakawaga et al. in 
reprogramming using laminin 511 
197
. This is in contrast with what we saw, nevertheless 
Nakawaga was able to do it using laminin in conjugation with StemFit medium. This is of 
particular importance as the most likely explanation for the successful reprogramming is the 
fact that this medium contains albumin. Albumin has many biological and physical roles, 
with proven efficacy in the reprogramming process as it was frequently used in the past to aid 
the reprogramming process.    
 
 
We have shown here a method of reprogramming that combines an integration-free process 
(episomal plasmids) with fully defined, xeno-free culture conditions, that is amenable to 
GMP process
155
. The time will soon come when the first GMP grade iPSC is derived, a first 
important step towards cellular therapy using iPSC derived products. However, ultimately 
these hPSCs will be directed to specific cell lineages for various applications in tissue 
engineering and regenerative medicine. The same quality control and safety regulations will 
need to be applied for the direct differentiation of these cells as it was for all the other steps. 
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4.3 What comes next? 
 
The development of GMP compliant iPSCs has as an ultimate goal: their use in cellular 
therapy. IPSCs cannot be used in their pluripotent state not only because they carry 
tumorigenic risk, but also because there is no cell in the adult human body that is pluripotent. 
There are stem cells in the adult human body such as haemotopoietic stem cells but these are 
multipotent and not pluripotent. And so their use for cellular therapy relies on the in vitro 
differentiation towards a desired lineage.  
Work has been done on differentiating PSCs to virtually every cell of the human body with 
different levels of success. It is not surprising that in vitro conditions are not enough for 
correct phenotypic differentiation of the cells as we know that the natural in vivo environment 
is very complex relying on intrinsic and extrinsic methods for cellular specification. 
Understanding of these signals has greatly improved, much due to animal work, and it is due 
to this knowledge that differentiation protocols were developed. 
There has been a major interest of PSCs and their differentiation in the context of liver 
disease (with numerically the greatest number of publications) mainly in hepatocyte 
differentiation work. Additional advantages of iPSCs derived hepatocytes apply in the field 
of disease modelling and drug toxicity. In the next chapter we focus on the hepatic 
differentiation process and characterization of the hepatocyte-like cells.  
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Chapter 5 Hepatic differentiation of human iPSC  
 
5.1 Introduction 
 
Cellular therapy in the context of regenerative medicine is closer than ever to a routine use. 
The advances in the field of stem cells, mainly with the discovery of iPSC in 2006
14
, have 
allowed for autologous, patient specific therapies to become a reality. The improvement of 
damaged organs following stem cell transplantation as shown by several studies 
75, 198-200
 
gives strength to this line of research. Virtually all organ systems could benefit from cellular 
therapy for the restitution of normal function from damage or diseased conditions. 
Applications in liver disease, if therapeutically successful, would revolutionize the field of 
clinical hepatology.  
The liver is the largest gland in the body and is responsible for both endocrine and exocrine 
functions
201
, making it an important regulator of normal physiological processes and 
therefore vital to life. Due to this, liver disease is associated with high rates of morbidity and 
mortality which results in a high economic burden. Currently liver transplantation is the only 
curative procedure for patients with end stage liver disease. Unfortunately the availability of 
livers for transplant is not enough for the demand. Hepatocytes are the main cell type of the 
liver accounting for 70-90% of total liver mass, and upon transplantation they have been 
shown to be able to reconstitute the liver and even the correction of metabolic disorders 
202
. 
The large number of cells required and the limited availability of hepatocytes makes the 
generation of hepatocyte-like cells (HLCs) from PSCs highly appealing. 
But cellular therapy is not the only application these cells have, even though it is considered 
the most exciting one. The generation of functional hepatocytes has interests in areas such as 
drug screening, disease modelling and even human bio-artificial liver (BAL) construction. 
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The use of hepatocytes in the pharmaceutical industry is not a new endeavor and 
allows expedition of novel human drug development. With iPSC technology and the 
ability to obtain lines with specific genetic backgrounds, it is possible to take into 
account variability in drug metabolism (as due to P450 polymorphisms) while testing 
new drugs. 
As iPSC technology allows generation of lines in the context of specific genetic 
backgrounds, several lines were derived from patients with inherited liver diseases
203-
205
. When these lines are taken down the hepatic differentiation, the characteristic 
abnormalities that recapitulate key pathological features are observed. This shows the 
feasibility of disease modelling in the context of the liver, which not only helps to 
increase the knowledge on the disease phenotype but also provides an in vitro system 
to search for therapies.  
BALs work as an ex vivo device that takes over the liver functions, working as a 
bridge to transplantation or regeneration. These devices require living cells that 
express liver specific functions, but with it important questions arise such as what 
type of cells, how many, from which source and cultured in what form. Most BALs 
focus solely on hepatocyte population as these cells are responsible for most of the 
liver functions, even though other cell types (kupffer and hepatic stellate cells) have 
shown to contribute in cytokine and growth factor production. When it comes to the 
source of hepatocytes, human are the best option as non-human, even though readily 
available, carry risks of compatibility and contamination. Scarcity of hepatocytes and 
problems associated with foetal and cancer derived lines makes the possibility of stem 
cell derived hepatocytes for BALs highly appealing. Despite the barriers that still 
exist for the therapeutic use of BALs, these may be easier overcome than 
transplantation as the ex vivo setting allows an extra line of safety for the patients. 
Regardless of the application, the main constraint remains the difficulty in sourcing and 
maintaining viable hepatocytes. Despite the regenerative potential that hepatocytes show in 
vivo
206
, such as their proliferative ability, the difficulty in maintaining and expanding those 
cells in culture present a major hurdle. The artificial environment created in vitro does not 
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provide the signals to maintain hepatic phenotype, and we witness a loss of their 
characteristic features and differentiation soon after culture
207
.  
Stem cells have the potential to differentiate into hepatocytes both in vitro
208
 and in vivo
209
. 
Several hepatic differentiation protocols have been developed
63, 210-212
 by which the complex 
stimuli of in vivo liver development is attempted in an in vitro setting. As good as these 
multi-step protocols are, none has been able to obtain a population of true mature 
hepatocytes. The HLCs exhibit many morphological, phenotypical and functional 
characteristics of primary hepatocytes, with varying degrees between different groups
63, 210-
212
. In most cases cells present a foetal phenotype that is marked by expression of ɑ-feto 
protein (AFP). Moreover HLCs perform at a reduced level when compared to freshly isolated 
hepatocytes, which shows they still are not completely mature and/or functional. Even though 
it is commonly accepted that hepatocytes derived from human iPSC resemble the foetal stage 
of development they have been shown to engraft, survive and perform functions analogous to 
adult hepatocytes when transplanted into animals. 
It might be that further technological advances in the field of cell culture are required for 
better in vitro differentiation protocols, but understanding of the in vivo process of liver 
development becomes crucial information for improved hepatic differentiation protocols. 
 
5.1.1 Liver development 
Using animal models we now have an understanding of the reciprocal tissue interactions that 
lead to liver and hepatocyte differentiation. These studies show that much of hepatogenesis is 
evolutionary conserved 
Early during development three germ layers are formed: endoderm, mesoderm and ectoderm. 
The interactions between endoderm and mesoderm lead the endoderm to take form as a 
primitive gut tube, further subdivided into foregut, midgut and hindgut. Liver bud formation 
results from foregut endoderm and its response to stimuli from the surrounding mesenchyme. 
Upon establishment of the liver bud, the hepatoblasts (bipotent stem cell population) 
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differentiate towards hepatocytes or biliary epithelium. A simplified schematic of the process 
can be seen in Figure 25. Understanding of the signals required at each stage are the key 
features required for the development of a multi-step hepatic differentiation protocol 
 
 
 
Figure 25 – Simplified schematic of route of differentiation from pluripotent state to hepatocyte  
 
5.1.2 Definitive endoderm and foregut development 
During gastrulation the 3 germ layers develop, with Nodal signalling  playing a crucial role in 
endoderm and mesoderm determination
213
. This happens in a concentration dependent 
manner with low Nodal doses inducing mesoderm and higher doses inducing endoderm
214, 
215
. Nodal signalling stimulates expression of a group of endoderm transcription factors 
including SOX17 and Foxal-3
215
.  
Following gastrulation, definitive endoderm migrates to form the primitive gut tube which 
consists of a single sheet of cells surrounded by mesoderm. The foregut contains the common 
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precursors of the liver, gall bladder, pancreas and lungs
216-218
. Overlapping temporal and 
spatial gradients of Wnt, FGF, BMP and retinoic acid secreted from the adjacent mesoderm 
appear to regulate regional identity of the endoderm
219-223
. The hepatic potential is probably 
due to the expression of transcription factors such as foxa2, gata4/6 and HEX, which have 
important roles in early foregut organogenesis
224, 225
. 
 
5.1.3 Hepatic lineage 
Following BMP and FGF inductive signals on the ventral foregut endoderm, liver induction 
occurs and the liver bud becomes apparent. Some studies suggest that BMP and FGF 
signalling work together in regulating hepatic specification, with analysis of downstream 
pathway  showing that FGF regulates hepatic gene expression through MAP kinase pathway 
and hepatic growth through PI3 kinase pathway
226
. 
Soon after the formation of the primary liver bud, angiogenesis and vasculogenesis proceed 
as the bud is permeated by angioblasts and endothelial cells mediated by the Notch signaling 
pathway. The bipotent hepatoblasts then differentiate into either hepatocytes or biliary 
epithelial cells. Hepatoblasts start expressing liver specific genes such as AFP, TTR and 
Albumin.  
 
Bearing in mind the possibilities of HLCs for research and therapy we focused our efforts in 
differentiating iPSCs down the hepatic lineage. Considering the extensive literature on the 
subject, we optimized the hepatic differentiation process and characterized the cells in their 
liver specific functions as way of assessing the quality of the differentiation. Considering the 
risk associated with PSCs therapies, mainly the tumorigenic risk, we also performed some 
preliminary studies on their tumorigenic risk throughout the differentiation process.  
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5.2 Hepatic differentiation 
 
Hepatic differentiation protocols try to mimic the embryonic development of the liver general 
in a multi-step approach.  Our protocol, based on work by Chen et al., follows the same 
strategy and comprises 3 separate stages
63
. The first stage differentiates iPSC into definitive 
endoderm (DE), which represents the earliest precursors of endodermal organs (liver, 
pancreas, lung, gut and thyroid). In the second stage, DE are differentiated into hepatic 
progenitors while in the third and last stage of the protocol, the progenitors undergo a 
maturation step. A detailed schematic of the differentiation protocol can be seen in Figure 26.  
 
Figure 26 - Schematic of the hepatic differentiation protocol. Representation of the hepatic differentiation protocol from 
iPSC to HLCs. Components for each stage specific medium are provided. Briefly, cells were collected using accutase and 
plated at 2.6x105 cells/cm2 in mTeSR1 medium supplemented with Y27632 ROCK inhibitor. For endodermal differentiation 
mTeSR1 medium was replaced with RPMI-1640 with B27, 100 ng/mL activin A, 50 ng/mL Wnt3a, and 10 ng/mL HGF for 
3 days, medium changed daily. During the next step, the culture medium was replaced with hepatic commitment medium: 
knockout/DMEM containing 20% knockout serum replacement, 1 mM L-glutamine, 1% NEA, 0.1 mM 2-mercaptoethanol, 
and 1% dimethyl sulfoxide. By the end of the hepatic commitment stage, cells were collected using accutase and plated at 
2.1x105 cells/cm2, cultured in IMDM supplemented with 20 ng/mL oncostatin M, 0.5 µM dexamethasone, and 50 mg/mL 
ITS. 
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5.2.1 Endoderm differentiation 
Much work on endodermal differentiation was already available, and so we took advantage of 
the knowledge and combined it in order to obtain a more robust differentiation step. 
In vitro endoderm differentiation requires Activin-A, a common feature to all culture 
systems
63, 212, 227-230
. Activin-A activates the Nodal pathway, crucial for DE specification
213, 
214
. Besides Activin-A, composition of media for endoderm differentiation vary greatly, from 
the basal medium to the cytokines used. A common basal medium employed is RPMI 1640, 
either with or without B27, as it has shown to help endoderm differentiation as much as some 
cytokines.  Teo et al. showed that using this approach they were able to obtain a population 
80-95% CXCR4+ (endoderm specific marker)
231, 232
. HGF and Wnt3a are other factors 
shown to help obtain a DE population and improve early hepatic lineage formation. Wnt3a 
together with Activin A signalling stimulates synergistic activation of Nodal and Wnt-β-
catenin signalling which in turn promotes more efficient DE generation from PSCs
233, 234
. 
HGF is known to have several effects on cells in culture, and for its involvement during liver 
development
235
. Its addition to Activin-A and Wnt3a further increases the synergistic effect 
on DE formation, improving it
63
.  
When optimizing the DE differentiation step, one possible change to Chen et al.’s protocol 
was starting from a single cell population of iPSCs. Human PSCs in general do not like to be 
in a single cell format and if not kept under the appropriate conditions (such as presence of 
ROCK inhibitor) spontaneously differentiate. The use of a single cell starting population for 
endoderm differentiation has also been employed by others, even adopted by StemCell 
technologies Definitive Endoderm differentiation kit. The resulting DE population showed 
equivalent endodermal marker expression to colony format. Starting from a single cell 
population ensures a more homogeneous final population, as it allows all cells the same 
conditions to differentiate. In colonies, cells in the centre and on the outside of the colony are 
under different pressures as they differentiate which leads to a more heterogeneous DE 
population (Supplementary figure 2).  
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We decided to compare starting in colony against single-cell format, on the quality of the DE 
cells. To assess the quality of the endodermal differentiation we characterized the cells in 
terms of endodermal specific markers. FACS analysis of cells grown as single cells and 
colony format shows no differences in surface marker % of SOX17 and CXCR4 (Figure 27) 
which shows that starting as single cells does not affect the quality of the DE cells. 
 
 
Figure 27 – Endodermal marker expression. Different iPSC lines differentiated towards endodermal cells (day 3 of 
hepatic differentiation protocol) and analysed for surface markers of endodermal cells. Analyses of two endodermal markers 
– SOX17 and CXCR4 –under different starting conditions: single-cell and colony format. Percentage of positive cells as 
analysed by FACS. No significant difference between single cell and colony in both markers. 
 
Indeed by starting with a single cell population of iPSC (80-90% density), we are able to 
obtain a homogeneous population of endodermal cells. And so our endodermal differentiation 
step combines these findings, in a very efficient step with >98% CXCR4 and >80% SOX17 
positive cells across different cells lines (Figure 28A, Figure 28B and Supplementary figure 
3). 
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Figure 28 - Endoderm specific markers present in cells after endoderm differentiation stage. Characterization of iPSC 
derived endodermal cells (from single cell starting population) by detection of endoderm specific surface markers: CXCR4 
and SOX17 A. Graph with average percentage of endoderm specific markers CXCR4 and SOX17 in cells from iPSC state to 
day 4 of the hepatic differentiation protocol (n=3) B. FACS plot showing CXCR4 and SOX17 double staining in RDP2 iPSC 
and cells at day 4 of the hepatic differentiation protocol. C. Immunostaining of SOX17 intracellular marker in cells at day 4 
of the hepatic differentiation protocol. 
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Immunostaining supports FACS data, with most of the cells staining positive for SOX17 
(Figure 28C and Supplementary figure 4). Gene expression analysis allows to better 
characterize the transcriptome of the cells by the end of the endodermal differentiation.  
DeLaForest et al. characterized cells through the hepatic differentiation protocol and 
identified a list of genes specific to each of the stages of differentiation
236
. RNA sequencing 
data showed identical expression patterns to DeLaForest’s, confirming the DE phenotype of 
cells (Figure 29 and Supplementary figure 5). Not only do we observe downregulation of 
pluripotent specific genes but an overall upregulation of endoderm specific genes (Figure 29 
and Supplementary figure 6). Pluripotent genes show a downregulation when compared to 
iPSC, but some can still be detected in DE cells. This is not surprising as these cells 
correspond to early stages of development, and so still possess an immature phenotype. Gene 
expression by qPCR was also performed for a subset of genes, and overall confirms the data 
seen by RNA sequencing with detection of endodermal specific markers and absence of other 
lineage markers (Supplementary figure 6). 
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Figure 29 - Gene expression during hepatic differentiation. Gene expression of cells at different stages of hepatic 
differentiation and liver sample (positive control) Gene expression obtained from RNA sequencing data. Expression assessed 
as log2(FPKM+1) A. Pluripotent specific genes. B. Endoderm specific genes. 
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During this stage we observe a high level of cell death, shown to be associated with exposure 
to Activin-A and Wnt3a
228
. Proliferation of cells is also observed, counteracting the numbers 
lost to cell death. The balance between these two affects density of cells in culture which, 
depending on the cell line, can vary (Figure 30). This variability is not surprising as iPSC, 
even though pluripotent, have shown to have propensity for certain lineages when left to 
spontaneously differentiate
237-239
.  
The rapid and efficient generation of endodermal cells during this stage is important for the 
following hepatic commitment stage as only DE has the ability to form the liver  
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Figure 30 – Cell density at day 4 of the differentiation protocol from two different iPSC cell lines. Representative phase 
images of endodermal cells (day 4 of hepatic differentiation)  from different cell lines. Cell densities can vary between 
different lines 
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5.2.2 Hepatic commitment and maturation 
In the first stage of our hepatic differentiation protocol, human iPSC were converted to 
endoderm cells that are propitious for hepatic commitment. Step 2 and 3 focus on hepatocyte 
specification.  
Following Chen et al.’s protocol, by the end of the endodermal differentiation stage, cells 
maintain a high confluency (variable between cell lines and passages) ranging from 70-100%. 
As cells enter the hepatic commitment stage, levels of proliferation and cell death attenuate, 
but cell division is still observed and cells quickly become over-confluent Contact inhibition 
or lack of contact signalling can affect the cells’ phenotype. Hepatocytes are particular when 
it comes to the seeding density, as over-seeding hepatocytes can lead to cell death, while 
under-seeding provides inferior functional results. As cells were too confluent, we decided to 
add a passaging step. The addition of this step improved the quality of the final population by 
giving cells improved contact signalling for the remainder of the differentiation. An added 
advantage of this passaging step is the possible positive effect it can have in removing PSCs 
as these do not enjoy being passaged and kept in a single cell state.  
To assess the quality of HLCs, characterizations of their hepatic phenotype is required. 
Detection of both AFP and Albumin expression in cells of our differentiation protocol 
(Figure 31) are encouraging signs of correct hepatic lineage commitment, as these are liver 
specific factors. AFP is a liver specific marker expressed during foetal development, being 
lost after birth
240
.  On the other hand, albumin is the most abundant protein synthesized by 
adult hepatocytes, expressed at lower levels in early foetal liver that keep increasing until 
these mature
241
. While cells at day 8 show some level of expression of AFP (Figure 31A and 
Supplementary figure 4), it is at day 13 that cells present a strong hepatocyte-like phenotype 
with high levels of AFP, and detection of Albumin (Figure 31). The expression levels of 
these genes indicates a foetal phenotype as AFP is strongly present, both at mRNA and 
protein level, while albumin is detected at reduced levels (Figure 31). This is also in 
accordance to what is seen in the literature, as no complete mature phenotype has been 
achieved in hepatic differentiation. 
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Figure 31 - Expression of liver specific markers during hepatic differentiation protocol. Characterization of iPSC 
derived hepatocyte-like cells by detection of liver specific markers: AFP and Albumin. A. AFP and Albumin gene 
expression levels during hepatic differentiation (iPSC, day 4, day 8 and day 13) and adult liver (as control) detected by 
qPCR. Expression levels normalized to GAPDH endogenous control.  B. AFP and Albumin immunostaining of HLCs at 
day13 of hepatic differentiation protocol. 
 
Besides AFP and Albumin expression, we used RNA sequencing data to compare our cells to 
the stage specific markers DeLaForest defined in his differentiation protocol
236
. RNA 
sequencing data again showed that our cells presented a correct expression profile for each of 
the stages (Figure 32 and Supplementary figure 5). Gene expression by qPCR also showed 
upregulation of liver specific genes such as HNF4a and TTR (Supplementary figure 6). 
Detection of stage specific genes in our differentiation protocol supports the claim that indeed 
our cells are following the hepatic lineage. 
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Figure 32 - Gene expression during hepatic differentiation protocol: stage 2 and 3. Gene expression of cells at different 
stages of hepatic differentiation and liver sample (positive control) Gene expression obtained from RNA sequencing data. 
Expression assessed as log2(FPKM+1) A. hepatoblast specific genes. B. Genes turned on at the Hepatic maturation stage 
 
Even if HLCs show a transcriptional landscape similar to foetal phenotypes by the end of the 
differentiation protocol (day 13), it is important to confirm that cells possess functional 
characteristics of hepatocytes as these are the relevant features for the use of HLCs in 
research and therapy. Glycogen storage is an important function of hepatocytes and can be 
assessed by using periodic acid-Schiff (PAS) staining. This staining method relies on 
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oxidation of groups in the sugars (glycogen in this case) that when react to the Schiff reagent 
give a purple/magenta colour. HLCs at day 13 show ability to store glycogen, shown by the 
presence of purple/magenta stained cells as seen in Figure 33A. PAS staining also shows us 
that the HLCs consist of a heterogeneous population as not all cells are able to store 
glycogen.       
 
 
Figure 33 – Functional characterization of HLCs. Characterization of HLCs based on hepatocyte known functions such as 
albumin production and glycogen storage A. PAS staining of HLC d13 as a functional test of HLCs ability to store glycogen. 
B. Albumin production by HLCs d13 as assessed by human Albumin ELISA Kit. iPSC as negative control for Albumin 
production.  
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Albumin production is another functional test usually used to assess quality of hepatocytes in 
culture. Albumin is the most abundant protein synthesized by adult hepatocytes, and despite 
previously showing expression and transduction of this protein in HLCs day 13 (Figure 31), 
we checked albumin levels present in the supernatant of cells by ELISA. As shown in Figure 
33B, albumin can be detected in the supernatant of cells even if at low levels.     
Even with the presence of functional features of hepatocytes, HLCs present a foetal 
phenotype and consist of a heterogeneous population, features that can affect the transfer of 
HLCs for clinical use. This is common to several hepatocyte differentiation protocols, even if 
improvements have been made. This can be a problem of the differentiation protocols but 
might also result from the stability of the hepatic phenotype in culture. It is known that long 
term culture affects quality of primary hepatocytes
242
, and the same mechanisms that affects 
primary hepatocytes in culture might affect cells of the differentiation protocol as these reach 
a hepatic phenotype.  
Regarding the heterogeneity observed, it is possible that cells find themselves at different 
developmental stages during the differentiation, with some reaching a hepatocyte-like state 
earlier than others. Another possibility is that the heterogeneity is actually a requirement for 
correct hepatic differentiation, as different cells are necessary for production of the proper 
signals required for hepatic differentiation. 
Quality of HLCs has routinely been assessed by comparison to reference controls such as cell 
lines of immortalized hepatocytes or primary hepatocytes. Immortalized hepatocytes offer a 
reproducible reference but they show reduced quality in hepatocyte physiological 
functions
243
. On the other hand primary hepatocytes, even though the gold standard, show 
high level of variability among different samples, making it challenging to compare results 
across platforms. This together with the different criteria used to characterize the cells, makes 
it challenging to assess the quality of HLCs and the different differentiation protocols.  
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The in vitro systems might never be able to replicate in vivo conditions and so proper 
maturation of cells might require an in vivo step. Moreover, the best way to check HLCs for 
hepatocyte functions is to use them in an in vivo model of liver failure and check if the liver 
can be rescued. 
 
5.2.3 Liver failure rescue 
For a deeper functional analysis and to assess the therapeutic use of the HLCs we used them 
in a mouse model of liver failure.  
Carbon tetrachloride (CCl4) is one of the most potent hepatotoxins and is commonly used for 
both chronic and acute models of liver failure, with varied methods being employed
63, 230, 244-
247
. An optimization step resulted in liver failure by injection of CCl4 diluted 1/10 in oil, in 
nude mice via inter peritoneal (IP) injection at 2.5ml/kg concentration. Upon IP injections of 
CCl4, the mice showed clear signs of pain and over the 48h following hours died from liver 
failure. Analysis of the livers showed the devastating effect of CCl4, with high level of cell 
death with disruption of the normal liver architecture (see Figure 34 A).  
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Figure 34 - H&E of mouse Livers. Fulminant hepatic failure was induced by IP injection of CCl4 2.5 mL/kg body weight; 
1:10 v/v in mineral oil. For liver rescue, 24 hours after CCl4 administration, mice were injected with HLCs.  1x106 
cells/mouse diluted in PBS were administered via tail vein injection in a total volume of 100µl. H&E to assess damage and 
rescue of mice livers.  A. Liver sections of mice treated with CCl4 24-48h after injection B. Liver sections of surviving mice 
treated with CCL4 and HLC transplant, 60 days post injection. 
 
To try and rescue the phenotype and assess the HLCs, intra venous (IV) injections of the cells 
were performed in mice previously treated with CCl4. This resulted in survival of 3 in 4 mice 
(see Figure 35A) for a period of >60 days with no signs of health problems, rescue of normal 
liver architecture (Figure 34B) as well as detection of human albumin in their blood at 9 
weeks post HLC injection (Figure 35B). Survival of HLC injected mice and human albumin 
detection indicates that HLCs were able to engraft and assume hepatocyte specific functions.  
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Figure 35 – HLC engraftment experiment analyses. Fulminant hepatic failure was induced and for liver rescue, 24 hours 
after CCl4 administration, mice were injected with HLCs. Survival and presence of human albumin in treated mice as proof 
for HLC engraftment A. Survival curve of mice treated with CCL4 (n=4) and CCL4+HLC (n=4) B. Albumin detection in 
surviving mice serum (n=3) against control mice (n=3) using human Albumin kit.    
 
It is possible that engraftment of the HLCs and their in vivo survival allows for further 
maturation and establishment of a better hepatic phenotype than when cells are cultured in 
vitro. With this in mind, the previous experiment was planned so mice were injected with 
cells at different stages of hepatic maturation: HLC at day 8 and HLC at day 13 (two mice 
each). 
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Cells at day 8 are more immature, which carries a higher risk of tumour formation, but since 
they have already committed into the hepatic lineage they might be able to engraft, mature 
and take up liver functions and in doing so rescuing the liver failure phenotype. The mice 
engrafted with these cells showed two different outcomes: one survived and one died. The 
fact that one of the mice survived indicates that HLCs at day 8 are capable of liver failure 
rescue, although a ½ success rate is not encouraging. Unfortunately the surviving mouse 
presented a tumour in the spleen, which puts into question the safety of these cells (Figure 
36). On the other hand, HLCs at day 13 were able to rescue the liver failure in both mice with 
no signs of tumours present.  
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Figure 36 - Tumour in liver failure rescue with HLC. Fulminant hepatic failure was induced and for liver rescue, 24 hours after CCl4 administration, mice were injected with HLCs. Survival 
and presence of human albumin in treated mice as proof for HLC engraftment A. Survival curve of mice treated with CCL4 (n=4) and CCL4+HLC (n=4) B. Albumin detection in surviving 
mice serum (n=3) against control mice (n=3) using human Albumin kit. 
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The low number of animals in the initial study makes it statistically weak and hard to take 
meaningful conclusions, mainly when it comes to the condition with HLC at day 8 as survival 
of ½ animals is not encouraging. And so a second study was planned with a bigger cohort of 
animals, following the schematic of Figure 37.  
 
 
Figure 37 – Schematic of mouse liver failure experiment. After preliminary study with 4 mice, bigger experiment was 
planned with 5 mice for each condition: CCl4 liver failure, CCl4 liver failure + HLC d8 rescue and CCl4 liver failure + HLC 
d13 rescue.   
 
As previously, upon injection of CCl4 the mice showed signs of distress but unlike before 
they did not die over the next 48h. By day 4-5 of the experiment we realized that the liver 
failure model was not successful as the control animals were still alive and showed no signs 
of health problems. Indeed histological analysis of the livers of these mice showed normal 
architecture and no sign of cell death (Supplementary figure 7).  This shows that CCL4 was 
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not able to induce sufficient levels of liver damage and so it was not possible to assess the 
ability of HLCs in liver failure rescue. 
The use of CCl4 for liver failure has been extensively used in both chronic and acute models, 
but a big variability on the way it is employed is observed, from different concentrations, 
ways and number of administrations
230, 244-246, 248
. This together with the liver regenerative 
capacity makes the model of liver failure with CCL4 quite unreliable.  
Lack of time and resources does not allow for further optimization of the CCl4 model. The 
use of fumarylacetoacetate hydrolase (FAH) deficient mice would prove a better option for 
future liver failure studies. These transgenic mice are a genetic model of hereditary 
tyrosinemia, and develop liver failure when NTBC drug treatment is removed. This model is 
more reliable, as liver failure is always observed in the absence of NTBC. This would allow 
better assessment of liver rescue using HLCs.  
Overall we have a model of hepatic differentiation where HLCs show characteristics of 
hepatocytes both at expression and protein level. Functional tests also show characteristics of 
hepatocytes such as glycogen storage. Liver rescue might be the best way to assess if indeed 
these cells can perform hepatocytes functions, and even though we have a reduced number of 
animals, we do show rescue from liver failure. 
All these analyses have been routinely used to characterize the quality and resemblance of 
HLCs to mature hepatocytes. We thought to characterize the cells on other aspects, focusing 
more on their pluripotent origin than the hepatic phenotype and so decided to look at their 
tumorogenicity.  
      
126 
 
5.3 Tumorigenicity of HLCs 
 
Hepatic differentiation from pluripotent stem cells carries the risk of undifferentiated or 
partial differentiated cells being present and contaminating the final population. Pluripotency 
is an important feature of iPSC but it becomes a risk when we talk about cellular therapy.  
The ability to reprogram somatic cells to a pluripotent state has challenged the concept of 
terminal differentiation. While stability of a cell’s state is crucial for survival of the organism, 
there is evidence showing that in a stress situation, stemness has been activated in 
differentiated cells. This poses the question whether the term stable differentiation isn’t more 
appropriate than terminal differentiation. Natural occurring “stemness” activation has only 
been observed in lower organisms (eg: planarians)
249
 but the potential might still be there in 
higher organisms, we just need to tap into the right signals to do so. To tap into the in vivo 
plasticity of differentiated cells one would need to manipulate cells, their environment or 
both. 
Another example of how the somatic state of a cell has been shown to change is in Cancer. 
Cancer is a very complex disease with a high degree of diversity both between cancer types 
and within an individual tumour. It is well accepted that cancer results from a stepwise 
accumulation of mutations that lead to a disruption of normal balance between cell division 
and cell loss. As mutations accumulate normal tissue architecture is lost with a growing mass 
of tissue emerging, termed tumour or neoplasm. But tumours are more than just a mass of 
cells, being complex structures with several cell types and its own microenvironment (Figure 
38).  
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Figure 38 – Complexity of tumours. Tumour niche is dynamic, composed of several components including neoplastic 
cells, extracellular matrix, vascular endothelial, stromal and immune cells.   
 
The evolution from normal cells to a neoplastic state is characterized by the acquisition of 
distinct and complementary capabilities that enable tumour growth and metastatic 
dissemination, these are termed as the hallmarks of cancer
250. “These functions are acquired 
in different tumour types via distinct mechanisms and at various times during the course of 
multistep tumorigenesis”99. In 2000 a paper defined 6 hallmarks for the development of 
cancer
250
, with subsequent research increasing the understanding of cancer and in 2011 this 
list was updated
99
. Figure 39 shows a schematic with all the hallmarks and this can be 
reviewed in Hanahan and Weinber
99
.   
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Figure 39 – Hallmarks of cancer. Adapted from original paper “hallmarks of cancer: next generation”99 
 
The different processes that lead to tumour formation are complex and distinct with the 
ultimate aim of survival and proliferation of cancer cells, which is achieved by steps such as 
genomic instability, avoidance of immune destruction, replicative immortality and even 
resisting cell death (Figure 39). The increased complexity is also marked by the presence of 
various cell types that work both individually and collective for tumour survival and 
expansion. One cellular type believed to be present in many if not most tumours are cancer 
stem cells (CSCs). CSCs are the cells able to form new tumours upon transplantation into a 
host
251, 252
. These were initially detected in hematopoietic malignancies
253, 254
 and are usually 
fractioned according to cell-surface markers. Identification of a tumour specific cell surface 
marker is challenging and no universal cancer marker has been identified, and most likely 
does not exist due to the heterogeneous profile of tumours. Nevertheless the existence of 
cancer cell surface markers has led to the development of new possible therapies for 
cancer
255
.  
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5.3.1 Surface marker expression 
Taking this into account we decided to have a look at the tumorigenic potential of cells 
throughout the differentiation protocol. In a first instance we looked at a range of surface 
markers associated with either pluripotency or tumorigenicity: TRA-1-60, TRA-1-81, SSEA5 
and ROR1. 
 
 TRA-1-60 and TR-1-81 are widely used in the field as stem cell-specific markers that 
are then lost during differentiation. These are thought to be a keratin sulfate 
proteoglycan and to have roles during development. They have also been tested as 
carcinoma markers, showing their potential for use as tumour markers
256
. 
 
 ROR1 is expressed during early embryogenesis, where it contributes to 
organogenesis
257-259
.  It is subsequently lost, and in the adult it is only detected in 
adipose tissue at low levels, and almost undetectable in pancreas, lung and a subset of 
intermediate B cells
260-262
. It is however detected in numerous blood and solid 
cancers
263
, with increasing evidence suggesting a role of ROR1 in cancer biology.  
 
 SSEA5 antibody was raised for detection of teratoma-forming cells and allow their 
removal from a population of differentiated cells
264
. Even though SSEA5 ab alone 
proved insufficient to completely remove the teratoma potential it proved better than 
classic hPSC markers and when in conjugation with other hPSC markers complete 
removal was achieved
264
. 
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Figure 40 - Expression of surface markers assessed by FACS. Expression of different surface markers associated with 
tumorigenicity and pluripotency during the hepatic differentiation. A. Example of FACS profile of RDP2 iPSC line during 
hepatic differentiation. B. Average expression values for 3 different cell lines: RPD2, BJ and HPS1 
A 
B 
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We show that all surface markers go down during the hepatic differentiation protocol, with 
variability among markers and different cell lines. Despite the decrease in marker % there are 
still positive cells detected at day 13 of the protocol (Figure 40 andSupplementary figure 8). 
A closer look shows us that ROR1 marker is the one with the most marked decrease, 
especially in initial stages. ROR1 has been extensively studied in CLL/blood malignancies 
where its use as a biomarker for CLL opened the door for therapeutics using ROR1 as a 
target. Besides being a biomarker, it might also provide a potential prognostic indicator as 
expression of ROR1 increases through the progression of CLL
265
. The same observation was 
seen in other blood malignancies
260, 265-267
. In the context of breast cancer ROR1 expression 
levels also showed correlation with higher grade and more aggressive disease, with likely 
involvement in the metastatic ability of cells
268
, possible by its involvement in epithelium-
mesenchymal transition (EMT)
269
.  
Presence of a metastatic population in cancer is associated with later stages and more 
aggressive disease. CSCs have also been associated with metastatic ability
270
, and this 
population is crucial for cancer development when engraftment experiments were 
performed
270
. Removal of the CSCs showed decrease in tumour formation, pinpointing the 
crucial role of these cells as cancer initiating cells. Absence of this population becomes a 
priority when using any cellular therapy, especially for PSCs derived technologies. ROR1 has 
shown correlation with more aggressive stages of cancer, but whether or not it can be used to 
sort out the whole metastatic population still remains to be addressed. 
The marked reduction of ROR1 expression during the hepatic differentiation, especially in 
the first stages of the protocol, can be seen as a positive feature as me might be removing the 
most aggressive cells and therefore reducing the risk of tumour formation significantly.  
SSEA5 was raised as a marker against teratoma-forming cells. Unlike ROR1, it does not 
show such a decrease in expression until day 13 of the protocol. The final population is the 
one we are interested for cellular therapy, and therefore the one we require to be safe in a 
tumorigenic context. Still, the different pattern when comparing to ROR1 indicates that 
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ROR1 might be insufficient to assess the tumorigenic initiating population while it can still 
be a good prognostic for more aggressive cells. 
The pluripotent surface markers (TRA-1-60 and TRA-1-81) also show a significant decrease 
from day 0 to day 13, which is expected as cells have committed themselves into the hepatic 
lineage. The genomic plasticity of PSCs gives them the ability to differentiate into multiple 
cellular types, but as cells differentiate this plasticity decreases to a point where their state is 
locked to a single somatic type. The high levels of pluripotent surface markers present at day 
4 and even day 8 indicate a high plasticity of these cells. On one hand, DE cells are expected 
to have a high degree of plasticity as they are multipotent cells found early during 
development. On the other hand, cells at day 8 would be expected to have reduced plasticity 
as liver commitment has already occurred. This indicates presence of a population that, even 
though shows liver specific characteristics, still presents immature features.  
The marked decrease observed between day 8 and day 13 might be a result of the passaging 
step. One of the possible advantageous of this step was the removal of PSCs as these do not 
like to be in a single cell state. The data suggests that indeed this step is important in 
removing some of the less differentiated cells.  
Overall we confirm the decrease of the pluripotent potential of cells along the differentiation 
protocol, also observed by the decrease in gene expression levels of pluripotent genes and 
upregulation of hepatic specific genes (Figure 29A, Figure 32, Supplementary figure 4 and 
Supplementary figure 6). This is expected as the transition from a pluripotent state to a 
somatic one decreases the genomic plasticity of cells.  
The presence of a small population of cells positive for these markers indicates presence of 
cells with teratoma-initiation potential. The question remains whether this population will 
induce tumour formation in an in vivo scenario. 
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5.3.2 Teratoma potential 
To assess the pluripotency of stem cells one of the most stringent test in the teratoma 
formation, by which injection of the cells into mice (routinely in the testis) lead to the 
formation of teratomas. If the cells are truly pluripotent the teratomas are made up of cells 
from the 3 different germ layers. The tumorigenic risk associated with iPSC and its 
derivatives does not necessarily require the cells to be pluripotent as any unorganized mass of 
cells that forms tumours could be dangerous for patients. By FACS we show a reduction of 
surface markers associated with pluripotency and tumorigenicity. But to better assess the 
tumorigenicity of the cells we decided to adapt the teratoma formation test used for iPSC and 
use it for the cells of the hepatic differentiation protocol.  
Animals are injected with the cells and kept until tumours can be detected as an outgrowth, 
with times ranging between 6 and 8 weeks until it can be detected. As soon as tumours can be 
detected, mice are culled with the tumours removed for histological analysis. To allow direct 
comparison we kept all animals for the same period of time even if there was no evidence of 
tumour formation. 
Table 5 - Adapted teratoma assay to assess tumoriginecity of cells during hepatic differentiation protocol 
Number of 
mice 
Cells injected Outcome 
2 iPSC Teratomas with cells from 3 lineages 
present 
2 Endodermal cells  
(d4 of hepatic differentiation) 
Teratomas with cells from 3 lineages 
present. Abundance of cells from 
endodermal lineage 
2 Hepatoblasts  
(d8 of hepatic differentiation) 
No teratomas detected. Histologic 
analysis shows disruption of normal tissue 
architecture 
2 Hepatocyte-like cells 
(d13 of hepatic differentiation) 
No teratomas detected. Normal tissue 
architecture 
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At the time point the animals were culled both iPSC and endoderm cells showed clear signs 
of tumour formation while testis of HLCs day 8 and day 13 showed no sign of tumour 
formation (Supplementary figure 9). Histological analysis of the samples provides more 
information on the effect of cells upon injection in the testis. As shown before, tumours of 
mice injected with iPSC show presence of cells from the 3 germ layers, confirming their 
pluripotency (Figure 41A). Mice injected with cells at day 4 of the differentiation protocol 
also resulted in tumour formation with cells of the three different germ layers. Cells at day 4 
correspond to endodermal cells and indeed we see a prevalence of cells derived from the 
endoderm lineage in the tumours, but we also detect cells from mesoderm and ectoderm 
(Figure 41B). It is not surprising to observe cells of all germ layers as cells at day 4, even 
being mainly endoderm (>90% CXCR4 positive and >80% CXCR4 double positive SOX17 
positive), still present very high levels of pluripotent markers (Figure 40).  
Endoderm cells are multipotent and can give rise to a range of different cell types (including 
the liver, lung, pancreas, gut). The ability to differentiate into different cells is characteristic 
of stem cells, with different levels of stemness existing, dependent on the genetic plasticity of 
cells. The higher plasticity the less differentiated cells are, and the lower plasticity the more 
committed they are. This is also shown by the reprogramming process by which the higher 
plasticity cells possess the easier it is to reprogram them into a pluripotent state (eg: 
haemotopoietic stem cells (HSCs) generate 300x more iPSC colonies than terminally 
differentiated B and T cells
15
).  
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Figure 41 – Teratoma formation with cells at different stages of hepatic differentiation. Evaluation of tumorigenicity of cells during the hepatic differentiation assessed using teratoma 
assay. A. Histological slides from teratomas of mice injected with iPSC cells B. Histological slides from teratomas of mice injected with HLC d4 cells C. Histological slides from testis of mice 
injected with HLC d8 cells D. Histological slides from testis of mice injected with HLC d13 cells.  
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Furthermore the endodermal differentiation step is an artificial process that tries to replicate a 
process that is highly regulated and complex in a simple 2D process that lasts only 3 days. 
The short time frame and the artificial setting might be insufficient for the genetic changes to 
stabilize, and so when cells find themselves in the in vivo environment, the different signals 
they receive from the niche might be enough for transdifferentiation from the endodermal 
lineage to other lineages.  
While macroscopically mice injected with HLC d8 showed no signs of tumour formation 
(Supplementary figure 9), histological analysis of the testis shows a slightly different story. 
These showed disruption of the normal tissue architecture and presence of other cell types 
(Figure 41C).  
Of note is the fact that the testis did not show the multitude of cell types as iPSC and HLCs 
d4 did, rather just showing tissue disruption with cellular growth. Some endodermal 
structures might be present but it is not clear. Unlike cells at day 4, cells at day 8 find 
themselves down the hepatic lineage and so their genetic plasticity is reduced, making it 
harder to transdifferentiate into cells of other lineages. Finally testis of HLC d13 injected 
mice showed no signs of tumours or abnormal tissue architecture (Figure 41D).  
Absence of tumour does not mean cells are not tumorigenic. As in cancer, where cells can 
have different levels of aggressiveness, cells in vitro can also possess different levels of 
tumorigenicity. This tumorigenicity model allows cells at different stages of the 
differentiation protocol to incubate in vivo for the same period of time. Same incubation 
periods allow a direct comparison between the tumorigenic potential of these cells but might 
restrict the growth potential of cells from later stages. The fact that mice injected with HLCs 
day 8 show disruption of normal testis cellular architecture with presence of foreign cellular 
structures shows that even if no tumours are yet formed, the base for it to happen is already 
set.  FACS showed a decrease in tumorigenicity of cells as we go down the hepatic 
differentiation. The lower percentage of cells with the ability for tumour formation affects the 
rate at which tumours can arise. And so even if no signs of tumour formation were present we 
cannot exclude the possibility that longer incubation periods would allow for tumours to 
grow. 
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Nevertheless it is important to note that this model gives cells permissive conditions for 
tumour formation: very high number of cells in a matrigel matrix which provides a niche for 
cells to survive, aggregate and proliferate. In the context of cellular therapy there should not 
be such permissive conditions for tumour formation so one must be careful when interpreting 
these results. 
Ideally cellular therapy requires a population of terminally differentiated cells that have no 
risk of losing their phenotype. Even in the human body – the gold standard for correct 
signalling and differentiation – the loss of phenotypical stability is observed. The body has 
regulating mechanisms to prevent survival of deregulated cells but these sometimes escape 
them which can result in the development of cancer. 
Ex vivo generated cells might never fulfil all the safety criteria for transplantation. The saying 
“better be safe than sorry” is behind stem cell regulations when it comes to cellular therapy, a 
cautionary approach that has the patients interests at heart. Even if in vitro models were 
perfect differentiation systems, the risk of developing cancer can never be excluded, as it is a 
natural occurring phenomenon that results from loss of regulating mechanisms. Increased 
knowledge about cancer and the mechanisms for its development might help improve the 
stem cell field including the regulations for their therapeutic use.  
A possibility that has come to light is to genetically modify cells by introducing suicide 
genes. This allows the removal of cells from the organisms in case any problem occurs. This 
option is appealing in theory but it brings up new problems such as the introduction of 
genetically modified cells into patients. This encompasses a whole new field that has its own 
ethical and legal problems and regulations. Besides, by the time a problem is recognized it 
might be too late for the use of a suicide gene approach. As a tumour forms a 
microenvironment is created that can recruit host cells, change their phenotype and 
incorporate them in the tumour. So even if the genetically modified cells might be 
responsible for tumour formation, in the end the tumour will comprise of a variety of cells, 
not all resulting from the transplanted cells. So the suicide gene approach might clear the 
genetically modified cells but clearance of the tumour is not guaranteed.  
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Challenges still remain regarding the use of PSCs derived cells for cellular therapy, but with 
the first clinical trials taking place a better idea of their safety and efficiency should soon be 
accomplished. But before stem cell therapies can be applied in liver disorders a better 
understanding of the cells is required. We know cells present some phenotypical and 
functional characteristics of hepatocytes but a more detailed study on one of its specific liver 
functions could give us better insight on their quality.  
Due to the importance of coagulation for life, and the major role the liver plays in it, 
coagulation presents itself as a good strategy to evaluate the quality of our liver development 
model using iPSC. 
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Chapter 6  Coagulation during development  
 
6.1 Introduction  
 
Being one of the biggest organs in the body, the liver is responsible for a variety of functions, 
amongst them the production of coagulations factors important for homeostasis. Homeostasis, 
from the Greek homeo + stasis meaning “standing still”, is the balance between blood 
coagulation and fibrinolysis, securing normal blood flow in the body. In case of injury it is 
crucial for the prevention of blood loss and repair of damaged tissue or vasculature.   
In this way homeostasis comprises the process of blood coagulation and fibrinolysis 
(dissolution of the blood clot). These processes are connected and need to be highly regulated 
to avoid either blood loss or thrombosis. Many components are part of these processes, as 
depicted in Table 6. These proteins depend on interactions with each other and their 
surroundings for proper regulation of homeostasis. Many of the proteins are serine protease 
enzymes that circulate in the blood as inactive zymogens waiting for an activation trigger. 
Upon presence of the activation trigger, often a form of vascular injury, the process of 
coagulation is activated with a cascade of zymogen activation takes place that culminates in 
repair of the damaged tissue by production of a fibrin plug.  
 
Table 6 - Components of blood coagulation 
Factors Descriptive name Function  
Procoagulants   
I Fibrinogen Precursor of fibrin 
II Prothrombin Precursor of thrombin 
III Tissue factor Cofactor  
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V Labile factor Cofactor in the prothrombinase complex 
VII Proconvertin Linked to TFc activates FX and FIX 
VIII Antihemophilic factor Cofactor in tenase complex 
IX Christmas factor Activates FX 
X Stuart-Prower factor  Converts prothrombin to thrombin 
XI Plasmathromboplastin antecedent Activates FIX 
XII Hageman factor Activates FXI 
XIII Fibrin-stabilizing factor Crosslinks fibrin polymers 
 Prekallikrein activates FXII 
HMWK Kininogen Activation cofactor for FXII and FXI, generates 
bradikinins 
Anticoagulants    
 Antithrombin  Inactivates thrombin, FIXa, FXa, FXIa and FXIIa 
 Protein C Inactivates FVa and FVIIIa 
 Protein S Enhances protein C activity 
 Heparan sulfate Links activating antithrombin III 
 Thrombomodulin Thrombin receptor allowing linking to protein C 
TPFI Tissue factor pathway inhibitor  Inhibits TFc, FVIIa and FXa 
 Heparin cofactor II Inactivates thrombin 
Fibronolytic   
 Plasminogen  Precursor of plasmin 
tPA Tissue plasminogen activator Activates plasminogen 
 Urokinase Activates plasminogen 
Antifibrinolytic   
PAI-1  Inhibits tPA 
PAI-2  Inhibits tPA 
 ɑ-antiplasmin Inactivates plasmin 
TAFI Thrombin activatable fibrinolysis inhibitor Inhibits plasminogen activation 
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This view of coagulation led to the presentation of the cascade model of coagulation in the 
1960s
271
, also known as the classical model, as it explains the process of coagulation by 
which sequential activation of coagulation factors results in the formation of thrombin, that 
converts fibrinogen to fibrin. It proposes sequential steps by which one clotting factor leads 
to the activation of another, eventually leading to fibrin generation (Figure 42). 
 
 
Figure 42 – Original cascade model representation271 
 
The original model has since been modified to include the observation that not all coagulation 
factors possess enzymatic activity but rather function as cofactors for proper activation of 
other factors. This model is often presented with two distinct activating pathways that 
converge at the level of Factor X (FX) in the common pathway (Figure 43). The two 
pathways – intrinsic and extrinsic – are often presented as distinct, independent activating 
pathways. Even though this presentation helps display the different interactions of the factors 
and how they work in a more logical and simplified way, it is too simple to explain the 
physiological events that occur in vivo. In reality the factors in the two pathways do not work 
independently from each other but rather interact in complex and interconnected ways with 
each other and the cells involved in the clotting process
272-274
. Despite not being a true 
representation of biological events, it is a good exemplification of the coagulation process in 
laboratory based tests.  
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Figure 43 – Classical model of coagulation 
 
A new model trying to incorporate the involvement of cells – cell base model – tries to 
present the process in a more similar way to what happens in vivo. Here the process of clot 
production is shown with interactions of cells and the different coagulations factors, derived 
in part from experiments that use cells as source of tissue factor (TFc) (like fibroblasts) and 
activated platelets as surface for thrombin generation
275, 276
. Coagulation is presented as three 
different stages, which even though not independent events, can be divided as: initiation, 
propagation and amplification
276, 277
.  
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Figure 44 - Initiation step of cell based coagulation model 
 
Coagulation is triggered when there is disruption of the vasculature. Blood crosses the 
disrupted site and TFc bearing cells become exposed to blood. FVII present in the blood 
enters in contact with TFc (its cofactor), becomes activated and there is formation of the 
TFc/FVIIa complex – crucial for activation of coagulation (Figure 44). This TFc/FVIIa 
complex at the site of injury acts on circulating FX and FIX, resulting on their active forms 
FXa and FIXa, respectively. FXa interacts with its cofactor FV, activating it and forming the 
prothrombinase complex (FXa/FVa) at the surface of TFc bearing cells. If FXa diffuses from 
the cell surface it is quickly inactivated by TFc pathway inhibitor or antithrombin. However 
the prothrombinase complex at the surface of cells acts on prothrombin, with production of 
small amounts of thrombin. Even though we cannot really separate the phases as it is all 
happening at the same time, formation of thrombin represents the end of the initiation phase. 
Besides the main line of events that results in the production of thrombin, during the initiation 
phase a loop signalling also occurs by which the activated FXa, FIXa or thrombin also act on 
FVII, further activating it to FVIIa. 
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Figure 45 - Amplification step of cell based coagulation model 
 
Production of low levels of thrombin in the initiation phase is not enough for fibrin clot 
formation, but is enough to initiate a burst of thrombin generation. During the amplification 
phase (Figure 45), the thrombin from the previous stage acts at different levels to amplify the 
signal for thrombin production. Activation of platelets is essential for clot formation as these 
are required not only for signalling purposes but also as the first level for the clotting plug. 
Platelets localize at the site of injury by binding to collagen or via von Willebrand factor 
(vWF), which partially activates them. For fully activation the thrombin produced in the 
previous step is required, activating the platelets via protease-activated receptors (PARs). 
This activation results in degranulation that releases partially active FV which is then fully 
activated by thrombin. Thrombin also cleaves FVIII, releasing it from vWF. Furthermore, it 
converts FXI at the platelets surface into its active form FXIa. By the end of this stage the 
activated platelets present at their surfaces all the elements for the propagation phase and the 
burst of thrombin production. 
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Figure 46 – Propagation step of cell based coagulation model 
 
Propagation phase (Figure 46) follows amplification, occurring at the surface of the activated 
platelets recruited in the previous phase. FXIa from previous phase acts on FIX generating 
more FIXa, and the presence of platelets allows FIXa to roam to its surface and bind the 
activated FVIIIa forming the intrinsic tenase complex (FIXa /FVIIIa) on the platelet surface. 
This complex is crucial for the activation of FX to FXa for the production of high levels of 
thrombin. The production of FXa by the tenase complex at the surface of platelets is crucial 
since FXa produced during the initiation phase at the surface of TFc bearing cells is quickly 
inactivated when it diffuses away from the cells. The FXa at the surface of the platelets binds 
to its co-factor FVa forming the prothrombinase complex allowing for thrombin generation. 
It is at the surface of the platelets that enough thrombin is produced to act on fibrinogen and 
form fibrin that spontaneously polymerizes into strands that form the fibrin network over the 
platelet plug and eventually closing the wound. The thrombin produced at this stage is 
sufficient and required for fibrin production but it also has other functions, like the activation 
of FXIII to FXIIIa, activating TAFI and even being incorporated in the clot.  
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The damping down of the signal for fibrin production is very important as an over production 
of clots can lead to thrombosis, and greatly impede life. In the same way, it is also very 
important that the coagulation process stays localized to the site of injury. And so, there are 
mechanisms in place to allow the correct localization and timely termination of the 
coagulation process. This termination process is initiated as the fibrin clot is being formed 
and is crucial for correct homeostasis. Many proteins are involved in the inactivation process 
as can be seen in Table 6 and these can be anticoagulation, fibrinolytic or antifibrinolytic 
factors. Besides these proteins, it is thought platelets also play a crucial role in the damping 
down of the coagulation signal. There is a theory that there are different populations of 
activated platelets during the process of coagulation, with distinct and important functions for 
wound healing. The platelets refereed previously are activated and possess thrombin 
generating ability (COllagen And Thrombin stimulated - COAT platelets), that results from 
the ability of coagulation factors and co-factors to bind at its surface and leads to the eventual 
production of thrombin. Non-COAT platelets (without ability to produce thrombin) are 
thought to join at the site of injury closer to the end of the process and join the plug. The 
absence of coagulation signalling functions allows to damp down the pro-coagulation signal 
as the clot starts to close the wound.  
 
The cell base model is a truer representation of coagulation as it happen in vivo, and looking 
back at the cascade model we can consider that the factors of the extrinsic and common 
pathway – TFc, FVII , FX, FV, Prothrombin and fibrinogen – could be looked at in a 
different perspective as the factors required for the initiation phase. In the same way, the 
intrinsic factors are the ones required for the signal propagation for the production of the 
fibrin clot. This model shows that indeed the two pathways are not redundant, with the 
extrinsic pathway operating on the surface of TFc-bearing cells to initiate the coagulation 
process, while the intrinsic pathway operates on the activated platelets surface to produce the 
burst of thrombin for the production of the fibrin clot.  
The present cell base model also fits better with the current knowledge of bleeding disorders 
such as Haemophilia. Haemophilia is a disorder in which patients have defective blood 
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clotting system, normally the result low or absent levels of clotting factors. The most 
common forms are haemophilia A (FVIII deficiency) and haemophilia B (FIX deficiency). If 
the cascade model was accurate, the absence of either FVIII or FIX should not affect clotting 
as the impairment of the intrinsic pathway would in theory be compensated by the extrinsic 
pathway, and that is not observed. Haemophilic A and B patients bleed because the intrinsic 
tenase complex (FIXa/FVIIIa) is not formed properly, which impedes the activation of 
enough FX for the burst of thrombin production. And so, patients have a slow and inefficient 
formation of blood clots, with the severity of the disease being dependent on the levels of the 
coagulation factors in the plasma. The cell-based model is also able to explain why FXI is not 
essential for coagulation. It is known that patients with FXI deficiency have mild or no 
bleeding tendency. FXI works as an enhancer or booster for FIX activation, and in the 
context of this model the activated platelets allow for FIX activation even without FXI
278
.  
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6.1.1 Coagulation during development 
While coagulation has been characterized extensively in the adult, not much is known at 
earlier stages, especially during development. Levels of the factors are reduced with only 10-
25% of adult levels at 19-23 weeks of human foetus gestation. Levels increase progressively 
and at time of birth only a few have reached adult levels
279. Based on “adult” understanding 
of coagulation, it would be expected that regulation of the factors involved in coagulation 
would be temporally coordinated, while in fact some discordant expression is observed
280
.   
Indeed there is evidence indicating a preferential expression of the extrinsic pathway factors 
earlier during development
281
. 
 
Figure 47 - Table of expression of haemostasis specific genes in mouse embryos. Copied from Ong et al (2000). Legend: 
- no signal; +, ++, +++ increasing signal strength    
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Ong et al., in an attempt to understand haemostasis during embryonic development, 
characterized expression of several components of blood coagulation at different stages of 
mouse development. Figure 47 is a table from their paper with semi-quantitative gene 
expression analysis done by RT-PCR of different haemostasis-specific genes. Focusing on 
coagulation factors, it seems that indeed there is earlier expression of the extrinsic pathway 
factors. From their analysis by day 7.5 of gestation (E7.5) expression of extrinsic factors is 
on, while only at E10-E11.5 can most of the intrinsic factors be detected. 
Moreover, Hans et al. showed that the levels of human coagulation factors before birth and in 
newborns are not identical to adults. During late stages of foetal development and the first 
months of life, the extrinsic pathway factors show equivalent levels of expression to the adult, 
while the intrinsic factors have reduced levels
281
. Only from 6 months onward do all factors 
have levels similar to adults
281
.  
As described above, the extrinsic pathway factors alone cannot sustain effective coagulation 
in the body. For wound healing and a fibrin clot to be formed, coagulation requires more than 
just the extrinsic phase factors, as these by themselves do not produce enough thrombin for 
fibrin production (Figure 44). The thrombin produced at this stage acts on other levels such as 
the activation and recruitment of platelets to the site of injury for the formation of the loose 
platelet plug (that works as a scaffold for the fibrin network). This process sets the scene for 
the other stages of coagulation – activated platelets are required for the FVIIIa/FIXa complex 
which is fundamental in the propagation phase for production of higher amounts of thrombin 
and consequently fibrin, required for clot formation. And so the extrinsic factors are crucial 
for the initiation phase of coagulation.  
And so, one hypothesis for why the extrinsic factors are turned on earlier during 
development, rather than all factors together, could be connected to their role in the 
recruitment of cells during the initiation phase, with possible involvement in vasculature 
formation.  
“Embryonic blood vessels arise via a complex series of linked processes including the 
primary differentiation in situ of endothelial precursors (angioblasts) from mesodermal 
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precursors, their alignment into vascular cords to form a primary vascular plexus, and the 
subsequent generation of additional endothelial cells and vessels by the sprouting and 
splitting of pre-existing vessels”279. This is a complex process by which extensive 
remodelling and maturational changes occur. Coordination of the signals and recruitment of 
cells for proper vessel formation is important, as well as to make sure no haemorrhage or 
thrombosis occurs. The presence of some coagulation factors prior to vasculature formation 
and the lethal phenotype associated with their inactivation
282-284
 (Table 7), especially the 
observation of defective blood vessel formation in TFc-/- mice
284
, supports the idea of 
embryonic involvement of coagulation factors in vasculature formation. Nevertheless the fact 
that not all extrinsic pathway factors result in embryonic lethality makes the role of the 
extrinsic pathway factors unclear
285
, with the possibility that only some factors take part in 
functions in vasculature formation.  
 
Table 7 – Table with phenotypic manifestations of coagulation factors deficiency both in mouse and human 
Deficiency Mouse  Human 
Fibrinogen Bleeding associated with trauma 
Abnormal wound healing 
Abortion due to maternal bleeding 
Bleeding 
TFc Embryonic lethality due to defective blood vessel 
formation 
Unkown 
FV Embryonic lethality &  
Postnatal lethality due to severe spontaneous bleeding 
Bleeding 
FVII Postnatal lethality due to severe spontaneous bleeding Bleeding 
FVIII Bleeding Bleeding 
FIX Bleeding Bleeding 
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And so it is possible that these factors are there either as a requirement for small scale level of 
coagulation during development, or as necessary elements for the production of vasculature 
during development.  
Moreover, there is evidence implicating some coagulation factors with other functions, such 
as potent mitogens 
286
, role in tumorigenesis
287
, inflammatory roles
288, 289
 and even with nerve 
regeneration
290
. This shows us that indeed the understanding of coagulation during 
development is incomplete and that some factors might be involved in other aspects besides 
coagulation.   
In terms of evolutionary biology, the hypothesis that the extrinsic pathway factors are turned 
on earlier during development is very interesting. Coagulation first appeared as a separate 
system in vertebrates, as a very simple system when compared to higher mammals. This basic 
system, as exemplified in lamprey (Figure 48), consists of the factors we refer to as the 
extrinsic pathway factors. 
 
 
Figure 48 – Coagulation system in lamprey. Figure from Doolittle291 
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Along the evolutionary road, the increased complexity of animals required for more complex 
systems to control haemostasis. Previous to vertebrates – the protochordates – have simple 
circulatory system and the clumping of circulating cells at the wound site is thought to be the 
only requirement in terms of a coagulation system
292
. The lack of clotting factor genes in the 
genome of some of these protochordates reinforces the idea that no specialized clotting 
mechanism existed at this stage of evolution
293
. 
Jawless fish are among the first vertebrates to appear, and it is with them that the invention of 
coagulation happens. The system is much simpler than in higher animals, but there is fibrin 
clot formation, produced by the action of thrombin. It is believed that thrombin precedes 
fibrinogen, probably with an early role in clumping cells (platelets ancestors) at the site of 
injury, a function it still has to this day
294
. The appearance of fibrinogen would allow a wider 
range of action, with a sturdier clot being formed, composed of both cells and fibrin. 
Duplications of the prothrombin gene would allow the appearance of coagulation factors VII 
and X. It is well known that many of the coagulation factors are related to each other, 
resulting from gene duplications, as shown by several studies
294-296
.  
And so, the simple coagulation system observed in lampreys consisting of FX, FVII, FV, 
prothrombin and fibrinogen (as seen in Figure 48), introduces an evolutionary correlation to 
the earlier expression of the extrinsic and common coagulation factors. This could be 
connected to gene regulatory mechanisms that date back to the beginning of coagulation.   
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6.2 Do HLCs express coagulation factors? 
 
Our model of liver development is focused on differentiating iPSC into HLCs. As depicted in 
chapter 5, HLCs from several differentiation protocols, including ours, present a foetal 
phenotype. While a foetal phenotype is not desirable in the context of cellular therapies, it 
gives us the chance to study an early developmental stage of hepatocytes in an in vitro 
setting.  
Considering the hypothesis that the extrinsic pathway factors might be turned on earlier 
during development, this unique feature of our model allows to study coagulation during 
development uncover what is really happening.  
And so we decided to look at expression of coagulation factors (FG, FII, FV, FVII, FVIII, 
FIX, FX, FXI, FXII and FXIII) at each of the stages of differentiation: day 0 (iPSC stage), 
day 4 (endodermal stage), day 8 (hepatic commitment stage) and day 13 (hepatic maturation 
stage). The relative expression is done comparing to adult liver (where all factors are highly 
expressed).  
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Figure 49- Coagulation factors gene expression data in RDP2 iPSC line hepatic differentiation. Gene expression by 
qPCR at different time points of hepatic differentiation protocol: day 0 (iPSC), day 4, day 8 and day 13. Adult liver as 
positive control.  Expression levels normalized to GAPDH endogenous control. Stats using unpaired t test. Legend: * 
statistically significant (p<0.05) 
 
As shown in Figure 49, we can observe upregulation of coagulation factors from day 4 to day 
8 of the hepatic differentiation protocol. This interval day4-day8 corresponds to the stage of 
liver commitment during development. The association between liver development and 
expression of coagulation factors makes sense as it is widely accepted that the liver, and 
primarily the hepatocytes, are the main site of production of the coagulation factors, even if 
some reports show production in extra hepatic sites
297, 298
.  
Not all coagulation factors are upregulated, and the factors that are detected correspond to the 
extrinsic and common factors: FGA, FGB, FGG, FII, FV, FVII and FX. Absence of intrinsic 
factors expression in the HLC model of liver development corroborates the hypothesis that 
the extrinsic pathway of coagulation is turned on earlier during development. As mentioned 
previously, this hypothesis is supported by evolutionary evidence and by the possibility of 
other roles these factors might have during development. If the hypothesis is true, the foetal 
phenotype of HLCs can justify the absence of intrinsic factors expression, that otherwise 
should be detected. 
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6.3 What is happening in vivo? 
 
The data in HLC seems to corroborate the hypothesis that the extrinsic pathway factors are 
expressed earlier during development, which might indicate an important role of these factors 
during embryogenesis. Nevertheless it is important to ask whether our model indeed 
replicates the in vivo situation, and if so validating the hypothesis.  
 
6.3.1 In human model 
Human samples from embryonic/foetal stages are not easy to acquire as these can only be 
obtained from legal abortions. As a result not much has been done regarding coagulation 
during human development using human models. In 1990, Hassan et al. showed preferential 
expression of the extrinsic factors during human foetal development
281
. They looked at gene 
expression by northern blot and showed that levels of expression of the extrinsic pathway 
factors were equivalent to adult levels while intrinsic factors, particularly FIX, showed 
reduced expression. Even though this study points for a preferential role of the extrinsic 
pathway factors during development, it also showed expression of the intrinsic factors even if 
at lower levels.  
And so, using human foetal samples of our own (kindly provided by HDBR), we evaluated 
expression of coagulation factors at 2 different stages of liver development: week 5 post 
conception (pc) and week 20 pc. 
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Figure 50 - Coagulation factors expression in human foetal samples. Expression levels by qPCR of coagulation genes in 
human foetal samples at week 5 and week 20 of gestation. Expression normalized to GAPDH endogenous control. Stats 
using unpaired t test. Legend: * statistically significant (p<0.05) ** very statistically significant (p<0.01).  
 
As shown in Figure 50 all coagulation factors can be detected as early as week 5 pc. There is 
no consensus pattern that applies to all factors but in general adult liver presents significant 
higher levels of expression compared to earlier time points. 
Both week 5 samples show similar levels of expression across the different factors, while 
week 20 samples show variability in some of the factors: one of the samples is closer to adult 
levels of expression, and the other to week5 samples.  The variability observed between 
samples, both from same stage and different stages, is not surprising as it is known that 
hepatic samples show a high degree of gene expression variability. Furthermore, the samples 
were obtained at different times and kept frozen until requested. Different storage time and 
any possible differences in manipulating the samples could have affected their quality. A 
higher number of samples could help obtain a better trend.  
In the paper by Hassan et al., the extrinsic pathway of coagulation is implicated as the 
preferential pathway during development because the expression levels detected were 
equivalent to adult liver, while the intrinsic factors have lower levels of expression. Unlike 
Hassan et al. we do not see a preference to the extrinsic factors, and while FX and FGB show 
equivalent levels of expression to adult liver, other extrinsic factor are significantly reduced 
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(Figure 50). We also see some intrinsic factors with equivalent expression to adult levels 
(Figure 50). Their observations were based on RNA levels assessed by northern blot, a semi-
quantitative method. The accuracy of northern blot can put into question their results 
especially since our data was obtained using qPCR, a highly sensitive method. 
Of note is the fact that FIX has very low levels of expression in all samples. FIX is crucial for 
the tenase complex (FVIIIa/FIXa), and its absence is known to cause bleeding disorder – 
haemophilia A. Absence of FIX could indicate that the extrinsic pathway is the active one but 
presence of all the intrinsic factors makes it hard to support the claim. Another curious fact is 
the high levels of expression of FXIIIa during development. 
With these results, our human foetal samples aren’t able to validate the hypothesis. Earlier 
time points might be necessary to confirm earlier expression of extrinsic and common 
pathway factors, but obtaining samples earlier than week 5 is not viable.  
Looking at the developmental stage of the liver of Week 5 embryos, classified at Carnegie 
stage 15, we see that the liver is already quite developed, with its typical architecture already 
present.  Figure 51 shows sections of the embryo where it is possible to see that the liver 
makes up a significant part of the embryo, occupying most of the central plate. Presence of a 
mature liver structure, significant in size, makes it less surprising that as early as week 5 all 
coagulation factors can be detected. 
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Figure 51 – Sections of human embryo at Carnegie stage 15. Liver can be observed to take a big portion of the central 
plate of the embryo. Figures obtained from: http://www.ehd.org/virtual-human-embryo/stage.php?stage=15   
 
As earlier human samples are not possible to obtain we decided to turn to other models for 
the validation of our hypothesis. 
 
6.3.2 In mouse model 
Mouse is the most common model used to study human development, not only due to the fast 
and easy way to breed them but also for its similarities to human. Much of what is known 
regarding liver development was obtained from mouse studies and so it is logical to use mice 
as our model to assess coagulation expression patterns during development.  
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The study by Ong et al. showed earlier expression of the extrinsic coagulation factors, 
detected as early as E7.5 (Figure 47). Detection of coagulation factors this early in mouse 
development is surprising as liver development is known to start around E8.0. Liver in mice 
originates from the ventral foregut endoderm starting at E8.0 while the first morphological 
evidence is the formation of the hepatic diverticulum next to the heart at around E9.0. Bi-
potent hepatic specialized cells – the hepatoblasts – arise and the liver bud undergoes a period 
of accelerated growth between E10-E15. Maturation is gradual and occurs until after birth, 
with adoption of the typical architecture of the liver that allows execution of the several 
hepatic functions. Hence expression of coagulation factors prior to liver development is 
counter intuitive.  Furthermore, gene inactivation studies with coagulation factors shows 
lethality between E9.5 and E11, which is more in line with the timeline of liver development.   
To dissect what is really happening during development we decided to look at expression of 
coagulation factors in mouse embryos. 
In a first instance we looked at coagulation factors expression in GEO datasets that used 
mouse embryonic samples. GEO datasets stores original submitter-supplied records (series, 
samples and platforms) as well as curated datasets that are publicly available, even providing 
tools to identify, analyse and visualize data to specific queries.  
We used GEO to obtain the original gene array data containing mouse embryonic samples 
and analysed it using Affymetrix console with regards to coagulation factors. Datasets with 
whole embryo RNA were inadequate. RNA from coagulation factors is not detected, most 
likely due to dilution of coagulation factors mRNA in the whole embryo mRNA spectrum. 
GEO datasets with embryonic mouse liver RNA were available, with the earliest time point 
being E10.5. Going back to Figure 47 it is not clear whether the intrinsic factors are present 
or not at E10.5. Analysis of the data (Figure 52 and Supplementary figure 11) shows us that 
indeed all factors are already expressed at E10.5 and so earlier time points are required for 
better assessment of the expression pattern for coagulation factors. 
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Figure 52 – Coagulation factors expression in mouse embryonic liver samples in GEO dataset. Example of coagulation 
factors from Intrinsic, Extrinsic and Common pathways of coagulation. Expression analysed in Transcriptome Analysis 
Console (TAC) from Affymetrix 
 
To obtain mouse embryonic RNA we dissected mouse embryos and isolated liver bud 
structures in order to obtain a higher liver specificity and therefore increased concentration of 
coagulation factors mRNA. We were able to do so for embryos from E8.5 forward, as in 
earlier time points liver structures are not developed enough to be isolated from the embryo 
and so total RNA was collected (example of E7.5 and E11.5 embryos in Supplementary 
figure 12) 
Analysis of gene expression data shows that all coagulation factors are turned on between 
E9.5 and E10.5 of mouse development (Figure 53). Levels of coagulation factors expression 
at E10.5 and E11.5 are significantly reduced when compared to adult mouse liver, which is 
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expected and once again disproves Hassan et al. theory that the extrinsic pathway factors 
have equivalent levels to adult
281
. 
Upregulation of these genes between E9.5 and E10.5 makes sense in a developmental point 
of view as liver structures start to emerge during this period. How were Ong et al able to 
detect expression by 7.5 is unknown
279
, especially when considering that qPCR is a more 
sensitive method than RT-PCR and so it should provide more reliable data.  
Coagulation factor expression was only detected in the dissected liver structures of mouse 
embryos at E10.5 and E11.5. FVIII and FXIIIa were detected in E11.5 embryo RNA (minus 
liver) which can indicate extra-hepatic production of these factors during development. The 
exclusive expression of most coagulation factors to dissected liver structure reinforces the 
correct dissection of the embryos. 
A curious fact is the observation that FXIIIa has higher expression levels during development 
than in the adult state. This observation is consistent across species and experiments (Figure 
53, Figure 50 and Supplementary figure 11) and might implicate an important role of FXIIIa 
during development. Other factors involved in the fibrinolytic system – tissue plasminogen 
activator and plasminogen activator inhibitor -  have shown a similar trend, with increased 
levels during development than in the adult
299
. The biological significance of these elevated 
values still remains to be clarified. 
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Figure 53 – Coagulation factors expression in mouse embryonic samples at different time points of development. 
Gene expression by qPCR of coagulation factors in mouse embryonic samples at different stages of development (E7.5, 
E8.5, E9.5, E10.5 and E11.5) and adult mouse liver (as positive control). Relative expression to GAPDH mRNA levels 
(endogenous control). Stats using unpaired t test. Legend: * statistically significant (p<0.05), ** very statistically significant 
(p<0.01).  
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The fact that we observe activation of all coagulation factors together indicates that there 
doesn’t seem to be preferential expression of the extrinsic pathway. If so, the pattern of 
expression observed in our HLC model might just be an artefact from in vitro culture.  
This has implication regarding the quality of HLCs. The characterization routinely done to 
HLCs relies on a set of tests that focus on specific liver markers and functions, but these can 
vary among labs. The liver is responsible for many functions, many that have never been 
investigated in HLCs, such as coagulation. We show here that HLCs do express coagulation 
factors, even if intrinsic pathway factors expression is not detected. As this appears not to 
recapitulate expression patterns during in vivo development, it can imply that HLCs have a 
different profile than hepatocytes when it comes to coagulation.  
Quality of HLCs as a model for liver development and coagulation can be disputed, with 
these results able to be used on different sides of the argument: the detection of coagulation 
factors does show engagement of HLCs regarding coagulation but the different pattern of 
expression compared to in vivo development disputes the reliability of this engagement, a 
possible consequence of the effect of in vitro culture in the quality of hepatic differentiation.  
It is expected that in vitro differentiation can never fully replicate the in vivo process, with 
implications on the quality of the final population. To what extent does the in vitro setting 
affect the profile of cells is not known and most likely varies according to cell types and the 
in vitro systems.  
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6.4 HLC as a model to study coagulation 
 
The expression pattern of coagulation factors in our HLC model is the only evidence that 
supports the hypothesis that the extrinsic pathway factors are turned on earlier during 
development. In contrast to HLC model, in vivo data does not support the hypothesis. Data 
from in vivo experiments has stronger credibility as it represents the natural system, while in 
vitro systems aim to replicate it but seldom are 100% successful.  
This implies that the observation in HLC model could be an artefact from the in vitro 
differentiation system. Whether this observation is only seen in our model or is present in 
other in vitro differentiation system is a relevant question, as if it is model specific it implies 
that our differentiation protocol is not robust and should be abandoned.  
One way to assess this is to use GEO datasets of other hepatic differentiation protocols and 
look at expression of coagulation factors. Analysis of gene array data from a different hepatic 
differentiation protocol
236
 showed no intrinsic factors of coagulation expression (Figure 54). 
Even though the differentiation protocol is slightly different, being longer and using slightly 
different cytokines, it also recapitulates in vivo development going through similar stages 
(endoderm differentiation, hepatic specification and maturation). They also characterize the 
cells, and not only show hepatic specific functions, but the same transcriptional profile as we 
assessed by RNA sequencing, therefore cells should have a similar phenotype to our HLCs. 
The absence of intrinsic coagulation factors indicates that this observation is not specific to 
our differentiation protocol and it might be a problem of the in vitro differentiation systems. 
We cannot conclusively say that all hepatic differentiation protocols show the same 
expression pattern but the fact that 2 distinct protocols show the same pattern strongly 
suggests this might be a feature seen in all in vitro hepatic differentiation systems. 
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Figure 54 – Hierarchical clustering of coagulation factors expression detected in GEO dataset of cells during hepatic 
differentiation protocol. Output from TAC affymetrix console.Legend: 1- HLC at day5 of differentiation protocol 
(endodermal cells), 2- cells at day 10 (hepatoblasts), 3- cells at day 20 (HLCs). Green to red shows upregulation of gene 
expression between different stages. Only coagulation genes detected: FGA, FGB, FGG, FII and FX. 
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Even though in vivo data doesn’t confirm the observation in HLCs, there is still a possibility 
that the hypothesis is indeed true. The possibility exists that the extrinsic and common 
pathway factors are turned on earlier in development, with the window of expression being 
too short to detect in the mouse model, while the in vitro systems prolongs or gives 
preference to this period and therefore we are able to detect it.  
One experiment that might help shed light on the matter would be longer culture periods of 
HLCs to see if we can detect expression of intrinsic pathway factors. If upregulation of the 
intrinsic factors is observed at later time points of the differentiation protocol, a case could be 
made regarding the veracity of the hypothesis.  Independently from supporting the 
hypothesis, if all coagulation factors could be detected in the in vitro system, HLCs would 
present a closer phenotype to adult hepatocytes.  The problem with longer culture periods is 
the loss of the hepatic phenotype, as we know hepatocytes do not stand well in vitro 
conditions.   
The only way to truly know what happens during human development would be to confirm 
using human samples. As it is impossible to obtain samples that early in development, the use 
of other in vivo models with longer developmental periods could pose an alternative. 
Whether or not it is an in vitro artefact or real representation of what happens during 
development, the upregulation of coagulation factors between day 4 and day 8 of the 
differentiation protocols suggests that there is a common regulatory pathway being activated 
during this period. The next chapter will focus on this, with the aim of trying to identify the 
regulators of coagulation factors.   
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Chapter 7 Regulation of coagulation factors expression  
 
7.1 Introduction 
 
Transcriptional regulation is the process that controls conversion of information from DNA to 
RNA form. This process allows cells to continually adapt to changing conditions in their 
environment but is also crucial for the cell-type diversity observed in multicellular organisms. 
The process of regulating gene expression is complex and multiple processes can influence 
expression, ranging from the chromatin state to the use of transcription factors (TFs) that bind 
DNA at specific regulatory sites. The genomic loci where the TFs bind are called 
transcription factor binding sites (TFBSs) and constitute the cis-regulatory elements. These 
cis-regulatory elements are classiﬁed into promoters, enhancers, silencers, and insulators 
among others
300
. Both promoters and enhancers are short genomic loci that serve as platforms 
for the binding of TFs. While promoters are usually located in the immediate vicinity 
upstream of genes, enhancers can be many kilobases away from the gene they regulate
301
. 
 
 
Figure 55 – Gene regulatory region where transcription is initiated  
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The schematic in Figure 55 is a simplified version of the eukaryotic gene regulatory region, 
and shows that gene expression relies on complexes formed by multiple TFs, where the rule 
“one transcription factor per TFBS” does not usually apply. This increases the complexity of 
gene expression regulation but also helps reduce the number of elements required during 
transcriptional regulation of genes within a cell, as each of these elements can act on multiple 
networks and have several functions. In this way, a TF can be involved in the expression of 
multiple genes, a central idea in the concept of common regulatory pathways. It is also 
possible that some regulatory pathways are controlled by master regulators, TFs responsible 
for regulating the specific network by acting on other regulatory elements. Usually the 
concept of master regulator is used in the context of lineage specification as the TF(s) 
required and sufficient for programming a specific cell fate
302
. The same concept can be 
applied at a smaller scale, in smaller and clustered regulatory networks instead of the entire 
cellular phenotypes and lineage specification. While master regulators have been detected for 
certain pathways
303
, it does not imply every pathway will have a master regulator.  
The transcriptome is the full repertoire of transcripts expressed in a cell at a given 
developmental stage and condition. Identifying the transcriptome is essential for 
understanding cellular mechanisms such as the ones that govern developmental and disease 
states. Human genome-wide expression analysis using next generation sequencing, such as 
RNA-sequencing (RNA-seq) data, provides an opportunity for in depth profiling of 
fundamental biological activity such as gene expression and regulation.  
RNA-seq is a DNA sequencing technology that provides a high throughput method for cDNA 
sequencing, generating information about mRNA content and quantifying gene expression. 
This technology has the added advantage of reducing background noise, being un-biased 
(does not require a control genome) and sensitive enough to detect wider range of the 
transcriptome
304
, especially when compared to other available technologies such as gene 
arrays. RNA-seq has clear advantages over existing methods and is helping to better 
understand the transcriptome of various species, including in humans
304-306
. 
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7.2 In the search for a master regulator 
 
The observation that all common and extrinsic coagulation factors are upregulated between 
day 4 and day 8 of the differentiation protocol (chapter 6 section 6.2) led us to the hypothesis 
that there is a common set of TFs responsible for the upregulation of these extrinsic and 
common pathway coagulation factors. It is likely that these TFs are upregulated prior to day 
8.  We, therefore, decided to search for possible master regulator(s) of these coagulation 
genes using RNA-seq, motif and network analysis in order to improve our understanding of 
the mechanism(s) regulating the so-called extrinsic and common pathway. This pathway is 
preserved through evolution and is critical for the initiation of blood clot formation.    
We carried out a combination of in vitro and in silico work in search of candidate master 
regulators. Using RNA-seq, we looked for differential expression of TFs at different time 
points of the hepatic differentiation of iPS cells. We then performed an in silico exercise to 
identify putative transcription binding sites in the upstream region of the coagulation genes. 
Additionally, we searched the published databases for known protein-protein interactions. 
This allowed us to narrow down the TFs that may be involved in regulating the extrinsic and 
common pathway genes. 
 
7.2.1 RNA-seq data analysis 
RNA-seq analysis was carried out as described in methods (Chapter 2 section 2.14). In brief, 
RNA was harvested in triplicates from iPS cells, and differentiated cells at day 4, 8 and 13. 
For comparison, we also harvested RNA from primary human liver hepatocytes (Life 
Technologies). Our collaborators in Cambridge (Professor Willem Ouwehand, Dr. Mattia 
Frontini, Dr. Myrto Kostadima and Dr. Romina Petersen) performed RNA sequencing on 
these samples and assisted with parts of the initial analysis. The RNA-Seq read counts were 
imported into DESeq2 and their variance stabilizing transformation (VST) was quantified. 
The log fold change was plotted against the mean gene expression (Figure 56). The plot in 
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Figure 56 shows the unshrunken log2 fold changes from the four different time points over 
the mean of normalized counts (i.e. the average of counts normalized by size factors).  
 
Figure 56 – Mean average (MA) plot representation of differential expression of genes in the sample overall (using 
DESeq2). The red dots are differentially expressed while black dots are not. 
 
Because fold changes are non-additive and asymmetrically distributed, all of our RNA-seq 
analysis uses log (fold change) scale. The log (fold change) are normalized before any further 
analysis, to enable comparison between different time points and conditions. The log (fold 
change), quantity that measures a gene’s expression, was calculated from the fragments per 
kilobase of transcript per million fragments mapped (FPKM) after normalization. The relative 
abundances of transcripts are described in terms of the expected biological objects 
(fragments or total counts) observed from a RNA-seq experiment.  
Following the differential expression analysis using MMDIFF (refer to Chapter 2 section 
2.14.3), only those with a posterior probability p>0.5 were considered, allowing to greatly 
reduce the number of differentially expressed genes from the pool of potential regulators of 
coagulation (Table 8). Genes were further categorized based on up- and down-regulation 
(Table 8), but we narrowed our focus on TF that were up- or down-regulated since we were 
interested in factors that control expression of the coagulation genes.  
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Differential expression was performed between the sequential time points of the hepatic 
differentiation protocol – d0 (iPS cells) vs d4, d4 vs d8 and d8 vs 13 – allowing us to assess 
what happens between each stage. An additional analysis looked at difference between iPSCs 
and day 4 Vs day 8 and day 13.  
Table 8 - List of differentially expressed genes between different time points in the study. 
p>0.5 d0d4 d4d8 d8d13 d0d4 vs d8d13 
Expressed genes 1024 1673 665 4766 
Upregulated 620 849 493 2334 
Downregulated 377 787 155 2302 
TF 100 173 68 565 
Upregulated TFs 69 98 53 293 
Downregulated TFs 31 75 15 272 
Coagulation 0 5 2 7 
 P*: posterior probability – the probability of assigning observations to groups given the data. Meaning, the probability of assigning up- 
or down-regulation with specific fold between two time points to a gene, given the data being analysed. The revised probability of the 
gene in considering being up- or down- regulated between two different time points given that the gene has equal chances of being either 
up- or down- regulated. 
 
Table 8 shows upregulation of the  seven coagulation factors mRNA between d0d4 and 
d8d13, which is in concordance with our observations in a separate technical analysis using 
qPCR as described in  the results section of Chapter 6 (section 6.2). In terms of their 
log2(FPKM+1) values, a quantitative measure of expression, Figure 57 shows the normalized 
log mean expression values of each of the extrinsic and common coagulation genes at each 
stage of the differentiation protocol. The intrinsic coagulation factor genes were either not 
detected or at low levels, representative of background rather than expression. This may 
suggest that further differentiation in these iPS cultures may be required for upregulation of 
all coagulation factors.    
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Figure 57 –Quantitative measure of expression of the extrinsic and common coagulation genes at the different stages 
of the hepatic differentiation protocol and in liver control. Expression levels assessed by RNA sequencing  
 
Figure 58 shows the fold change in expression of the coagulation genes during the hepatic 
differentiation. Again, it confirms the upregulation of the common (FX, FII, FGA, FGB, 
FGG) and extrinsic coagulation factors (FV and FVII) occurring between day0/day4 (d0d4) 
and day8/day13 (d8d13). A negative value implies upregulation between two groups, 
meaning the gene is upregulated in the second group compared to the first. For example, FV, 
between d0d4 and d8d13 has a log2(FPKM+1) value of -1.6 which means that the gene is 
upregulated in the second group (d8d13) with respect to the first (d0d4). Individual analysis 
between each stage was also done, confirming upregulation of the extrinsic and common 
factors between day 4 and day 8.  
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Figure 58 – Bar chart showing the fold change in all the 14 coagulation genes. Fold change shown for different groups: 
Day 4 Vs Day8, Day 8 Vs Day 13, Day 13 Vs Liver 
 
As we are interested in the regulatory network for the coagulation genes, the period when 
coagulation genes are upregulated becomes the relevant time window to look for transcription 
factors. From the total 565 significantly up- and down-regulated transcription factors 
throughout the whole differentiation (Table 8), it is likely that the master regulator candidates 
are upregulated either along with the coagulation genes or before their appearance.  
To identify the relevant TFs in the coagulation gene expression network we decided to use in 
silico analysis of the upstream regions of the coagulation genes to identify consensus sites for 
TFs (motif analysis) and crosslink this with RNA-seq data. At this juncture, the master 
regulatory candidates could be any from the 167 transcription factors up-regulated between 
day 0 and day 8 (Table 8) in the RNA-seq analysis. We also keep a track of the TFs between 
day 8 and day 13 to check if we could find any possible TF of the other coagulation factors 
that would be expressed later during development. 
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7.2.2 Motif Analysis 
Motif analysis can help reduce the number of candidate TFs for the coagulation gene 
expression. Motifs are defined as a sequence pattern that is widespread and thought to have a 
biological significance. Using bioinformatics, motif analysis allows us to use knowledge of 
the DNA sequence of genes and upstream regions to look for consensus binding sites where 
possible regulatory elements (such as transcription factors) can bind.  
Considering that the upstream region of genes normally consists of non-coding DNA, the 
knowledge that functional elements (such as TFBSs) are known to evolve at a slower rate 
than non-functional elements makes conserved DNA sites good candidates for TFBSs. This 
method for TFBS discovery uses alignment scripts to find conserved regions, and normally 
takes into consideration sequence conservation of these TFBSs 
Coagulation genes are conserved between each other and are considered to have multiplied 
from a small number of core genes. Despite their evolutionary conservation, the promoter 
sequences do not share high homology. They only share 19% sequence similarity between the 
15kb upstream region of extrinsic and common coagulation factor genes. Despite the low 
homology, they do share common TFBS motifs.  
Using in-house databases (Supplementary table 1), we queried the 15kb upstream regions of 
our genes of interest to find TFBS motifs and identify the possible TFs that bind to them (for 
more detailed description refer to Chapter 9 section 9.3). From the list of all possible TFs that 
bind at various upstream motif regions of every coagulation gene, we filtered out duplicates 
and selected only those TFs that appear to bind to more than one coagulation factor. This 
because we are searching for master regulator(s), and by definition these will regulate 
multiple coagulation factors. Therefore, from the hundreds of transcription factors predicted 
to be binding to the 14 coagulation genes, only 95 possible transcription factors were 
common to more than one coagulation factor gene.  
Not all of the 95 TFs regulate the coagulation genes. Hence, we carried out over-
representation analysis (ORA) on these 95 potential master regulator candidates. ORA allows 
to check which of the 95 TFs are significantly enriched and associated with the coagulation 
      
182 
 
pathway. ORA reduced the number to 17 possible candidates, and with further filtering for 
liver specific TFs (in house database in Supplementary table 1), the number was reduced to 9 
possible candidates, found in Table 9.  
.  
Table 9 - Master regulator candidates from Motif analysis 
C/EBP 
APOA4 
GATA-3 
NF-1 
GR 
HNF1B 
HNF4A1 
NF-kappaB 
OCT1 
 
Of the 273 possible TFs differentially regulated between day 0 and day 8 of the hepatic 
differentiation, we filtered five master regulator candidates identified by the in silico motif 
analysis.  Combing the results of both RNA-seq analysis and sequence based motif analysis 
allowed us to shortlist five potential candidates for the regulation of coagulation: HNF4A, 
CEBPZ, HNF1B, GATA-3 and NF-KappaB1 (Table 10).  
Table 10 – Master regulator candidates from combining RNA-seq and Motif analysis 
Master TF 
candidate 
Posterior 
Probability 
log2(FPKM+1) Fold 
Change*  
description 
day0/day4 day8/day13 
HNF4A1 0.98 1.17 9.08 -3.14 hepatocyte nuclear factor 4, alpha  
HNF1B 0.99 1.63 25.58 -2.84 HNF1 homeobox B 
GATA3 0.99 1.45 12.44 -2.59 GATA binding protein 3 
C/EBPz 0.93 149.51 53.12 0.99 CCAAT/enhancer binding protein 
(C/EBP), zeta 
NFKB1 0.54 1.66 3.12 -0.89 nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
1 
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7.2.3 Gene network/Pathway analysis 
Gene network/pathway analysis is another strategy that allows us to independently shortlist a 
set of possible master regulators for coagulation factors gene expression. To build this 
network for coagulation genes, the system biology approach was used. For such an analysis 
information from protein-protein interactions (PPI) networks (STRING and IntAct databases) 
as well as from pathway databases (KEGG and REACTOME databases) were used. From the 
human PPI, we generated a sub network with only those genes that are seen during RNA-seq 
liver differentiation analysis. Using this network as a template, we constructed multiple levels 
of regulatory networks starting from the 14 coagulation genes, to narrow down a set of 
possible master regulator candidates. Figure 59 represents the constructed network from the 
theoretical knowledge obtained from the different databases. 
 
 
Figure 59 – Gene network for coagulation genes. Knowledge based 
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Combining information from RNA-seq with the previous network, we were able to remove 
all the TFs that are not expressed during our hepatic differentiation and a new multilevel 
regulatory network was constructed allowing to further narrow down the number of possible 
master regulator for the coagulation genes (Figure 60).  
 
 
Figure 60 – Gene network for coagulation genes. Knowledge based information combined with RNA-seq data  
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Figure 60 shows a representation of the complex network obtained using this approach. In 
green, lies the starting point for this network: the coagulation factors. Several other proteins 
interact with them but only the factors in pink fit as possible regulators of the network. 
RNA-seq together with in silico approaches allowed us to shortlist candidates that are 
possible master regulators of the coagulation network. From the possible master regulators, 
we find three common TFs from two independent analyses: HNF4a, HNF1 and GATA3. The 
recurrence of these TFs from independent analysis makes them strong contestants for master 
regulator of the coagulation expression pathway.  
Both HNF4a and HNF1 are important TFs for liver phenotype, and while GATA3is also 
known to be expressed in hepatocytes, it is most known for regulating T-cell development 
and in endothelial cell biology. HNF4a has previously been implicated for its role in 
regulating coagulations genes
307, 308
 as well as regulating HNF1 expression in hepatocytes
309
. 
Together with its important role in the hepatic phenotype, HNF4a was regarded as the leading 
candidate as master regulator of coagulation factors expression. With this in mind, we 
decided to examine its role in coagulation factors expression.  
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7.3 Does HNF4a regulate expression of coagulation factors? 
 
HNF4a is a key regulator of liver homeostasis, shown to be involved in functions such as in 
lipid and bile acid synthesis, gluconeogenesis, amino acid metabolism, and even in blood 
coagulation. Knock out models have shown the importance of HNF4a for proper liver 
development during embryogenesis
310, 311
 and in adult disruptions of HNF4a expression has 
been associated with development of hepatocellular carcinoma
312, 313
. From a biological point 
of view, the strong relation of HNF4a with normal liver phenotype supports the view of 
HNF4a as the best candidate for master regulator of the coagulation pathway. 
Indeed, many of the coagulations factors are known to have HNF4a as an important TF for 
their expression (rulai.cshl.edu/LSPD/), but whether or not it is crucial for activation of all 
factors’ expression still needs to be determined. 
To assess the role of HNF4a in moderating coagulation factor gene expression, we decided to 
silence HNF4a expression in two liver cells lines: HepG2 and HUH7. These are cancer cell 
lines derived from human hepatocellular carcinomas (from 15 year old and 57 year old 
petients, respectively), and usually used as in vitro models for the study of human 
hepatocytes. Being cancer derived lines, they lack a healthy hepatic phenotype, but the use of 
hepatocytes is restricted by their availability and difficulty to maintain in culture.  The use of 
cell lines has its limitations, but overcomes the problems of using our HLC model. The HLC 
model is a differentiation where cells go from a pluripotent state to hepatocyte-like cells. 
During the 13 day period, the cells undergo a series of changes, many not clearly understood, 
which would make it difficult to quantify the exact effect of HNF4a knock down on the cells. 
The fact that they are a heterogeneous population that is still acquiring the hepatic phenotype 
would introduce additional variables on a knockdown experiment. Therefore, the HepG2 and 
HuH7 cell lines provide a simpler system for the initial evaluation of the effect of RNA 
HNF4a knockdown.  
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By using two distinct cell lines, we are also ensuring that the effect of HNF4a knockdown is 
reproducible and not just line specific. HUH7 and HepG2 are two cells lines routinely used as 
in vitro models to study the liver. Even though they are known to possess liver functions, an 
important first step is to make sure they express coagulation genes. Indeed, when we checked 
by qPCR both lines expressed coagulations genes (Figure 61), which allows us to use them to 
study HNF4a as the possible master regulator for coagulation gene expression network. 
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Figure 61 – coagulation gene expression in HUH7 and HepG2 cell lines. Gene expression by qPCR of coagulation genes 
in liver cell lines: HUH7 and HepG2. Expression levels normalized to GAPDH endogenous control. 
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The next step is to knockdown HNF4a and see the effect on expression of the coagulation 
factor genes. The use of small interfering RNA (siRNA) allows to check the effect of HNF4a 
knockdown in a fast and reliable way. siRNA works by causing the target mRNA to be 
broken down, impeding translation of the mRNA to protein. Upon introduction of the siRNA 
into cells, knockdown is usually achieved within 24 to 48 hours. While 48 hours are enough 
to assess knockdown of the target gene, we require longer periods as we want to assess the 
effect of the absence of HNF4a in coagulation genes expression. 
As assessed by western blot, the levels of HNF4a protein were greatly reduced in HepG2 
cells in the presence of HNF4a siRNA (Figure 62). While this is promising, some protein can 
still be detected. Surprisingly, we also observe reduced levels of HNF4a protein in our 
control siRNA, which should have not happened. There is no logical explanation for this to 
have happened and most likely it results from human error during handling (e.g. mislabeling). 
Together with the absence of protein detection in HUH7 samples, it is necessary for the 
experiment to be repeated. 
 
 
Figure 62 – HNF4a Protein levels after siRNA. Western blot of HepG2 and HUH7 cellular extracts for assessment of 
knockdown level upon siRNA transfection. A. HNF4a antibody B. GAPDH antibody. Legend: 1- HepG2 Untransduced, 2 – 
HepG2 siRNA control, 3 – HepG2 siRNA HNF4a, 4- HUH7 Untransduced, 5 – HUH7 siRNA control, 6 – HUH7 siRNA 
HNF4a 
 
Regardless of the unexpected results with HNF4a knockdown with our control siRNA, we 
went ahead and checked for coagulation factors expression levels. If HNF4a is indeed a 
master regulator of the coagulation network we should see an effect on the expression levels 
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of the coagulation factor genes. But despite the low levels of HNF4a protein present, 
expression of all coagulation genes could be detected (Figure 63). This could mean that 
HNF4a is not a master regulator for this network. While some reduced expression can be seen 
in FXI and FXII, for statistical significance we need to repeat the experiment in order to 
increase the significance level. 
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Figure 63 – Coagulation genes expression in HNF4a knockdown. Expression of coagulation genes in HepG2 cell line 
under 3 different conditions: untransduced (UT), control siRNA pool and HNF4a siRNA. Liver as positive control for 
expression and iPSC as negative control. Expression levels normalized to GAPDH endogenous control.  
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Considering some of the problems during siRNA knockdown, to conclusively exclude 
HNF4a we need to repeat the experiment. It is also important to consider other possibilities 
for the lack of effect from HNF4a knockdown. It is possible that the low levels of the HNF4a 
protein present in the cells are still enough for regulation of the coagulation genes. Another 
possibility can be related to the incubation period of cells with the siRNA. Even if HNF4a 
protein levels are low enough, the incubation period might not be enough for the knockdown 
of HNF4a to affect mRNA levels of the coagulation genes. It is necessary to allow time for 
the mRNAs to degrade while HNF4a is absent, permitting to see the real effect of HNF4a 
knockdown. And for that, a range of longer incubation periods need to be used.  
The use of other silencing techniques, such as shRNA, would represent another alternative as 
these give a more sustained knock down of HNF4a, and allow to better asses its role in 
regulating coagulation genes network. Despite its advantages at a more stable knockdown, 
shRNA has the disadvantage of longer optimization periods and, it being an integrative 
method, can affect genomic stability.  
Another important consideration relates to the list of candidate master regulators. We picked 
HNF4a under the belief that from the 5 candidates, it was the one with the strongest 
biological evidence on its role in coagulation. We also assumed that there was one master 
regulator for this network when it is possible that is possesses more than one master 
regulator. And so, to truly dissect the network and its master regulator(s), one must consider 
the possibility of multiple TFs taking up that role together. A good starting point would be to 
use the other candidates from our analysis (Table 10) as these show strong evidence as 
regulators of coagulation genes.     
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7.4 Discussion 
 
Using the coagulation system as a model system we have attempted to use the iPS-hepatic 
differentiation protocol to understand the ontology of coagulation factor expression. We show 
that the extrinsic and common pathway coagulation factor genes are switched on relatively 
early during this differentiation (between days 4-8). We then tried to identify the regulatory 
pathway that promotes the upregulation of these genes during this time point and identified 5 
possible candidates through a combination of RNA-seq and motif analysis. We hypothesised 
that HNF4 was likely a lead candidate because of the strong evidence connecting it to the 
coagulation factors. However, preliminary attempts at knockdown of HNF4 did not work as 
planned because of technical problems but there was a suggestion that expression of some of 
the extrinsic and common coagulation factor gene mRNA was modestly down regulated. 
These experiments need to be repeated with better siRNA reagents.  
Further work needs to be done before we can definitely say HNF4a is not the master regulator 
of the coagulation genes regulatory network. As discussed above, a range of experiments can 
be done to assess this: from repeating the siRNA, using shRNA and even consider other TFs 
as (co-)master regulators of the network. 
Even with the unanswered question, it is clear that combination of RNA-seq from our 
differentiation protocol samples with in silico methods allowed to increase the knowledge on 
the overall regulatory network for the coagulation genes. Despite the benefits of combining 
these analyses, one must be cautious with the limitations these methods possess. 
While RNA-seq represented an improvement on gene expression quantification methods, one 
must consider how well it captures the biologic reality. RNA-seq focuses on mRNA levels, 
used as proxy for protein levels estimates. While a lot of information can be acquired from 
mRNA levels (sequence information, relative gene expression and even information on RNA 
splice events
306
), it is the final protein products that have the functional role we are interested 
in. It is important to keep in mind that a gene’s expression level alone is not predictive of 
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protein abundance
314
. Furthermore, gene expression is tissue specific
315
 and even within 
tissues it is cell-type specific. Caution needs to be taken when interpreting data from a 
heterogeneous mix of cells as often it affects the data interpreted. Our model has shown to 
result in a heterogeneous population (Chapter 5 section 5.2.2), and while this can affect the 
data obtained from RNA-seq, we believe most of the variability observed results from 
different developmental stages of the cells rather than distinct cellular types. Presence of cells 
at different developmental stages can still affect data interpretation, especially as we are 
looking at differential expression between the different time points.    
RNA-seq has proved itself extensively in the amount and quality of data it provides, and 
while it has been almost a decade since the first RNA-seq was performed, data collection and 
statistical analysis are continuously under development. Differences in the methods used for 
analysis can greatly affect the results, and as large amounts of data are obtained from single 
experiments, it is possible for important data to be overlooked. These are true for any RNA-
seq data presented, and is a general limitation rather than specific to our experiment. 
Data from in silico analysis are predictive of biological events based on theoretical 
knowledge from previous research. A variety of algorithms has been developed for different 
analysis, such as motif analysis, with most showing low levels of predictive accuracy
316
. 
Increased accuracy can be obtained when biological knowledge is incorporated in the 
analysis, such as high-throughput data. Accounting for chromatin modification is an 
important example of biological data as it distinguish between TFBS that are accessible or 
not, and therefore their potential binding capacity under a given cellular conditions
317
.   
 
As this was done for coagulation, other liver specific pathways can be examined using this 
RNA-seq data in combination with in silico analysis. This avenue of research can also be 
used for other cell types, exemplifying how iPSC research can be used in ways normally 
overlooked. Most of the work with iPSCs, and stem cells in general, are greatly focused in 3 
main fields: disease modelling, drug toxicity and cellular therapies.  
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The stem cell field has great potential for research and therapy and as the field evolves new 
possible applications have come to light. While some hurdles still exist, the benefits are clear 
with a promising future for the field of iPSC. 
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Chapter 8 Final Discussion 
 
A great deal of work has been done regarding iPSC, both at the reprogramming and direct 
differentiation level. 
IPSC reprogramming has dramatically changed since it was first reported in 2006, with a 
wide range of methods currently available. All the different factors that can influence the 
reprogramming process, led to an unintentional barrier against their clinical use. The 
multitude of ways iPSC can be obtained results in populations that differ from each other. 
How their differences affect their quality is still being investigated, and until a standard 
criterion on the quality of these cells is set, cautious is recommended.    Considerations in 
terms of transcriptional signatures, epigenetic status, genomic integrity, stability, 
differentiation and tumour potential should be the focus of quality control of iPSC.  
While a standard iPSC has not been defined yet, some methods have known detrimental 
effects on the quality of the final population, as is the case with integrative methods.  As 
these cells can be used in different contexts, it has been proposed that different evaluation 
criteria could be employed
318
. Moreover, new avenues are emerging by which iPSCs without 
the ability to form teratomas might actually be more useful and safer for regenerative 
medicine. While much speculation exists on which are the best criteria to evaluate iPSC 
quality, a consensus on this would allow to remove variability when comparing results from 
different labs. 
With this in mind, we established a robust method of reprogramming that fulfils the current 
safety guidelines. The use of an integration-free, xeno-free method allows to remove most of 
the components that introduce variability to the process (feeders and serum containing 
medium) while maintaining genetic stability of the final population. These features are 
important in the context of clinical translational but also in establishing guidelines that can be 
followed for standardization of the reprogramming protocol. Despite the advantages of our 
adopted method, the variety of methods available has taught us that there is no one way when 
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it comes to reprogramming, and that similar quality iPSC can be obtained from different 
protocols. 
The adoption of a standard quality iPSC would also level the field of direct differentiation. 
Forward differentiation from PSCs has been observed to almost every cell type of the human 
body, with varying degrees of success. For one cell type, several differentiation protocols 
exist and the use of similar or identical starting populations would allow direct comparison in 
their efficiency/ability to do so. As with reprogramming, much has improved on the quality 
of differentiation protocols, but further improvements are still required. These try to 
recapitulate the in vivo developmental cues in an artificial setting and as with most artificial 
settings, they lack all the cues provided but the cells’ natural niche. 
It is accepted that differentiated cells most closely match embryonic or foetal stages of 
development rather than adult. The physical and chemical properties of the cellular 
environment have recently earned interest as a way to improve the developmental state of 
cells. The cell-material interface is not static with cooperative interactions dictating one 
another’s fate319. Differentiation can be affected by the substrate mechanical stiffness320, 321, 
the topography
322, 323
  and chemical composition
324, 325
.  
Composition of the material coupled with the concept of degradation by-product was realised 
to influence stem cell fate. An example is the release of ions (such as calcium, magnesium 
and fluoride) from dissolving inorganic mineral and its effects on stem cell phenotype
326, 327
. 
This concept can be applied to a range of natural and synthetic materials. Interestingly, this 
effect can also influence cell shape
328
 which also leads to changes in differentiation. 
Topography cues of the environment, such as shape can affect cell phenotype. Shape affects 
cytoskeletal organization of cells which in turn has shown to affect cell lineage fate
329
 in a 
“function follows shape” manner. A known example of topography effect is on 
cardiomyocyte functionality and maturation. Cardiomyocytes are muscle cells that possess 
contractibility features. While in vitro differentiation protocols result in cells that show a 
beating phenotype, these cells lack correct morphology, structure organization, mechanical 
output and electrophysiology. Culture of cells in rectangular patterns allowed cells to obtain 
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their typical elongated morphology, resulting in improved phenotype which is closer to 
mature cells
323
. Improvements in structural and electrophysiological features of 
cardiomyocytes show us how topography of the substrate can contribute to the maturation of 
the final population. 
The same way composition and topography can affect cell fate, stiffness of the substrate can 
elicit different responses in cell maintenance or differentiation. This has been shown for a 
range of different substrates, including collagen
330
, polymer networks
331
, PDMS
321
 and even 
nanofibers
332
. Stiffness can induce different cellular responses as it affects the signals 
provided from the interactions with the substrate, which in turn can modulate internal 
organization of cells.  
Although these mechanisms have been discussed in their individual ability to regulate cell 
fate, they work together in complex ways with the process being more challenging than just 
linear combination of the different inputs.  Indeed, similarly to what happens in biochemical 
induced differentiation, material-induced differentiation might require multiple steps by 
which the appropriate signals are provided in a specific temporal sequence for correct 
differentiation. 
This view that cell fate can be influenced by composition and physical properties of the 
substrate clashes with the traditional view by which molecules (such as growth factors) are 
the main drivers of differentiation. The reality is that the complex developmental cues cannot 
be recapitulated by individually using material or media, but rather a combination of all the 
possible technologies presents the best chance at obtaining optimal differentiation protocols.  
Along this train of thought, and with the realization of the limitations from 2 dimensional 
(2D) culture systems in replicating the in vivo environment, 3D systems started being 
employed. The differentiation process in 2D can have varying levels of efficiency, with the 
worst cases showing efficiencies <10% as is the case for pancreatic endocrine cells
333
 while 
neuron differentiation can achieve >80% efficiencies
118
. Even if efficiencies are satisfying, 
quality of the differentiated population is an important consideration. Together with the 
physical and chemical properties of the environment, 3D structures try to bring the 
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environment closer to the cell’s natural niche. 2D systems are known to reproduce 
inadequately the in vivo features, as exemplified by the interaction of cells with the ECM and 
neighboring cells via the basal region, affecting protein cell-surface distribution and the 
organization of the intracellular machinery and thus changing cellular responses
334, 335
. 
Differentiation in 3D scaffolds has showed to improve the quality of the differentiation
336
, 
organization
337
 and functionality
337, 338
 of cells, and different lineages have been obtained 
including neuronal
339
, cartilage
337, 340
, vascular
336, 341
 and liver
338
. In some cases the 
combination of 2D and 3D systems has proven advantageous, as in the case of intestinal 
tissue, with an initial stage in 2D for hindgut differentiation followed by a 3D step that allows 
polarization into villus-like structures and crypt-like proliferative zones that express intestinal 
stem cell markers
342
. 
The growing movement in 3D culture together with research in developmental biology and 
cell dissociation and re-aggregation allowed for organoids to be derived from human PSCs, 
including gut, kidney, brain, retina and liver structures
342-345
. Organoid is defined as an 
organized structure of organ-specific cell types that develops from stem cells or organ 
progenitors and that exhibits some organ specific function. As with the case of PSCs, 
organoids have great potential in regenerative medicine, including disease modelling, drug 
toxicity and cell or whole organ replacement therapy. 
Organoid development required a great deal of optimization as several factors can affect the 
success of a 3 dimensional structure forming: medium composition, density of cells, 
developmental stage of cells, temporal cues, among others. In some cases, success in 
organoid formation relied on presence of extracellular matrix components, such as matrigel 
for neural organoid formation
343
. However, the requirements of a 3D organization are 
variable. Some studies show that structural organization of cells is not a requirement for their 
functional use
346, 347
.  
A situation where a 3 dimensional structure has proven beneficial for functionality of 
differentiated cells was the development of liver-bud structures. This was done by mixing 
three different populations: human PSCs derived hepatic cells, human mesenchymal stem 
cells and human endothelial cells, as way of mimicking the early cell lineages of the 
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developing liver
345
. When mixed, the cells spontaneously aggregate into a 3D structure that 
resembles a liver bud. These organoid structures presented vascularization and when 
transplanted into mice showed ability to rescue liver failure and production of human specific 
metabolites
345
. Recreation of liver architecture allows for correct cell-cell and cell-matrix 
interactions to be formed and hepatocyte polarity to occur, which has been shown to be 
important for correct liver function
348
. 
There are two known mechanisms known to influence organ self-assembly: the first, known 
as Steinberg’s differential adhesion hypothesis, says that cells with similar adhesive 
properties segregate into domains that achieve the most thermodynamically stable pattern
349
; 
the second being “proper spatially restricted progenitor fate decisions”, by which stem cell 
division, and orientation,  balance of symmetric and asymmetric divisions, and migration of 
differentiated cells are required to occur in a correct way for normal tissue architecture 
development. This demonstrates the importance of the interplay of the different cell types that 
make up a tissue for proper differentiation of cells.  
Organoid technology carries its own limitations such as vascularization of the structures. 
Most organoids do not possess vasculature which imposes limitation in nutrient supply. This 
can affect the growth potential, and while spinning conditions have shown to improve 
nutrient exchange, the use of a function vascular network has proven the best alternative. Co-
culture with endothelial cells has shown to generate a vascular-like network with 
transplantation into recipient mice showing incorporation of this network into the host 
vasculature
345
. 
Furthermore, organoids resemble more primitive developmental structures and for full 
maturation, transplantation into a recipient might be necessary. The maturation state of cells 
is a recurrent issue in stem cell derived populations. It is possible that until better methods are 
developed, an in vivo step is the only way maturation of cells can be achieved. This shows 
that despite how far technologies have come in improving differentiation from stem cells, 
there are still hurdles along the way to be overcome.    
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The use of iPSC for cellular therapy depends on robust differentiation protocols that are able 
to produce cellular products able to rescue the disease or damaged phenotype. While 
maturation level of cells is still a concern, the use of PSCs as starting population remains a 
safety issue for many. A lot is still unknown regarding the quality of iPSC when it comes to 
genetic stability, and while resetting the epigenetic state of cells is a key requirement for the 
reprogramming process, it incurs risks for the quality of the final population. 
The conceptual idea of transdifferentiation (Figure 2) becomes highly relevant for cell fate 
conversion without requirement of passing by a pluripotent state. By the introduction of 
specific transcription factors, direct conversion of somatic cells has been observed to a range 
of different lines
350, 351
 both intralineage and across lineages (Table 11). By avoiding a 
pluripotent state, we might secure a higher genetic stability of cells. Overall, it is easier to 
transdifferentiate cells into related lineage phenotypes as their epigenetic signatures are closer 
and therefore easier to convert into one another.  
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Table 11 – Transdifferentiation between somatic cell states 
Somatic cells conversion 
(with germ layer) 
 Exogenous 
reprogramming 
factors 
Experimental 
setting 
 Reference 
Fibroblasts (mesoderm) 
converted to myocyte-like cells 
(mesoderm) 
 MyoD + 5-Azac Invitro           
Intralineage 
conversion  
 
352
 
B cells, T cells and Fibroblasts 
(mesoderm) converted to 
macrophage-like cells 
(mesoderm).  
 C/EBP ± PU.1 Invitro           
Intralineage 
conversion 
 
353
 
Cardiac fibroblasts (mesoderm) 
converted to induced cardiac 
myocyte-like cells (mesoderm) 
 Gata4, Mef2c and 
Tbx5 
Invitro           
Intralineage 
conversion 
 
354
 
Fibroblasts (mesoderm) 
concerted to induced neuron-
like cells (ectoderm) 
 Ascl1, Brn2 and 
Mytl1 
Invitro           
Cross-lineage 
conversion 
 
355
 
Pancreas exocrine cells 
(endoderm) converted to 
endocrine-like cells (endoderm) 
  Ngn3, Pdx1 and 
MafA 
Invitro           
Intralineage 
conversion 
 
356
 
 
The field of stem cell has seen an exponential level of development in the past years, with 
progresses in other areas permitting such growth. A great deal more is expected in the 
following years and hopefully the potential of this technology will soon be fulfilled.   
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Chapter 9 Supplementary Information 
9.1 Supplementary Figures 
 
 
Supplementary figure 1 – Reprogramming efficiency of different cell lines using episomal method. All cell lines 
showed similar reprogramming efficiencies using the episomal methd. In brief, 106 human fibroblasts were transfected with 
Yamanaka’s episomal plasmids (1µg each) using Amaxa Nucleofector kit and cultured in MEF medium and Nuff feeders. 
 
 
Supplementary figure 2 – Endoderm differentiation in iPSC from colony format. Endoderm differentiation from colony 
format results in different condition for cells at the periphery and centre of the colony A. cells at periphery of the colony. B. 
cells at the centre of colony 
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Supplementary figure 3 - FACS characterization of HLC day 4 using endodermal specific markers CXCR4 and 
SOX17. . FACS analysis of 3 different cells lines at day 4 of the hepatic differentiation protocol. Endodermal cells from 
different iPSC lines all show high levels of expression of endoderm surface markers: CXCR4 and SOX17.
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Supplementary figure 4 – Immunostainning of cells during hepatic differentiation protocol. Analysis using a range of different markers to characterize cells during hepatic differentiation 
protocol: SSEA5 (pluripotent marker), SOX 17 (endodermal marker), Nestin (ectodermal marker), HNF4a  and AFP (Liver specific marker). 
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Supplementary figure 5 - RNA sequencing analysis. A. Genes turned on at the endoderm stage and present 
throughout the hepatic differentiation protocol. B. Genes turned on at the hepatic commitment stage and present 
throughout the hepatic differentiation protocol.  
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Supplementary figure 6 – Gene expression of cells during hepatic differentiation protocol. Analysis using a 
range of different markers to characterize cells during hepatic differentiation protocol: Nanog (pluripotent 
marker), SOX 17 (endodermal marker), Nestin (ectodermal marker), Brachyury (mesodermal marker), HNF4a  
and TTR (Liver specific marker). 
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Supplementary figure 7 – Liver of mice treated with CCL4. H&E of mice livers after CCl4 treatment. Normal 
architecture can be observed as opposed to first round of CCL4 treatment that resulted in damaged liver.  
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A 
B 
Supplementary figure 8 - Expression of surface markers assessed by FACS. Assessment of pluripotent and tumorigenic 
associated surface markers in cells during hepatic differentiation A. FACS profile of BJ iPSC line during hepatic differentiation. 
B. FACS profile of HPS1 iPSC line during hepatic differentiation. 
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Supplementary figure 9 – Teratomas from HLCs at different time points. Macroscopic pictures of tumours 
after dissection. Tumours/testis are kept in Histochoice until sent to Histology. 
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Supplementary figure 10 - Coagulation factors gene expression data in BJ iPSC line hepatic 
differentiation. Gene expression by qPCR at different time points of hepatic differentiation protocol: day 0 
(iPSC), day 4, day 8 and day 13. Adult liver as positive control.  Expression levels normalized to GAPDH 
endogenous control. Stats using unpaired t test. Legend: * statistically significant (p<0.05) 
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Supplementary figure 11 - Coagulation factors expression in mouse embryonic liver samples in GEO 
dataset. Expression analyzed in Transcriptome Analysis Console (TAC) from Affymetrix 
 
 
 
Supplementary figure 12 - Pictures of mouse embryos during dissection. Example of E7.5 and E11.5 of 
mouse embryos.  
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9.2 Supplementary Tables 
 
Supplementary table 1 - In-house Database of protein coding genes with annotations for tissue specificity 
and transcription factors. The DB is built in MySQL using Relational Tables to match IDs and 
downloadable as .csv and .xml for analysis in R 
Number Of Genes Description Source 
23044 All Human Genes Ensembl and Uniprot 
1406 All Human Transcription Factors Jaspar, Aftb, Transfac, Uniprot, Msig 
Db, Fantom Project 
4721 All Human Liver Genes Uniprot, Literature Search, Human 
Protein Atlas Project 
1453 All Human Liver Transcription 
Factors 
Fantom, Protein Atlas, Literature 
Search 
867 Definite Liver Tfs Fantom, Protein Atlas, Literature 
Search, Uniprot, Manual Curation 
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9.3 Motif analysis 
A master database of ~1400 human transcription factors was built in-house by 
collecting data from Uniprot, TRANSFAC, Protein Atlas Project, MEME suite, 
Jaspar Database and data mining through biomedical publications. Matrix profile 
with frequencies of each nucleotide in columns were collected from Jaspar and 
TRANSFAC databases and results from Jolma et al.
357
 and Vaquerizas et al.
358
. The 
matrices are built based on the consensus nucleotide in each position having the 
highest score in column (Supplementary figure 13). Think of consensus as an 
“ancestor” motif, from which mutated motifs evolved Matrices obtained from 
JASPAR, TransFAC and MSIGDB In-house scripts to search for sequences from the 
matrices across the 15kb upstream sequences of the coagulation genes.  
Using an in-house script for treating duplicates and element searching, we parsed the 
TFBS matrices across the promoter sequences to check for potential regulatory 
regions in the coagulation genes. According to the hypothesis of this study, master 
regulators are those that regulate most of the genes, in the coagulation network. 
Therefore, from the hundreds of transcription factors predicted to be binding to the 
14 coagulation genes, only 95 possible transcription factors were common to 
coagulation genes and were short listed.  
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Supplementary figure 13 – Schematic representation showing how a TFBS binding at a specific sequence 
pattern is matched and scored  
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